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ABSTRACT 
 
DEVELOPMENT OF CANINE CHIMERIC ANTIGEN RECEPTOR T CELL 
THERAPY FOR TREATMENT & TRANSLATION 
Mohammed Kazim Panjwani 
Nicola J. Mason, BVetMed, PhD, DACVIM 
 
Chimeric antigen receptor (CAR) T cell therapy has had remarkable success targeting B 
cell leukemias in human patients, but unexpected toxicities and failures in other disease 
demonstrate the need for more predictive pre-clinical animal models than the murine ones 
currently used. Dogs develop spontaneous malignancies similar to humans in their tissues 
of origin, gene expression profiles, treatments, and disease courses, and have long been 
used as models for immunotherapy. I hypothesize that the development of CAR T cell 
therapy for dogs with spontaneous disease and that the treatment of these canine patients 
will recapitulate the observations found in human patients, and provide new insights into 
the safety and efficacy of this breakthrough therapy. To achieve this, I first established 
methods for growing primary canine T cells from healthy and disease-bearing donors to 
clinically relevant scale, developed RNA electroporation protocols to transiently express 
a CAR targeting the canine tumor-associated antigen CD20, demonstrated its function in 
vitro, and treated a relapsed canine B cell lymphoma patient with autologous CAR T cells 
as a proof of feasibility. I then developed methods to permanently express a second-
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generation cCD20-8-28-ζ CAR in canine T cells using lentiviral transduction, showed in 
vitro antigen-specific function and proliferation of CAR T cells, and treated four canine B 
cell lymphoma patients with CAR T cells. Based on my observations from those patients, 
I made iterative improvements to the T cell culture system and CAR construct, and 
treated a canine B cell lymphoma patient with cCD20-8-BB-ζ CAR T cells, whose tumor 
cells lost target antigen expression to avoid immune pressure. These results prove that it 
is not only possible to generate canine CAR T cell therapy, but that it recapitulates 
observations found until now only in human patients. In addition, novel findings 
regarding the recovery of T cells during ex vivo culture and the host immune response to 
the CAR demonstrate that this model can already inform human medicine. 
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CHAPTER 1: Background  
 
This thesis pulls together various threads, including the role of T cells in protective 
immunity and their mechanisms of action, the interactions between T cells and cancer, 
and the various animal models and immunotherapeutic modalities that have been 
generated to advance effective anti-tumor immunity. A brief review of these items is 
contained within this chapter, to provide the context, rationale, and structure for this 
thesis to the reader. 
 
An Overview of the Role of T cells in the Immune System 
T cells, and the cell-mediated immunity that they provide, form one arm of the adaptive 
immune system. Unlike the innate immune system, which generates a rapid defense of 
the host in response to pathogens based on the recognition of broad patterns and signals, 
the adaptive immune system is finely-tuned in its reactions to specific antigens. There is 
an initial tradeoff between speed and specificity in adaptive immunity, as the responses 
originate from single cells that must multiply and mobilize to mount an effective defense, 
but the beneficial outcome for the host is the development of immunological memory – 
rapid, specific, and long-lasting protection. These characteristics and how they are 
formed are best described through the example of T cell development and function. 
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T cells are broadly designed to recognize and counter the corruption of selfness within 
the host – detecting intracellular bacterial and viral infections present within host cells, 
and aiding in the removal of parasitic and extracellular infections shown to them by 
antigen-presenting cells. To do this, T cells develop in the specialized organ from which 
they derive their name, the thymus, where they receive signals to encourage productive 
development and prevent potentially deleterious outcomes. At the heart of this is 
formation of the T cell receptor (TCR), through which the T cell binds and recognizes its 
cognate antigen. In order to account for all possible antigens of all possible 
conformations, the recombination of V, D, and J gene segments along with the addition 
of P and N nucleotides results in trillions of possible TCRs (Davis and Bjorkman, 1988). 
This vast diversity of TCRs is trimmed down during development on the basis of two 
major criteria: compatibility with host presentation of antigens, and non-reactivity to 
host-derived antigens. The first of these steps, referred to as positive selection, is based 
on recognition of the host’s major histocompatibility complexes (MHC). MHC are the 
product of multiple genes, themselves among the most polymorphic in vertebrate 
genetics, resulting in a near-unique barcode for the host’s cells (Robinson et al., 2015). 
This surface protein displays short polypeptide sequences derived from proteins either 
generated within the cell (in the case of MHC class I on all nucleated cells) or taken up 
by the cells (in the case of MHC class II on specialized antigen-presenting cells), giving a 
window into each nucleated cell’s processes and health. In order to receive a survival 
signal and continue, the TCR of a developing T cell must be able to bind onto the host’s 
MHC as displayed on the surface of thymic epithelial cells, otherwise the T cell will die 
of neglect. Cells within the thymus present self-peptides on their MHC; therefore, to 
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prevent the development of T cells that could attack the host, T cells that have a TCR that 
binds too tightly to these MHC-peptide complexes because they recognize both the MHC 
and the self-antigen are signaled to undergo apoptosis and are also eliminated in the 
process known as negative selection. 
This delicate balance between assuring recognition and elimination of threats harmful to 
the host and avoiding pathology caused by attacking the host itself continues after 
development, when the T cell is mature and has exited the thymus. T cells that are naïve 
and encounter their cognate antigen for the first time must not only have a successful 
TCR-MHC-peptide interaction, but must also receive a co-stimulatory signal to carry out 
their effector functions and multiply (Mueller et al., 1989). Even so, the activation of the 
T cells response is accompanied by negative feedback loops. These include the 
upregulation of inhibitory receptors on the T cells that can dampen and prevent further 
activation, and other cells in their immediate environment taking actions to protect 
themselves by upregulating the corresponding ligands for these inhibitory receptors 
(Linsley et al., 1991). 
Upon successful activation of the T cells, they proliferate and can give rise to an array of 
population subtypes such as highly functional effector cells that die off after clearance of 
the infection or memory cells that persist either in the secondary lymphoid organs or in 
the circulation and tissues of the host to protect against challenges from the same 
pathogen. These cell fates, the fine distinctions between them and among subtypes of 
their categories, and how they are generated are active areas of research. Recently 
identified and relevant subtypes of T cells include naïve-like memory cells that are less 
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differentiated, and “exhausted” T cells that keep chronic infections in a stalemate without 
successful clearance or memory generation (Gattinoni et al., 2011; Pauken et al., 2016). 
The result of these processes and other factors is that the T cells populations of the 
immune system are poised to provide a potent, robust, and flexible defense of the host 
against any threats it may encounter. 
 
The Interactions between Cancer and T cells 
Perhaps the most challenging of these threats is the host’s own cells. Cancer has 
shadowed the existence of multicellular organisms likely since their evolutionary origin. 
That is not to say that the immune system has no role in the host’s defense against 
malignancy. The concept of cancer immunosurveillance, that the immune system 
eliminates the vast majority of neoplastic clones that arise over the lifespan of the host, 
was proposed over a century ago, and evidence supporting this built over the following 
decades as our understanding of both cancer and the immune system grew (Burnet, 
1957a, b; Ehrlich, 1909). As inbred strains of mice became available and were tested for 
transplant rejection and acceptance, it became clear that tumor rejection or outgrowth was 
linked to the same mechanisms that rejected or accepted transplants (Billingham et al., 
1954a; Billingham et al., 1954b). Mice with genetic knockouts that prevented the 
development of T cells or natural killer cells, their closely-related cytotoxic innate 
counterpart, or eliminated the ability to produce or respond to their key mediators such as 
IFNγ and STAT1 were more susceptible to spontaneous or induced tumor formation 
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(Kaplan et al., 1998). Additionally, humans with naturally occurring primary or acquired 
immunodeficiencies are also more susceptible to a variety of malignancies due to viral 
infection or impaired DNA repair (Salavoura et al., 2008). These and many other pieces 
of evidence led to a model where the immune system, largely mediated by T cells, 
eliminates most tumors, and those tumors that survive and thrive have adapted to its 
pressures. 
This model, known as immunoediting, consists of three processes: elimination, 
equilibrium, and escape. Elimination of the tumor is largely described by 
immunosurveillance. Cancer is a disease of genomic instability and, in the process of 
transformation and subsequent mutations during proliferation, a population of 
neoantigens that are recognized by the immune system as non-self are generated and 
targeted. However, another consequence of this genomic instability is that there is 
heterogeneity among the tumor population, and not all cells are always eliminated. 
Equilibrium can be viewed as a form of microevolution, where the tumor and immune 
system constantly adapt to each other’s tactical shifts until one finally gains the upper 
hand – either the immune system eventually pushes the tumor back to elimination, or the 
tumor progresses to escape the immune system. 
To escape the immune system, cancerous cells have at their disposal the entire cellular 
genome and with it the checks and balances hardwired into the immune system. Tumor 
cells may lose expression of the neoantigens being targeted by the host’s T cells, and they 
can also downregulate expression of MHC to render themselves effectively invisible to 
the T cells. Additionally, they can downregulate ligands that provide co-stimulation to T 
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cells and upregulate ligands for inhibitory receptors on T cells. Tumor cells can also 
create a hostile microenvironment for T cell activity, such as producing chemokines to 
prevent migration to the tumor site, producing suppressive cytokines, and recruiting 
suppressive cells such as myeloid-derived suppressor cells and anti-inflammatory 
regulatory T cells. Combinations of these and other steps entrench the tumor over time 
until it survives and escapes the immune response. 
Thus cancer, as we know it when it finally reaches clinical notice, is a select population 
that has evolved under intense survival pressure to stymie and outwit the natural immune 
response. 
 
A Brief Review of Cancer Immunotherapy Strategies 
However, just as our understanding of the interactions between cancer and the immune 
system has increased, so has our arsenal for augmenting a pre-existing anti-tumor 
immune response or generating one de novo. 
One of the earliest approved methods for augmenting anti-tumor responses is injection 
with the cytokine IL-2, to amplify the proliferation of reactive T cells in the host – 
including those presumably reacting to the tumor (Atkins et al., 1999). In a similar vein, 
IL-12 has been used to skew the T cell response toward a more inflammatory strategy 
(Atkins et al., 1997). As a logical extension of this, samples of the tumor have been 
excised and treated with high doses of IL-2 ex vivo, with the expectation that the tumor-
infiltrating lymphocytes present in this tissue will include tumor-specific T cells that will 
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selectively proliferate out and can then be infused back into the patient (Rosenberg et al., 
1985). 
Another strategy has been to manipulate the inhibitory axis of the tumor-T cell 
interaction, called checkpoint blockade. Monoclonal antibodies that block the interaction 
between PD-1 and PD-L1, which would short-circuit T cell activation, as well as 
antibodies blocking CTLA-4, an inhibitory receptor on T cells that also deflects and 
dampens activation, have been approved (Brahmer et al., 2012; Topalian et al., 2012; 
Wolchok et al., 2010). Depletion of regulatory T cells through a monoclonal antibody 
against CD25 has also been approved  (Rech et al., 2012). Antibodies against other 
inhibitory receptors and ligands such as LAG3, TIM3, GITR, and others are all in various 
stages of research and development. 
These strategies have found success in melanomas, smoking-associated lung cancers, 
mismatch-repair associated colon cancers, and other malignancies associated with high 
mutational burden and, with it, a large number of neoantigens to be targeted by the 
immune system – haystacks relatively rich with needles to find (Alexandrov et al., 2013). 
Other cancers require the creation of an immune response from the beginning. 
Treating cancer like any other pathogen, one strategy has been vaccination with tumor 
antigens in hopes of spurring a response. The first-ever FDA-approved cell-based 
therapy, outside of allogeneic hematopoietic stem cell transplants to induce graft versus 
tumor effects, was sipuleucil-T (Kantoff et al., 2010); this therapy used patients’ dendritic 
cells – the archetypal antigen-presenting cell – that had been grown ex vivo and loaded 
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with the tumor-associated antigen prostatic acid phosphatase before re-infusion back into 
the patients to induce a T cell response against the prostate cancer. More recent 
technological advances have allowed identification of the patient’s unique neoantigens 
and pulsing ex vivo expanded dendritic cells with these in hopes of a more specific and 
immunogenic response (Carreno et al., 2015). 
If anti-tumor responses cannot be elicited, they can be genetically encoded. TCRs 
specific for tumor-associated antigens have been sequenced, and can be expressed in bulk 
T cells from another patient to confer them with the same specificity and, ideally, anti-
tumor effect (Clay et al., 1999). However, this method has one major hurdle that is 
intrinsic to all TCRs: the MHC. These TCRs are restricted to how the peptide is presented 
in the MHC of their host of origin, and the diversity of MHCs precludes widespread 
applicability. Another consequence of MHC-dependence is that these transgenic TCRs, 
like any other TCR, are susceptible to tumor evasion by MHC downregulation. 
 
Review of Chimeric Antigen Receptors 
To circumvent the T cell’s MHC restriction and dependence on MHC presentation – in 
effect, to undo positive selection – the T cell would need to be engineered with a novel 
antigen receptor combining MHC-independent antigen recognition with the TCR 
signaling cascade – a chimeric antigen receptor (CAR). 
The first prototype was proposed in 1989 by Gross and Eshhar, combining the 
specificity-determining variable chains of an antibody to the constant chains of the TCR, 
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which successfully signaled when challenged with the native antigen expressed on a cell 
or even immobilized on a surface (Gross et al., 1989). While the target antigen was 2,4,6-
trinitrophenol (TNP), found in explosives but not pathogens, this demonstration was a 
proof of concept for future constructs intended “to kill tumor or virally infected cells.” In 
fact, the first design aimed for practical use was a direct fusion of CD4 with the CD3ζ 
subunit of the TCR complex, using the CD4 as the antigen-binding domain through its 
interactions with gp120 of HIV (Romeo and Seed, 1991). One more major innovation in 
the early 1990s was the full conversion of the immunoglobulin-TCR hybrid extracellular 
domain into a single chain variable fragment (scFv) that would endow the CAR designs 
with a full antibody-like repertoire (Eshhar et al., 1993). The use of scFvs as the antigen-
binding domain remains the most popular design to the present. As structure is function 
when it comes to antigen-binding, the choice of linker, hinge, and transmembrane 
domains are critical for the CAR to work, and needs to be assessed for each individual 
scFv. 
The intracellular, cytoplasmic signaling domains are also key – in order to synthetically 
engineer a successful T cell response, one must understand how a T cell signals in the 
first place. It became clear as T cell studies, both endogenous TCR and CAR-based, 
moved beyond select cell lines and into primary T cells that signaling through the TCR-
associated CD3 components alone is insufficient for a productive response and, in fact, 
can lead to anergy and cell death. As evidence built for the important role of antigen-
independent co-stimulation in normal T cell function, the best-characterized of these, 
CD28, was included in a CAR construct (Finney et al., 1998). The CD28 signaling 
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domain was in cis with the rest of the fusion protein, so that antigen-binding cued both 
signals and bypassed the need for the target cell to express the corresponding co-
stimulatory ligand. Other co-stimulatory receptor domains followed, including OX40, 
ICOS, 4-1BB, CD27, and many others as well some of NK cells (Finney et al., 2004; 
Milone et al., 2009; Song et al., 2012). This step in the evolution of CAR design was a 
critical leap, permitting its signaling to drive primary T cell function and expansion 
similar to natural T cell response. It is these second-generation CAR T cells, using CD28 
and 4-1BB co-stimulatory domains, which led to the partial and complete remissions of B 
cell malignancies in human patients reported in 2010 and 2011 (Kalos et al., 2011; 
Kochenderfer et al., 2010; Porter et al., 2011). 
At the beginning of this thesis work in 2012, ClinicalTrials.gov listed 21 active trials 
using CAR T cells as a therapeutic agent. As of 2017, there are at least 170 listed. Much 
has been learnt in the course of these years, both in patients and in vitro. Within CAR 
design itself, it has been found that not all co-stimulation is equal; the use of CD28 can 
lead to rapid proliferation and robust early function of the CAR T cells, but the use of 4-
1BB can lead to longer in vivo persistence (Milone et al., 2009). These differences can be 
exacerbated by the scFv used – one targeting the tumor-associated disialoganglioside 
GD2 was found to self-ligate, resulting in tonic signaling which, depending on the co-
stimulation used, could lead to self-exhaustion (Long et al., 2015). Another potential 
consequence of the scFv derives from its species of origin – the CAR is a novel protein 
being introduced into the host, and if a component is foreign, such as a murine-based 
scFv, it can be immunogenic and result in anti-CAR antibody responses (Maus et al., 
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2013). Beyond design, the nature of the T cells themselves being generated are still being 
explored, with the merits of effector memory and central memory cell types being 
weighed and attempts to skew the T cell population culture one way or the other before 
infusion and to identify an ideal ratio of CD4+ and CD8+ T cells are being made 
(Sommermeyer et al., 2015; Turtle et al., 2016). Within the patient, pre-conditioning with 
chemotherapy to reduce tumor burden and carve out a homeostatic nice for the incoming 
CAR T cells has been found to have significant effects on treatment outcomes and side 
effects (Turtle et al., 2016). This may be related to the finding that one of the most 
significant prognostic factors for treatment outcome is in vivo expansion of the CAR T 
cells after infusion. The chief non-antigen-directed adverse effect observed so far has 
been cytokine release syndrome (CRS), a massive inflammatory positive feedback loop 
in which IL-6 seems to be the lynchpin and can be lethal (Grupp et al., 2013); it is still 
unclear whether the early stages of this are necessary for tumor clearance, or if it is a side 
effect that can be decoupled from efficacy and avoided altogether. On the other hand, it 
has been found that CAR T cells remain susceptible to many of the mechanisms for T cell 
suppression, such as PD-1 interactions especially in solid tumor environments (Li, 2016; 
Moon et al., 2014). Even before they become CAR T cells, T cells from heavily pre-
treated patients with advanced disease may already be suboptimal for making a 
therapeutic cell product, and these patients may benefit from CAR T cells derived from a 
healthy, allogeneic donor if the effects of graft versus host disease (GVHD) can be 
avoided (Fraietta et al., 2016; Porter et al., 2015). 
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This first generation of successful CAR T cell therapy will need to be followed with 
advances in knowledge and technology to extend effective and safe treatment to a wider 
affected population. Innovations in our understanding of T cell differentiation and the 
consequences of CAR design will guide more precisely tailored therapies, and 
combinations with other experimental and approved agents such as checkpoint inhibitors 
will enhance CAR T cell activity beyond its current reaches. Next-generation gene-
editing has opened the door to even more possibilities, such as the deletion altogether of 
inhibitory genes, the insertion of suicide-gene cassettes for halting therapy post-infusion, 
and elimination of the TCR and MHC on CAR T cells for potentially safer allogeneic 
transfer. This diverse array of new options for potential CAR therapies will first need to 
be tested in pre-clinical animal models for efficacy and safety before advancing into 
clinical trials for humans. 
 
Animal Models for Immunotherapy 
Mouse models have been a favorite of the immunologist’s toolbox for decades. Given 
their genetic flexibility, with an abundance of gene knockouts already available or easily 
generated, they can be readily adapted to precise and elegant studies for basic and 
mechanistic insights into the immune system. Combined with their small size, rapid 
breeding, and relatively low maintenance that add up to inexpensive overhead costs, it is 
easy to understand why the use of mouse models for studying immunotherapies was a 
natural first step. However, the same factors that gave mouse models strength for 
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studying immunology are an Achilles’s Heel when it comes to testing cancer 
immunotherapy: the lack of background genetic diversity makes spontaneous malignancy 
either uncommon, or unnaturally homogenous. 
Several models for tumor-bearing mice have been developed in attempts to address this. 
For tumor induction, the chemical carcinogen methylcholanthrene has been widely used 
to identify genetic factors that prevent progression from DNA damage to overt disease 
but has found little ground in the field of treating already-formed tumors. Some mouse 
models have been bred to express oncogenes and spontaneously develop tumors, and 
some of them have been designed to even recapitulate common genetic lesions found in 
human disease; mice with K-ras G12D and p53 R172H mutations under a pancreatic 
progenitor-specific promoter develop a pancreatic adenocarcinoma strikingly similar to 
the human cancer, including histology and metastatic sites (Hingorani et al., 2005). 
However, the genetic background of the mice developing the cancer, and the cancer 
itself, lacks the genetic variegation that characterizes – and poses such a challenge in – 
humans. 
In order to better model human tumors and the response of human T cells, transplants of 
both were attempted in mice. However, this xenograft of human tissues requires a critical 
step that would limit the findings that could be derived from the model: the mouse’s own 
immune system needs to be crippled so that it would not reject the tumor or the T cells. In 
a sense, the host’s own immunoediting is lost. Many insights could still be gained from 
this chimeric system – trafficking of the T cells to the tumor site, tumor regression or 
progression, exhaustion within solid tumors, short-term persistence of the T cells. 
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However, interactions between the host and the tumor and between the host and the T 
cells are limited across the species barrier. A transplanted tumor has not undergone the 
evolutions elicited by the immune pressures a naturally-occurring malignancy has within 
its host, and has not established a similar immunosuppressive niche through interactions 
with host immune cells. Transformed cell lines do not have competing subpopulations 
that have the potential to escape the immune response or to form a therapy-resistant 
relapse later on. In fact, the transplanted human tumor will express the human tumor-
associated antigen being targeted, so there is little possibility of observing off-tumor on-
target toxicity against normal tissues expressing the antigen. The T cells are not derived 
from a host that has undergone extensive prior chemotherapy, and therefore been hobbled 
by the chemotherapy and previous interactions with the tumor. The cross-talk between 
the T cells and other immune cells of the host is cut short by the species barrier. 
Some of the most surprising findings during the CAR T cell clinical trials in human 
patients were surprising precisely because they were not predicted in the mouse models 
that preceded them and, in fact, could not have been. Targeting human carboxy-
anhydrase-IX on renal cell carcinomas or human Her2 on mammary carcinomas 
transplanted into mice would not have predicted dangerous and even lethal toxicity in 
response to normal antigen expression in the human bile duct epithelium or lung cells 
(Lamers et al., 2013; Morgan et al., 2010). A mouse would not generate antibodies 
against a murine scFv, especially mice that are deficient in B cells to allow tumor 
transplantation, yet humans do. The cross-reactivity of cytokines produced by human 
CAR T cells with the host cells of the mouse they have been injected into are limited, 
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therefore an inflammatory positive feedback loop leading to something like CRS would 
be hindered. Immunodeficient mice would not be pre-conditioned with chemotherapy as 
they are already absent of lymphocytes, and therefore cannot model the effects on 
homeostatic proliferation and engraftment of infused CAR T cells. Finally, mouse models 
rarely last long enough to account for CAR T cell memory formation and years-long 
persistence, along with post-remission relapses and tumor immune-editing, both due to 
the lifespan of the mice as well as eventual GVHD of the human T cells against the host 
mouse tissues. 
To model CAR T cell therapy, and cancer immunotherapy as a whole, a better animal 
model is required. While non-human primates are genetically as close as one gets to 
humans, malignancy is still rare, and they inhabit very different environments from 
human patients. Combined with the fact that they are prohibitively expensive for larger 
studies, along with ethical concerns about using closely related species for 
experimentation, it is unlikely that they will be the bridge to human clinical trials. An 
ideal pre-clinical animal model would develop spontaneous malignancies that occur at a 
comparable or higher incidence than humans, have similar genetic bases, and are treated 
with the same conventional therapies. They would be outbred to account for genetic 
variation, and a large number of them readily available so that a study could be powered 
to look beyond the background noise of the genetic variation, as well as share the same 
environment as humans so as to have the same exposure risk factors. In other words, the 
ideal pre-clinical animal model is actual cancer patients – just not human ones. 
 
16 
 
An Overview of the Canine “Model” of Cancer 
Canines are believed to be the first species domesticated by humans, with their remains 
buried alongside each other as early as over 14,000 years ago (Morey, 2006). Millennia 
of intentional co-existence between our species had resulted in unique opportunities for 
insight into genetic diseases, especially cancer. Unlike lab mice, dogs are a relatively 
outbred population that live alongside humans, but also have breed dispositions to 
particular malignancies due to selective breeding in recent centuries, accounting for both 
genetic and environmental risk factors. 
In fact, canines are estimated to have roughly ten times the incidence of cancer compared 
to humans, 5,300 diagnoses per 100,000 compared to 500 (Schiffman and Breen, 2015). 
In lymphoma, especially, there is no dearth of canine cases, with estimates of up to 
250,000 new cases in the U.S. in 2014. The pathology is similar enough to human disease 
that the same WHO criteria are used for classification, and a regimen of 
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is 
used as first-line induction therapy for both species. B cell non-Hodgkin’s lymphoma, the 
predominant type in both canines and humans, shares genetic similarities as well across 
species: divergence into activated B cell and germinal center B cell subtypes, NFκB and 
BCR signaling pathway activations, and IgH locus mutational activity, among others 
(Modiano et al., 2007; Richards et al., 2013). B cell lymphoma is an attractive target 
disease since it occupies the transitional space between leukemias, for which CAR T cell 
therapy has been largely successful, and other non-hematological solid tumors, where 
CAR T cell therapy has struggled to achieve lasting remissions. Canine cancer, 
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particularly B cell lymphoma, is an excellent model for human disease, and therefore an 
excellent candidate for modeling for cancer immunotherapy as well. 
Canines have a long history of being used as animal models for humans even outside of 
cancer immunotherapy. Beagles have been a popular breed to assess drug toxicology ever 
since the FDA required proof of safety from drug manufacturers in the early 1960s. 
Within the cancer field, the very first attempt at cell-based therapy – bone marrow 
transplantation for the treatment of leukemia – was grounded in work done by E. Donnall 
Thomas and Rainer Storb ranging back into the late 1950s performing transfers among 
canine littermates (Ferrebee et al., 1958; Storb et al., 1967). This work in canines formed 
a large part of the basis for pre-conditioning regimens of chemotherapy and irradiation, 
mechanisms of GVHD and GVL, and transplant biology in humans. 
More recent immunomodulatory cancer therapies, such as STAT3 signaling inhibitors 
and vaccination with tumor antigen-expressing Listeria, are also being tested in dogs with 
spontaneous malignancies as a model for human diseases (Couto et al., 2012; Mason et 
al., 2016). Infusion of ex vivo expanded autologous T cells back into canine B cell 
lymphoma patients has also been attempted (O'Connor et al., 2012). 
The use of canine patients as a pre-clinical model for cancer immunotherapy has gained 
increasing interest and support in recent years, from experts in both the human CAR T 
cell and veterinary immunotherapy fields, as well as the Institute of Medicine’s National 
Cancer Policy Forum (Kalos and June, 2013; Mata et al., 2014; National Cancer Policy et 
al., 2015). 
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Rationale and Structure of this Thesis 
CAR T cell therapy is a living drug – it reproduces, metabolizes, adapts, differentiates, 
engrafts, kills, and dies. The true test of its risks and benefits, its limitations and potential, 
is in action in a system as complex and realistic as the challenge it will eventually face 
inside humans. Canine patients, which spontaneously develop malignancies similar to 
ours in genetics, pathology, treatment, and outcomes, are the closest model we have to 
human cancer patients. The development of CAR T cell therapy for canine patients will 
allow more accurate and predictive testing of the next generation of CAR T cell 
therapies, which in turn will lead to safer and more efficacious treatment of both humans 
and their millennia-long companions. 
This thesis is structured into six parts. This first chapter has provided the background and 
rationale for this thesis. The second chapter focuses on efforts to make treating canine 
patients with lymphoma feasible. This involves the development of early-stage methods 
and reagents to grow canine T cells ex vivo and their characterization, the validation of 
mRNA electroporation as a strategy for efficiently genetically modifying primary canine 
T cells to express a CAR, in vitro testing of canine B cell-targeting CAR constructs, and 
concludes with the first-ever use of CAR T cells to treat a canine patient in a veterinary 
clinical trial and the observations gained from this. The third chapter focuses on the 
development of methods to permanently express a second-generation CD28-containing 
CAR construct gene in primary canine T cells through transduction with lentivirus, and 
clinical and immunological observations from four canine B cell lymphoma patients 
treated with this therapy. The fourth chapter focuses on following up on these findings in 
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the patients to develop improvements at each step in the production process to make CAR 
T cell therapy in canine patients more effective. This involves modifications to the 
culture system and the CAR construct itself to enhance growth and the formation of 
memory cells, and tracking clinical and immunological outcomes in a canine lymphoma 
patient treated with CAR T cells grown in these conditions and expressing a 4-1BB-
containing construct. The fifth chapter consists of a discussion of the work and its 
broader implications in the context of the field, as well as suggestions for future 
directions. This is followed by a chapter describing the materials and methods designed 
and used in these experiments and studies, as well as a bibliography of the cited 
references throughout the thesis. 
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CHAPTER 2: Establishing the Feasibility of CD20-Targeted CAR T Cell Therapy 
in Canine Patients with Spontaneous B Cell Lymphoma 
 
Abstract 
While murine models are widely used for CAR T cell therapy, they are inadequate in 
modeling the complexities of human disease and in predicting safety and efficacy. 
Therefore, we set out to develop a full-cycle system – from initial blood collection to 
patient infusion and monitoring – to evaluate CAR T cell therapies in canines with 
spontaneous malignancies. First, we developed physiological methods to expand primary 
canine T cells ex vivo to a clinically relevant scale. Then, we expressed a functional first-
generation canine CD20-targeting CAR construct transiently. Finally, we treated a canine 
patient with relapsed B cell lymphoma to demonstrate safety and beginning-to-end 
feasibility. These methods and findings lay the groundwork for future studies that use a 
permanently expressed second-generation CAR construct, as described in Chapter 3. 
 
Introduction 
CAR T cell therapy has demonstrated extraordinary success against particular 
hematological cancers, especially B cell leukemias (Grupp et al., 2013; June, 2014; Porter 
et al., 2015; Porter et al., 2011). However, its advances have been largely limited in solid 
tumors. One reason is that there is a paucity of tumor-associated antigens that are both 
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safe and effective beyond the B cell field. While CD19 is expressed on both malignant 
and healthy B cells, B cell aplasia is considered an acceptable organ toxicity and can be 
mitigated by intravenous immunoglobulin infusions into patients. This stands in contrast 
to unintended pulmonary damage from Her2-targeting which can be lethal  (Morgan et 
al., 2010). Another is that the tumor microenvironment is suppressive in a way that 
circulating malignant cells are not, and CAR T cells can be suppressed and become 
hypofunctional in these solid tumors (Beatty et al., 2014; Caruana et al., 2015; Chen et 
al., 2013; Lo et al., 2015; Moon et al., 2014; Textor et al., 2014). Other factors have 
hindered progress, such as the development of antibodies against the murine scFv of the 
CAR, or poor expansion of patient T cells ex vivo to make a product or in vivo after 
infusion (Fraietta et al., 2016; Maus et al., 2013; Porter et al., 2015). Even in the best case 
scenarios, where CD19 CAR T cell therapy has led to complete remissions, CRS and 
unexplained neurotoxicity remain concerning (Grupp, 2016; Kalos et al., 2011; Porter et 
al., 2011). None of these issues were predicted in the mouse models of CAR T cell 
therapy, relying on immunodeficient mice transplanted with xenograft tumors, nor could 
they have addressed them. Targeting human antigens on human tumors inside a host 
mouse will not demonstrate off-site toxicity, as there is no normal tissue distribution of 
human antigens within the mouse (Lamers et al., 2013; Linette et al., 2013; Morgan et al., 
2013; Morgan et al., 2010). Immunodeficient mice will not generate antibodies against 
murine components of the CAR, nor will they respond to human cytokines produced 
from human CAR T cells for observation of CRS. 
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New generations of CAR T cell therapies are in the process of in vitro and preclinical 
testing in the same mouse models that have failed to predict safety and efficacy before. 
Rheostatic recognition of antigen levels, ectopic production of pro-inflammatory and 
proliferative cytokines as well as chemokine receptors to aid trafficking to the tumor site, 
switch receptors to convert suppressive signals into activating ones, suicide genes as a 
safety switch, and TCR and MHC ablation for allogeneic therapy are but a few options 
currently being explored (Ankri et al., 2013; Di Stasi et al., 2009; Fedorov et al., 2013; 
Hoyos et al., 2010; Lanitis et al., 2013; Straathof et al., 2005). However, in order for 
preclinical testing to have any predictive value, it needs to be done in an animal model 
that has spontaneous, naturally-occurring malignancies with significant similarities to 
human disease. Canines are a well-established model for human cancers, especially B cell 
lymphoma (Breen and Modiano, 2008; Ito et al., 2014; Marconato et al., 2013; Schiffman 
and Breen, 2015). Therefore, we believed that they would make an excellent model for 
CAR T cell therapy as well. 
In order to make modeling CAR T cell therapy in dogs feasible, we would need to 
establish methods for growing primary canine T cells ex vivo to a large scale, design and 
validate a CAR construct that targets a canine tumor-associated antigen, genetically 
modify primary canine T cells to successfully express this CAR construct, and 
demonstrate that these canine CAR T cells have antigen-specific function. For each of 
these requirements, we sought as best we could to parallel the standards used in human 
clinical trials at the time, generating and adapting reagents and protocols as necessary due 
to the limited resources and knowledge available for canine T cell immunology. At the 
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end of this chapter, we provide the treatment of a canine patient with relapsed B cell 
lymphoma with autologous CAR T cells as a proof-of-concept. 
 
Results 
Expansion of Primary Canine T Cells using Stimulation through CD3 & CD28 
At the time of this work, use of the mitogenic lectins phytohemaglutinin and 
concanavalin A (ConA) or plate-bound agonistic anti-canine CD3 antibody were standard 
methodology for the short-term stimulation of canine lymphocytes in vitro (Graves et al., 
2011; Kato et al., 2007). As robust expansion of these cells is necessary for eventual 
clinical applications, we turned to methods that are used for human T cell adoptive 
immunotherapy. Expansion of human T cells has been achieved ex vivo using a 
combination of CD3 and CD28 stimulation, using agonistic antibodies against them 
conjugated to beads or loaded onto K562 cells expressing CD32/CD64 (Levine et al., 
1997; Levine et al., 1998; Maus et al., 2002; Suhoski et al., 2007). Therefore, we 
evaluated different expansion methods to determine if this combination of signals would 
elicit robust activation and proliferation of primary canine T cells. Freshly isolated, 
CFSE-labeled canine peripheral blood mononuclear cells (PBMCs) from healthy donors 
were stimulated with ConA alone (ConA), beads conjugated with agonistic anti-canine 
CD3 and anti-canine CD28 antibodies (Beads), or anti-canine CD3 antibody-loaded 
K562 cells transduced to express human CD32 and canine CD86 (artificial antigen 
presenting cell (aAPC) stimulation), or left unstimulated as a control. All three stimuli 
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induced lymphocyte division within 6 days of culture, but aAPC stimulation resulted in 
the greatest T cell division (Figure 2.1a) and cell expansion (5.8 ± 1.0-fold) compared 
with Beads (1.7 ± 0.8-fold) and ConA (0.4 ± 0.2-fold) (Figure 2.1b,c). Additionally, cells 
from all donors expanded in response to aAPCs, despite the inability of half the donor 
PBMCs to expand in response to Beads (Figure 2.1a, bottom, and Figure 2.1c), 
demonstrating that aAPCs consistently support largest expansion of primary canine T 
cells ex vivo. 
 
Supplementation with rhIL-2 & rhIL-21 Enhances Canine T Cell Expansion 
The addition of recombinant human IL-2 (rhIL-2) and IL-21 (rhIL-21) enhances human T 
cell proliferation and preferentially expands the CD8+ subset, respectively (Bucher et al., 
2009). Additional evidence from a contemporary publication suggested a similar effect 
for rhIL-21 on primary canine T cells (O'Connor et al., 2012). In order to determine the 
effects of these cytokines on ex vivo canine T cell expansion in our aAPC system, we 
stimulated enriched peripheral blood lymphocytes (PBLs) from healthy dogs with aAPCs 
in the presence of rhIL-2 and rhIL-21. Addition of rhIL-2, alone or in combination with 
rhIL-21, resulted in a dramatic increase in T cell expansion 2 weeks after stimulation 
(31.0 ± 4.0-fold for no cytokines, 229.1 ± 31.2-fold for rhIL-2, 41.4 ± 3.6-fold for no 
rhIL-21, 212.8 ± 39.1-fold for rhIL-2 + rhIL-21; Figure 2.2a). Quantitative reverse 
transcriptase-polymerase chain reaction (qRT-PCR) showed that expression of granzyme 
B was increased in cultures receiving rhIL-21, either alone or in combination with rhIL-2 
(0.5 ± 0.2-fold for rhIL-2, 17.9 ± 9.8-fold for rhIL-21, 6.0 ± 1.0-fold for rhIL-2 + rhIL-
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21, compared to no cytokines; Figure 2.2b). Flow cytometric analysis showed that, while 
all conditions resulted in an increase in CD8+ frequency and decrease in CD4+ frequency 
compared with baseline, this increase this increase in CD8+ frequency was greatest in 
cultures containing rhIL-21 (Figure 2.2c). 
 
Characterization of ex vivo Expanded Canine T Cell Product 
Having developed a method to expand a suitable number of primary canine T cells for 
transfer in vivo, we then set out characterize the population shift that occurs from initial 
PBL culture to final cell product two weeks later. We stimulated PBLs from five healthy 
canine donors using anti-canine CD3 antibody-loaded aAPCs and supplemented with 
rhIL-2 and rhIL-21. Characterization of peripheral T subsets in enriched PBLs from five 
healthy dogs at baseline revealed ~2:1 ratio of CD4:CD8 T cells (Figure 2.3a). At the end 
of the stimulation timecourse 14-15 days later, this ratio was reversed and a 
predominance of CD8+ T cells was observed among the five healthy donors (Figure 
2.3b). Additionally, the T cells contained a population of CD4+CD8+ double-positive 
cells (Figure 2.3b), a subset that has been reported to appear in highly activated CD4 and 
CD8 single positive populations (Bismarck et al., 2012). At baseline, CD79a+ B cells 
represented ~40% of CD4-CD8- live lymphocytes (Figure 2.3c, left panel) and 10.6 ± 
5.9% of live total lymphocytes (Figure 2.3c, right panel). At the end of culture, most B 
cells and human CD45+ aAPCs were no longer detectable (Figure 2.3d). Canine T cells 
from enriched PBLs could be expanded ~100-fold (Figure 2.3e, left), with an average of 
6.6 population doublings over 14 days (Figure 2.3e, right). Together, these data suggest 
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that the use of aAPCs loaded with anti-canine CD3 plus rhIL-2 and rhIL-21 drives robust 
expansion of canine peripheral blood T cells, especially the CD8+ subset, to sufficient 
numbers required for autologous T cell therapy. 
 
Expanded Primary Canine T Cells Transiently Express cCD20-Specific CAR Following 
mRNA Electroporation 
The majority of human CAR T cell therapy success has been in the field of B cell 
malignancies, targeting the pan-B cell antigen CD19. There is no commercially available 
validated anti-canine CD19 antibody. Four anti-human CD19 scFvs were tested for cross-
reactivity by cloning them into CAR constructs that were then expressed in human T 
cells; these human CAR T cells were challenged with canine CD19-expressing CLBL-1 
cells or human CD19-expressing K562 cells in a cytotoxicity assay. While activity 
against human CD19 was confirmed, none of the four constructs showed specific activity 
compared to non-transduced human T cells against canine CD19-expressing CLBL-1 
cells (Figure 2.4). The B cell antigen CD20 is expressed on all canine B cell lymphomas 
in published reports (Ito et al., 2015; Nadler et al., 1981). Using a scFv against canine 
CD20 (cCD20), we designed first-generation CAR constructs using a human CD3ζ 
intracellular signaling domain targeting cCD20 or human CD19 (hCD19) as a negative 
control (Figure 2.5a). We chose human CD3ζ due to its long history of validation and use 
in the CAR field, and with the expectation that it would signal in canine T cells due to 
84% protein identity within the intracellular domain. These constructs were cloned into 
RNA vectors; electroporation of CAR-encoding mRNA has led to highly efficient 
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expression in primary human T cells, and would bypass any species-specific barrier for 
retroviral or lentiviral transduction at the steps of viral entry, post-entry processing, 
genomic integration, and host cell transcription. Additionally, mRNA electroporation 
leads to transient expression in humans, creating a built-in safety mechanism when 
moving into first-in-canine in vivo studies (Schutsky et al., 2015; Zhao et al., 2010). We 
chose a first-generation CAR design since many of the benefits of second-generation 
constructs – enhanced proliferation, cytokine production, in vivo persistence – are moot 
in the scenario where daughter cells no longer express the CAR. 
To optimize mRNA electroporation of primary canine T cells, ex vivo expanded T cells 
were electroporated with various voltages, pulse lengths, and amounts of mRNA (Figure 
2.5b-d). The greatest transfection efficiency and viability was achieved using 500 volts 
(Figure 2.5b). Longer pulse duration led to reduced viability without a dramatic increase 
in CAR surface expression (Figure 2.5c). The highest transfection efficiency was 
achieved using 2 μg CAR mRNA/106 T cells (Figure 2.5d); however, the minor increase 
in CAR surface expression compared with 1 μg CAR mRNA/106 T cells did not justify 
doubling the amount of mRNA used for large scale CAR T cell production. 
The cCD20-ζ CAR was highly expressed on the surface of both canine CD4+ and CD8+ 
T cells 24 hours post-electroporation (Figure 2.6a). We observed a gradual reduction in 
both cCD19-ζ and cCD20-ζ CAR frequency (Figure 2.6b,c) over 14 days, confirming 
transient surface expression of the CAR by T cells after electroporation. Although 
transient, high frequency of cCD20-ζ CAR expression were consistently observed in 
expanded T cells from multiple canine donors 24 hours post-electroporation (Figure 
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2.6d). We did consistently observe that the loss of surface expression of the CD19-CAR 
was more rapid than that of the cCD20-CAR, suggesting that this finding is construct-
dependent. Given that there was no measureable difference in mRNA quality between the 
two constructs (260nm/280nm spectrophotometer readings of 2.20 and 2.22, and 
260nm/230nm spectrophotometer readings of 2.46 and 2.36 for hCD19-CAR and cCD20-
CAR mRNA, respectively, and Figure 2.7), we hypothesize that the hCD19-CAR mRNA 
is less efficiently translated, more rapidly degraded, or of an inferior quality that has not 
been detected by standard methods. 
 
Primary Canine CAR T Cells Demonstrate Potent Effector Function in vitro 
Our next step was to determine if canine T cells transiently redirected with CAR mRNA 
possess antigen-specific, CAR-mediated effector functions against cCD20+ targets. First, 
we validated surface cCD20 expression on the target cell lines. Murine 3T3 and human 
K562 cells engineered to express cCD20 (3T3.cCD20 and K562.cCD20, respectively), 
but not their parental cell lines, specifically expressed cCD20 (Figure 2.8a). The canine 
malignant B cell lines GL-1 and 17–71 do not express cCD20 (Figure 2.8b). However, 
CLBL-1, a canine B cell lymphoma line, showed high level surface expression of cCD20 
antigen (Figure 2.8b), beyond that of generated target cell lines. To determine antigen-
specific cytokine production, we next co-cultured target cells with cCD20-ζ or hCD19-ζ 
CAR T cells 24 hours after electroporation with mRNA CAR vectors (Figure 2.8c,d). 
cCD20-ζ CAR T cells specifically secreted IFNγ in response cCD20+, but not cCD20-, 
cell targets. Control hCD19-ζ CAR T cells did not produce IFNγ in response to the 
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cCD20+ cell lines, but specifically recognized the hCD19+ target cell line, K562.hCD19 
(Figure 2.8c). As effective T cell-mediated anti-tumor activity is dependent upon 
cytotoxic T cell function, canine CAR T cells were evaluated for antigen-specific 
cytolytic activity. hCD19-ζ CAR T cells specifically lysed the BxPC-3.hCD19 human 
cell line (Figure 2.8d). cCD20-ζ CAR T cells demonstrated antigen-specific lysis of 
cCD20+ 3T3.cCD20 and CLBL-1 cell lines, but not of cCD20- 3T3 or GL-1 cell lines 
(Figure 2.8d). Together, these results demonstrate that canine CAR T cells exhibit CAR-
mediated, antigen-specific IFNγ production and cytolytic activity. 
 
Feasibility of CAR T Cell Production from a Canine Cancer Patient for in vivo 
therapeutic use 
Having shown high-efficiency transfection and CAR-mediated effector function of 
cCD20-ζ CAR T cells generated from healthy dogs in vitro, we investigated the 
feasibility of CAR T cell production for therapeutic use in a privately-owned dog with 
relapsed spontaneous B cell lymphoma. Patient 434-001 presented with relapsed B cell 
lymphoma 1 month after finishing CHOP-based chemotherapy for the treatment of stage 
IIIa, multicentric lymphoma. At relapse, the dog was treated with a single dose of L-
asparaginase and referred for CAR T cell therapy. At initial presentation, the dog was 
asymptomatic and clinical disease was limited to mild, bilateral submandibular 
lymphadenopathy. Routine bloodwork showed no significant abnormalities. Flow 
cytometry indicated that only 6% of leukocytes within the therapy target node were 
CD79a+cCD20+ B cells (Figure 2.9a, left). After 2 weeks, 1 day prior to the first T cell 
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infusion, the submandibular lymph nodes had enlarged, and cytology confirmed the 
return of an aggressive B cell lymphoma (data not shown). Flow cytometry revealed that 
86% of the cells in the therapy target node were now CD79a+cCD20+ B cells (Figure 
2.9a, right). 
Starting at day -16 relative to first T cell infusion, three peripheral blood collections were 
drawn a week apart to generate three separate infusion products (Figure 2.10). PBLs 
consisted of a normal 2:1 ratio of CD4:CD8 T cells at baseline (Figure 2.9b, left). 
Following aAPC stimulation, expanded cell products contained a predominance of CD8+ 
cells (Figure 2.9b, right), and underwent between 5 and 7 population doublings, 
providing ~10
9
 cells per infusion product (Figure 2.9c). Overall, PBL preparations 
underwent 34-, 162-, and 120-fold expansions for infusion products #1, #2, and #3, 
respectively (Figure 2.9d). 
At day 14 post-stimulation, expanded canine patient T cells were electroporated with 
cCD20-ζ CAR mRNA, resulting in ~90% surface expression of CAR in both CD4+ and 
CD8+ T cells (Figure 2.11a). Parallel electroporations with hCD19-ζ and cCD20-ζ CAR 
vectors were also performed to evaluate the duration of CAR expression and antigen-
specific effector function of T cells expanded from this lymphoma patient in vitro. Both 
hCD19-ζ and cCD20-ζ CARs were highly expressed (>90%) 24 hours post-
electroporation, and their surface expression gradually decreased over 14 days (Figure 
2.11b,c). We also performed CAR-mediated cytokine production and cytolytic assays to 
determine the functional capacity of the redirected T cells. Patient cCD20-ζ CAR T cells 
co-cultured with target cells secreted IFNγ in response to all cCD20+ cell lines, (Figure 
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2.11d). Minimal or no IFNγ was secreted in response to cell lines that did not express 
cCD20. hCD19-ζ CAR T cells specifically produced IFNγ in response to hCD19+ 
targets, and did not recognize hCD19- cell lines. Similarly, patient cCD20-ζ CAR T cells 
demonstrated antigen-specific lysis of cCD20+ target cells, but not of cCD20- target cells 
(Figure 2.11e). Together, these data indicate that large numbers of functional, cytolytic 
CAR T cells can be derived from canine patients with spontaneous lymphoma. 
 
Assessment of Clinical Efficacy of mRNA CAR Treatment in a Canine Cancer Patient 
Patient 434-001 received a total of three infusions of cCD20-ζ CAR T cells at weekly 
intervals (Figure 2.10). Infusions #1 and #2 were administered intravenously (IV), and 
infusion #3 was split between IV and intranodal (IN) injection. No overt, serious adverse 
effects of treatment were observed. Following the third infusion, the dog developed a 
mild, transient fever that resolved following fluid therapy. Within 72 hours of each 
infusion, the diseased lymph node volume increased and then remained stable until the 
next infusion (Figure 2.12a). Flow cytometric evaluation of the target lymph node at 72 
hours after each infusion revealed a modest reduction in CD79a+cCD20+ B cells, which 
returned to pre-infusion levels by the next infusion (Figure 2.12b, left). Concomitant with 
the decrease in B cell frequency, an increase in CD5+ T cell frequency was observed 
following each treatment dose in the measured lymph node (Figure 2.12b, right). 
Absolute counts of CD5+ T cells and CD79a+cCD20+ B cells in the peripheral blood 
both increase over the 72 hours after each infusion, with the most drastic increase for 
both subsets occurring after the third infusion (1.95-fold for CD5+ T cells, 4.59-fold for 
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CD79a+cCD20+ B cells, Figure 2.12c). That CD5 excludes canine B cells was validated 
in healthy canine peripheral blood by co-staining with the pan-B cell marker CD79a 
(Figure 2.13), and co-expression has not been found in 19 canine patients with B cell 
malignancies that we have screened to date for clinical trials. Molecular evidence of CAR 
T cell presence in the patient’s peripheral blood was tested for by RT-PCR for the human 
CD3ζ component of the CAR construct, but was not detected (Figure 2.14). 
 
Serum Cytokine and Antibody Production Following CAR T Cell Therapy 
Using cytokine bead array, we observed a 2.63-fold increase in serum levels of IFNγ 24 
hours post-infusion #1, which was the largest single IV dose administered (Figure 2.15a). 
This increase was confirmed by enzyme-linked immunosorbent assay (data not shown). 
Since human clinical investigation with CAR T cell therapy has shown significant 
toxicities associated with increased serum IL-6, we also examined serum IL-6 by 
cytokine bead array (CBA) (Kalos et al., 2011; Porter et al., 2011). Serum IL-6 levels 
increased 1.75-fold and 1.45-fold 24 hours following dose #1 and dose #2, respectively 
(Figure 2.15b). Serum levels of IL-8, IL-10, IL-15, IL-18, and MCP-1 were also 
measured on the CBA panel, and all increased within 24 hours of dose #1 (Figure 2.15c-
g). 
In human clinical trials, patients have developed human anti-mouse immunoglobulin 
antibodies and anaphylaxis upon repeat administration of CAR T cells expressing a 
xenogenic murine scFv (Beatty et al., 2014; Kershaw et al., 2006; Maus et al., 2013). We 
hypothesized that canine anti-mouse immunoglobulin antibodies (CAMA) may also be 
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induced following multiple injections of cCD20-ζ CAR T cells. We found that serum 
CAMA levels were undetectable until the time of infusion #3, and sharply rose over the 
following 72 hours (Figure 2.15h), indicating that, as in humans, dogs develop anti-
mouse immunoglobulin antibodies following repeated exposure to the murine scFv 
expressed on the CAR T cell surface. 
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Figure 2.1. Expansion of canine T cells varies in response to different activation 
stimuli. (a) Proliferation kinetics of CFSE-labeled canine PBMC as determined by flow 
cytometry, gated on lymphocytes. Two representative healthy donors are shown, one per 
row. (b) Enumeration of live cells post-stimulation at each time point indicated. Data 
represent mean ± SEM of four independent canine donors. (c) Calculated fold change of 
total live cells at day 6 post-stimulation. Each symbol represents one of four canine 
donors from independent experiments. Horizontal bars represent the mean. *p < 0.05 as 
measured by Dunn's multiple comparison test following one-way analysis of variance 
(ANOVA). 
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Figure 2.2. Supplementation with rhIL-2 & rhIL-21 enhances canine T cell expansion. 
Enriched PBL from 3 dogs were stimulated with aAPCs in the presence or absence of 
cytokines. (a) Calculated fold change in 7AAD-, CD5+ T cell number at day 14 post-
stimulation. (b) qRT-PCR analysis of canine granzyme B (GZMB) expression at day 14 
post-stimulation. Expression is compared to the no cytokine condition. *p < 0.05 as 
measured by Dunn's multiple comparison test following one-way ANOVA. (c) Flow 
cytometric evaluation of CD4 and CD8 subsets among live T cells (size, 7-AAD-, CD5+) 
at baseline (pre-activation) and 14 days post-stimulation with aAPCs in the presence or 
absence of cytokines. 
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Figure 2.3. Characterization of cellular phenotype and expansion following activation 
with aAPC plus rhIL-2 and rhIL-21. Flow cytometric evaluation of CD4 and CD8 
expression among live lymphocytes in a representative donor and quantified in healthy 
canine donors (a) pre-stimulation (n = 5) and (b) 14–15 days post-stimulation (n = 5). 
Frequencies underneath bar graphs represent mean ± SEM of five healthy canine donors 
from two independent experiments. (c) Flow cytometric evaluation of CD79a expression 
pre-stimulation. Histogram from a representative donor, gated on CD4-CD8- 
lymphocytes (left panel); Quantified values of CD79a+ B cells, gated on live 
lymphocytes (right panel) from four healthy donors. (d) Representative histogram of 
CD79a staining for B cells (left panel) 14 days post-stimulation. Populations are gated on 
live, CD4- and CD8- lymphocytes. Human CD45 staining (right panel) on day 0 (gray 
line) and day 14 (black line) post-stimulation. Populations are gated on live cells. (e) Fold 
change (left panel) and population doublings (right panel) of canine T cells 14 days post-
stimulation from counts of live cells by trypan blue exclusion. Data and number indicated 
represent mean ± SEM of five healthy canine donors. 
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Figure 2.4. Failure of anti-human CD19 scFvs to react to a CD19-expressing canine B 
cell line. Left, PCR of CLBL-1 cDNA on a 1% agarose gel. Lane 1 is a 1kb+ DNA 
ladder, Lane 2 is cDNA amplified for GAPDH, Lane 3 is cDNA amplified for canine 
CD19. Right, specific lysis of CLBL-1 cells by human T cells expressing first-generation 
CARs containing four different anti-human CD19 scFvs, normalized to lysis by 
untransduced human T cells. Data represents technical replicates from one primary 
human donor. Each scFv tested in 2-3 independent experiments using different primary 
human donors. 
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Figure 2.5. Determination of optimal electroporation conditions for canine T cells. (a) 
Schematic of canine CD20 (cCD20) and human CD19 (hCD19) CAR mRNA constructs. 
Cultured canine T cells were electroporated with varying (b) voltages, (c) pulse lengths, 
and (d) amounts of cCD20-ζ CAR mRNA used per 106 canine T cells. Surface CAR 
expression was assessed by flow cytometry 1, 3, 5, and 7 days post-electroporation. 
Viability (7AAD-) was examined by flow cytometry 24 hours post-electroporation. Data 
show a representative canine donor per condition set. 
  
40 
 
 
Figure 2.6. The cCD20-ζ CAR is efficiently and transiently expressed in canine T cells 
after mRNA electroporation. (a) Surface expression of the cCD20-ζ CAR in CD4+ (left 
panel) or CD8+ (right panel) T cells 24 hours post-electroporation. (b) Kinetics of cell 
surface expression of CAR in T cells. (c) Frequencies of hCD19 or cCD20 CAR-
transfected T cells over time. (a-c) Representative healthy donor shown from 3 dogs 
analyzed. Gray histogram indicates cells electroporated with no mRNA, black line 
indicates cells electroporated with CAR mRNA. Populations are gated on live 
lymphocytes. (d) Frequency of cCD20 CAR+ cells 24 hours post-electroporation in nine 
healthy canine donors. Frequencies displayed under graph represent the mean ± SEM. 
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Figure 2.7. Comparison of hCD19-ζ and cCD20-ζ CAR mRNA quality. 2 μg of hCD19-ζ 
RNA (Lane 2) and cCD20-ζ RNA (Lane 3) run on a 1% TAE-Agarose gel alongside a 
1kb+ DNA ladder (Lane 1). Bands run in the vicinity of ~850bp DNA ladder band. 
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Figure 2.8. cCD20-ζ CAR T cells secrete IFNγ and lyse target cells in an antigen-specific 
manner. (a-b) Expression of cCD20 on the surface of (a) murine and human or (b) canine 
target cell lines. Anti-cCD20 mAb staining (open histograms) overlaid with isotype 
control (gray, filled histograms) as assessed by flow cytometry. Numbers in the right, 
upper corner represent signal-to-noise ratios, which were calculated using the median 
fluorescence intensity (MFI) of anti-cCD20 antibody binding versus isotype control. (c) 
Canine T cells electroporated with hCD19-ζ CAR, cCD20-ζ CAR, or no mRNA were co-
cultured with the indicated cell lines at a 1:1 effector to target (E:T) ratio. After 24 hours, 
IFNγ was quantified by ELISA. Data represent mean ± SEM of two healthy canine 
donors from independent experiments. (d) Canine T cells electroporated with hCD19-ζ 
CAR or cCD20-ζ CAR RNA were cultured with chromium-labeled tumor cell lines at a 
10:1 E:T ratio. Specific lysis was calculated after 4 hours. Data is normalized to lysis of 
target cells when cultured with T cells electroporated with no RNA. Error bars represent 
mean ± SEM of sextuplicate wells from three healthy canine donors. 
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Figure 2.9. Generation of CAR T cell product for a canine B cell lymphoma patient. (a) 
Flow cytometric evaluation of B cell frequency (CD79a) and cCD20 expression among 
live lymphocytes in the target lymph node 16 days prior and 1 day prior to treatment. (b) 
Flow cytometric evaluation of CD4 and CD8 populations among hCD45-, live 
lymphocytes in enriched PBLs prior to stimulation (Day-15) and one day prior to 
infusion (Day-1) for product #1. (c-d) Growth kinetics of all three infusion products. 
Enumeration of live, canine T cells by trypan blue exclusion. (c) Fold change and (d) 
population doublings over time post-stimulation. Number on graph indicates mean of 
three infusions products for Patient 434-001. 
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Figure 2.10. Timeline of patient treatment. Diagram depicting the PBMC isolation (Iso.), 
enriched PBL stimulation (Stim.), electroporation (Electro.), infusion, and post-infusion 
sample collections (hr, hour) of each dose used to treat Patient 434-001. 
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Figure 2.11. The cCD20-ζ CAR is expressed and functional in canine patient T cells after 
mRNA electroporation. (a) cCD20-ζ CAR expression among CD4+ and CD8+ T cells 24 
hours after electroporation with cCD20-ζ CAR mRNA (empty histograms) or no mRNA 
(filled gray histograms). Populations are gated on live lymphocytes. (b) Kinetics of the 
expression of CAR on the cell surface of canine T cells following electroporation. (c) 
MFI of CAR expression on the cell surface at the time points indicated post-
electroporation. (d) 24 hours after electroporation, patient T cells were co-cultured with 
the indicated cell lines at a 1:1 effector to target (E:T) ratio. IFNγ in 24 hour supernatants 
was quantified by ELISA. Bar graphs represent mean ± SEM. (e) 24 hours after 
electroporation with cCD20-ζ CAR mRNA or no mRNA, patient T cells were cultured 
with chromium-labeled target cell lines at a 10:1 E:T ratio. Specific lysis was calculated 
after 4 hours. Data is normalized to lysis of target cells when cultured with T cells 
electroporated with no mRNA. Data represents mean ± SEM of sextuplicate wells. 
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Figure 2.12. Effects of RNA CAR treatment in a canine B cell lymphoma patient. (a) 
Volume of the target lymph node (LN), as calculated from ultrasound measurements. 
Arrows indicate the time of CAR T cell infusions. (b) Flow cytometric evaluation of LN 
aspirates enumerating the frequency of CD79a+cCD20+ cells (left panel) and CD5+ cells 
(right panel) among live lymphocytes pre-infusion and 72 hours post-CAR T cell 
infusion. (c) Absolute numbers of CD5+ (red line, left axis) and CD79a+CD20+ (blue 
line, right axis) cells in the peripheral blood as calculated from flow cytometry analysis 
and clinical complete blood count (CBC), arrows indicate the time of CAR T cell 
infusions. 
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Figure 2.13. CD5 does not label canine B cells. Representative flow staining of CD79a 
and CD5 of live lymphocytes from the PBMCs of a healthy donor and a B cell lymphoma 
patient. 
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Figure 2.14. RT-PCR of cCD20-ζ CAR from Patient 434-001 samples. PCR amplifying 
the CAR from cDNA of PBMCs and lymph node aspirate cells (prescapular and 
popliteal) taken from Patient 434-001 following each infusion, run out an agarose gel 
alongside 1 kb+ DNA ladder. Arrows represent expected product size, - represents 
negative control (water), + represents positive control (CAR plasmid template). 
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Figure 2.15. Serum levels of cytokine and anti-CAR antibodies in Patient 434-001. (a-g) 
Serum levels of (a) IFNγ, (b) IL-6, (c) IL-8, (d) IL-10, (e) IL-15, (f) IL-18, and (g) MCP-
1 at the indicated time points for each infusion as measured by cytokine bead array 
(CBA). Data represents mean of duplicate tests. (h) Serum levels of canine anti-mouse 
antibody (CAMA) at the indicated time points as measured by enzyme-linked 
immunosorbent assay (ELISA). Data represent means of duplicates for CBA, mean ± 
SEM of triplicate wells for CAMA. Dotted line represents the lower limit of detection 
(LLOD) for each assay. 
  
51 
 
Discussion 
Adapting methods from work performed previously or concurrently by others, we 
generated a robust, physiological system for expanding primary canine T cells ex vivo to 
a clinically relevant scale (Mata et al., 2014; O'Connor et al., 2012). Using aAPCs 
modified to express a co-stimulatory ligand and loaded with agonistic anti-canine CD3 
antibody along with rhIL-2 and rhIL-21 supplementation, our system provided the 
classical three signals for successful T cell activation and achieved an average of 213 ± 
39-fold expansion of canine T cells from the peripheral blood in 14 days – the largest 
reported expansion for a single-stimulation protocol at the time (Mata et al., 2014; 
O'Connor et al., 2012). 
This aAPC expansion protocol is successful enough to have grown three infusion 
products for Patient 434-001, who had undergone two relapses. This is particularly 
interesting in light of our expansion data in response to Beads, where there is a stark 
bimodal response where some healthy donors do not expand. The Beads are a 
reductionist system, providing only CD3 and CD28 signals, suggesting that there is a 
population or phenotype of canine T cells that are resistant to these stimuli alone and 
require additional support from factors that the aAPCs provide; in fact, this may be an 
issue across species, as potential subjects for human CAR T cells therapy are excluded 
because their T cells do not expand ex vivo in response to anti-human CD3/CD28 beads 
(Fraietta et al., 2016; Porter et al., 2015). Challenges in expanding T cells from 
lymphoma patients, and potential contributions from aAPCs are explored further in 
Chapter 4. 
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CAR expression by mRNA in primary canine T cells was highly efficient, functional, and 
transient, much like has been found in humans (Schutsky et al., 2015). Despite robust 
effector activity against canine cCD20+ B cell lymphoma cells ex vivo, we observed 
modest, transient anti-tumor effects after adoptive cell transfer of three doses of mRNA 
cCD20-ζ CAR T cell therapy in Patient 434-001. We observed growth of a target lymph 
node immediately following each intravenous CAR T cell infusion, associated with a 
decrease in cCD20+ B cell frequency and increase in T cell frequency. These data 
support the hypothesis that infiltrating CAR+ T cells partially account for the initial 
growth of the lymph node, potentially reducing the cCD20+ B cells in the 72 hours post-
infusion. Still, the transient nature of mRNA-based CAR expression may explain the 
rebound effect seen prior to infusion of dose #2 and #3. The absence of CAR gene 
expression in the peripheral blood by RT-PCR is unsurprising. Most template mRNA is 
expected to degrade within the cells within 24 hours, and infusions were performed the 
day following electroporation; the remaining CAR gene template, distributed among the 
infused cells, would be diluted in the large circulating blood volume present in a 50 kg 
patient infused with a relatively small number, 54-240 x 10
6
, of redirected T cells. 
Despite cCD20-specific cytokine production and cytotoxicity by cCD20-specific CAR T 
cells in vitro, it is possible that the transient, in vivo effects seen here were independent of 
CAR activity. Systemic infusion of autologous, polyclonal, activated T cells following 
successful CHOP based chemotherapy has previously been shown to prolong 
progression-free survival and overall survival in a small group of dogs, an effect that 
might be associated with nonspecific immune activation, such as enhanced CD40-CD40L 
interaction (O'Connor et al., 2012). Additionally, the concurrent increase in peripheral 
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blood B and T cells in the 72 hours following each infusion is interesting. The increase in 
T cells can be explained by the infusion products, but the increase in B cells could have 
several origins. One possibility is that the frequency of B cells in the lymph nodes 
decreased because they entered into circulation, perhaps in reaction to inflammation in 
the lymph nodes caused by CAR T cell activity. Another possible explanation is that 
these infused, activated T cells were supporting B cell expansion through CD40L 
presentation after CAR expression had disappeared; however, the kinetics of the 
peripheral blood B cell increase and decrease is the opposite of what one would expect in 
this scenario, as the B cell population in the blood decreases when the CAR is expected 
to no longer be present. 
The most striking consequence of CAR T cell therapy in this patient was the development 
of CAMA after the second infusion, much like has been seen in humans and 
understandably unobserved so far in mouse models (Kershaw et al., 2006; Maus et al., 
2013). The recapitulation of this effect across species emphasizes the need to make CARs 
less immunogenic in their host, through the use of humanized or caninized scFvs. Of 
additional note is that, while human CD19-targeting CAR therapy avoids HAMA due to a 
combination of lymphodepleting pre-conditioning and the ablation of B cell populations 
in the host as a consequence of therapy, this canine patient developed CAMA despite also 
receiving B cell targeting therapy. This suggests that B cells are able to mount a 
counterattack if they survive, and that anything short of complete response may 
eventually lose its gains. 
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While sustained anti-tumor effect such as through a stably expressed CAR may be 
necessary for significant tumor regression, the transience of mRNA CARs provides a 
critical built-in safety switch and makes the platform an attractive exploratory tool 
(Beatty et al., 2014; Zhao et al., 2010). With intentionally short-lived CAR expression, 
we are now able to preliminarily screen therapies for safety in “first-in-dog” trials 
targeting tumor-associated antigens that may also be expressed on normal host tissues. 
Candidate antigens deemed safe through our mRNA CAR platform could then be 
examined in stably-expressed CAR systems to assess long-term efficacy. Similarly, 
mRNA CARs could be used as a short-term, but potent pre-conditioning method to 
modulate the tumor microenvironment and potentiate stably-expressed CAR efficacy (Lo 
et al., 2015).  
Having demonstrated the feasibility of generating canine CAR T cell therapy at each step 
– developing methods to expand primary canine T cells ex vivo, genetically modifying 
them with CAR-encoding mRNA, demonstrating robust in vitro function of canine CAR 
T cells, and treating a canine cancer patient with autologous CAR T cells (Figure 2.16) – 
our next goal was to stably express a second-generation CAR in primary canine T cells 
and demonstrate efficacy. The efforts to undertake these steps are described in Chapter 3. 
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Figure 2.16. Translation of human CAR T cell therapy into canines. Diagram 
summarizing the adaptation of key steps in CAR T cell therapy for use in canine patients. 
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CHAPTER 3: Development of Permanently-Expressing cCD20-8-28-ζ Canine CAR 
T Cells and Their Effects in vivo 
 
Abstract 
In order to achieve long-term tumor control and elimination, the anti-tumor agent must 
continue to be present and active within the host. Success in human CAR T cell therapy 
has been through the use of permanently-expressed second-generation CAR constructs, 
which provide intrinsic co-stimulation and pass on the CAR gene to daughter cells, 
endowing them with the same tumor-specificity. To parallel this, we generated a cCD20-
8-28-ζ canine CAR construct and successfully expressed it in primary canine T cells 
using lentivirus in vitro. These CAR T cells lysed and proliferated in an antigen-specific 
manner. To determine the effects of this permanently-expressing CAR T cells in vivo, we 
treated four canine patients with relapsed or refractory spontaneous B cell lymphoma. We 
observed evidence of temporary local tumor control and stable disease in these patients, 
and indications that T cell health may be a major factor in CAR T cell therapy efficacy. 
Both of these findings parallel those in human patients, and form the foundations for 
exploring ways improve canine T cell quality in Chapter 4. 
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Introduction 
In Chapter 2, we successfully redirected primary canine T cells with a CAR to target and 
eliminate cCD20-expressing target cells, including canine B cell lymphoma cells, and 
treated a canine patient as a proof-of-concept. Effects were transient, reflecting the nature 
of mRNA electroporation-mediated redirection, but also demonstrated that there was no 
overt toxicity as a result of targeting canine CD20 in a fully autologous system. Durable 
tumor control requires long-term expression of the tumor-specific agent – the CAR. To 
that end, we undertook steps to permanently express the CAR in primary canine T cells. 
The use of gammaretroviruses and lentiviruses for gene transfer has been explored in 
canine hematopoietic stem cells, especially in naturally-occurring models of canine X-
linked severe combined immunodeficiency (Felsburg et al., 2015; Kennedy et al., 2011). 
Concerns about potential oncogenic insertion in the human field are paralleled in dogs. In 
fact, use of gammaretrovirus to restore the common gamma chain in dogs has been 
implicated in the development of a thymoma in one of the experimental subjects 
(Kennedy et al., 2011). However, the use of retroviruses in hematopoietic stem cells, 
where many proto-oncogenes are active and susceptible to integration, is different than in 
mature cells, and gammaretroviruses have had a safer history in human CAR T cell trials 
and in one in vitro publication transducing primary canine T cells with a CAR (Mata et 
al., 2014; Scholler et al., 2012). Nevertheless, the overall greater safety profile of 
lentiviruses and evidence in humans of their prolonged expression in comparison to 
gammaretroviruses led us to pursue this option for permanent transduction and 
expression of a CAR in primary canine T cells for therapy. 
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Taking advantage of observations in basic T cell immunology as well as human CAR T 
cell studies that co-stimulation is necessary for a productive T cell response, we chose to 
use a second-generation CAR construct incorporating intrinsic co-stimulation. Whereas 
the mRNA CAR in Chapter 2 lacked a co-stimulatory domain since CAR expression 
would be lost within days, survival and proliferation of the genetically modified T cells 
are advantageous when the CAR is maintained and passed onto daughter cells. CD28 and 
4-1BB are the co-stimulatory receptors whose intracellular signaling domains are most 
frequently used in human CAR T cell clinical trials. We use a construct including CD28 
in this chapter, and a construct using 4-1BB is described in Chapter 4. 
In order to generate canine CAR T cell therapy with a stably-expressed CAR, we 
determined a method for transducing primary canine T cells with a lentivirus, 
demonstrated that canine CAR T cells selectively expand in response to the target antigen 
ex vivo, and treated four canine B cell lymphoma patients that had either relapsed or were 
refractory to chemotherapy. The observations from each of these four patients form the 
basis for the hypotheses tested in Chapter 4. 
 
 
Results 
EF-1α Promoter Results in Higher Gene Expression than CMV Promoter in Primary 
Canine T Cells Transduced with Lentivirus 
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To maximize the efficiency of genetic modification by lentivirus, we first compared two 
commonly used promoters for human T cells, EF-1α and CMV (cytomegalovirus) 
(Milone et al., 2009). Using a third-generation, self-inactivating lentivirus system where 
the lentivector expressed GFP and only differed in the promoter, we infected Bead-
stimulated PBMCs from four healthy dogs with equal MOI of lentivirus and evaluated 
GFP expression 6 days after stimulation. Expression was modest, but in all four dogs the 
frequency of canine cells expressing GFP was increased after infection with the EF-1α 
promoter compared to the CMV promoter (Figure 3.1a,b, 6.20 ± 0.76% vs 4.33 ± 1.09%, 
respectively). The difference in the level of transgene expression among the transduced 
cells was dramatically increased with the EF-1α promoter compared to the CMV 
promoter (Figure 3.1c, 6053 ± 1343 vs. 686 ±198, respectively). As the EF-1α promoter 
resulted in both a greater frequency of transduced cells as well as higher expression 
among the transduced cells, just as in humans (Milone et al., 2009), we moved forward 
with lentivectors using this promoter to express the CAR construct. 
 
Stimulation with aAPC System Results in Canine T Cell Activation and Elimination of 
aAPCs from Culture 
While lentiviruses have the capability of infecting non-dividing cells, activation of the 
target cell is known to enhance transduction efficiency. We characterized the activation 
kinetics of primary canine T cells in the culture system we established in Chapter 2, using 
aAPCs with agonistic anti-canine CD3 and rhIL-2 and rhIL-21, by measuring 
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upregulation of CD25 on the cell surface. Stimulating enriched PBLs from three healthy 
dogs, CD25 is rapidly upregulated, with 83% of CD5+ cells expressing CD25 1 day post-
culture, and at least 95% expressing CD25 on days 2-4 post-culture (Figure 3.2a). 
VSV-G pseudotyped lentivirus has broad tropism, and this lentivector system has been 
optimized for modifying cells of human origin, such as the aAPCs. To reduce possible 
cellular competition for lentivirus in culture, we measured when the aAPCs are 
eliminated from culture. Enriched PBLs from six healthy dogs over two independent 
experiments were stimulated with the aAPC system, and the aAPCs were largely 
eliminated by day 4 post-culture (Figure 3.2b, 3.63 ± 0.68% remaining). 
The near-complete loss of aAPCs from culture coincides with the continued peak of 
CD25-expressing T cells, so we selected Day 4 post-culture for infection of primary 
canine T cells with lentivirus encoding the CAR construct. 
 
Expression and Function of cCD20-28-ζ CAR in Primary Canine T Cells 
A CAR construct targeting canine CD20 using the same scFv as in Chapter 2 was 
designed, using the following components from N to C terminus: canine CD8α leader, 
murine anti-canine CD20 scfV, canine CD8α hinge, canine CD28 transmembrane and 
intracellular domain, canine CD3ζ intracellular domain (Figure 3.3a,b). This construct 
was inserted into a lentivector under the EF-1α promoter that had been modified from 
earlier experiments to ease cloning, referred to as pELxPS. VSV-G pseuodotyped virus 
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was generated and used to infect enriched PBLs from a healthy dog 4 days post-aAPC 
culture, resulting in 26.4% transduction as measured by surface expression of the CAR 
(Figure 3.3c). 
This construct was functional in a canine lymphoma patient’s T cells, able to lyse targets 
in an antigen-specific manner; CAR T cells from this dog killed over 60% of cCD20+ 
target cells overnight at a 5:1 ratio of T cells to targets (1 CAR T cell per 2 target cells 
based on transduction efficiency, Figure 3.3e), but did not lyse cCD20- target cells, and 
non-transduced cells did not react with either target cell (Figure 3.3d, cCD20 expression 
of target cells shown in Figure 2.8b). 
The benefit of CAR gene integration is long-term expression of the CAR as well as 
passing on of tumor-specificity to daughter CAR T cells, resulting in quasi-clonal 
expansion of tumor-targeting cells. Frequency of CAR+ T cells among the canine 
lymphoma patient’s T cells in culture increased during sequential challenges with 
cCD20+ CLBL-1 target cells (Figure 3.3e). Calculating absolute number of CAR T cells 
in culture shows a numerical expansion of these cells  after each of the first two 
challenges (Figure 3.3f), indicating that the increase in frequency represents a 
proliferation of CAR T cells in response to antigen challenge, not just death of non-
transduced T cells in culture. However, following the third challenge, the absolute 
number of CAR T cells decreased but the frequency of CAR+ T cells remained similar, 
suggesting an eventual limit to its proliferative capacity (Figure 3.3f). 
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Summary of Clinical Trial for Canine B Cell Lymphoma Patients Treated with 
Lentivirally-Transduced cCD20-8-28-ζ CAR T Cells 
Having demonstrated successful transduction of primary canine T cells with a lentivirus 
to express a second-generation CAR, and antigen-specific cytotoxicity and proliferation 
of these canine CAR T cells, we initiated a clinical trial to investigate the use of 
autologous canine T cells transduced with lentivirus encoding the cCD20-8-28-ζ CAR in 
canine patients with spontaneous B cell lymphoma. The goal of this trial was to assess 
safety of CAR T cell therapy on an intermediate to long-term basis, clinical efficacy, and 
signs of CAR T cell activity and persistence. In addition to changes in tumor size and 
patient health, we examined the T and B cell populations in the peripheral blood and 
lymph node by flow cytometry. In particular, we looked for CD4+ and CD8+ frequency 
among T cells, as well as CD28 expression among CD4+ and CD8+ T cells. The split 
between Bead-responders and non-responders in Chapter 2 (Figure 2.1c) led us to 
consider that the ability of T cells to respond to stimulation through endogenous CD28 
may be indicative of in vivo responses. The four patients that were enrolled had all failed 
or relapsed following induction chemotherapy, much like human patients on CAR T cell 
trials (Porter et al., 2015), and CAR T cells were generated from their enriched PBLs 
using the aAPC method described. Details of each of their histories, treatments, and 
results are described below. 
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Treatment of Patient 429-001 
Patient 429-001 was diagnosed with at least stage IIIa B cell lymphoma, and treated with 
CHOP chemotherapy. Patient was declared to be in complete clinical remission after two 
months of therapy, but relapsed four months later. Patient was referred for CAR T cell 
therapy at this time, and blood for ex vivo T cell culture and modification was drawn 30 
days before infusion. In the intervening time, the patient developed a urinary tract 
infection which was successfully treated with antibiotics and resolved before receiving a 
pre-conditioning regime of busulfan IV on two consecutive days (-2 and -1) prior to 
infusion. Histopathology of a biopsy sample taken 2 days prior to infusion from the left 
submandibular lymph node (Figure 3.4) was described as follows: "the lymph node 
architecture is effaced and replaced by sheets of neoplastic intermediate to large 
lymphocytes (nuclei measuring 1.5-2 times the size of a red blood cell). Mitoses average 
5-8 in a single high power-field (mid-grade). Scatter tingible body macrophages are 
present." 
Cells from Patient 429-001 expanded 153-fold over the course of 14 days, and had 6.46% 
surface expression of the CAR by flow cytometry (Figure 3.5a). The majority of the 
CD5+ T cells were CD8+, with a large CD4+CD8+ population (Figure 3.5b). Due to the 
urinary tract infection, cells were cryopreserved. A portion of the lentivirus-infected cells 
were thawed 5 days prior to scheduled infusion, and co-cultured with irradiated CLBL-1 
target cells to expand the number of CAR T cells; at the time of infusion, the frequency 
of T cells expressing the CAR on their surface had increased to 29% (Figure 3.5c), 
demonstrating functionality and increasing the number of CAR T cells to infuse. With the 
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goal of treating the patient with an estimated 10
5
 CAR T cells per kilogram and 10
6
 total 
T cells per kilogram, additional non-infected cells that were cultured in parallel were 
thawed and mixed into the infusion product. The final infusion product contained an 
estimated 0.97x10
5
 CAR T cells/kg, and 1.13x10
6
 total T cells/kg, and was administered 
IV. 
Four days after infusion, the volume of the target lymph node decreased 52% (24.1 cm
3
 
to 11.66cm
3
), coinciding with a 82% increase (1.88% to 3.43%) in the frequency of 
CD5+ T cells within another lymph node (Figure 3.5d). The CD5+ T cell frequency in 
the lymph node dropped afterward, falling below 1% 14 days post-infusion and 
remaining there, as the target node then grew rapidly, reaching 92.32 cm
3
 26 days after 
infusion. The patient developed seizures at this timepoint, and was treated with L-
asparaginase as rescue therapy at day 27 post-infusion and continued on anti-epileptic 
medication as well as vincristine and cyclophosphamide chemotherapy. The patient 
developed seizures again 68 days post-infusion, and a brain MRI revealed a mass. The 
patient’s owners elected to euthanize at this time, and the autopsy determined the mass to 
be lymphoma. The number of peripheral CD5+ T cells was greatest at the time of 
infusion and declined during the course of follow-up, and the number of CD79a+ B cells 
rapidly increased following day 14 post-infusion (Figure 3.5e). The frequency of CD4+ 
and CD8+ T cells in the peripheral blood was stable throughout, and there was a decline 
in both populations among CD5+ T cells in the lymph node at the final timepoint of day 
26 post-infusion (Figure 3.5f). CD28 expression among the CD4+ T cells in the 
peripheral blood decreased at day 26 post-infusion while remaining stable in peripheral 
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CD8+ T cells, but within the lymph node CD28 expression steadily declined after 4 days 
post-infusion (Figure 3.5g). Molecular evidence for the presence or expansion of CAR T 
cells in vivo by qPCR for lentiviral integration within genomic DNA was not found. Of 
note, the patient did develop a profound and lasting thrombocytopenia and as well as a 
transient neutropenia, an expected side effect of the busulfan pre-conditioning (Figure 
3.5h,i). These flow cytometry data of T and B cells are consistent with the brief 
amelioration and then decline in patient health, suggesting a T cell component in 
determining the disease outcome. 
 
Treatment of Patient 429-002 
Patient 429-002 was diagnosed with at least stage IIIa B cell lymphoma, and treated with 
CHOP chemotherapy. The patient’s disease progressed over the next two months and the 
dog was switched to a MOPP (mustargen, vincristine, procarbazine, predinosone) 
chemotherapy regimen that is also used in humans, but did not respond. The patient was 
referred for CAR T cell therapy, and blood for ex vivo T cell culture and modification 
was drawn 16 days before infusion. In the intervening time, the patient continued 
receiving MOPP chemotherapy. 
Cells from Patient 429-002 grew only 22-fold over the course of 15 days, and had 1.51% 
surface expression of the CAR by flow cytometry (Figure 3.6a). The plurality of the 
CD5+ T cells were CD4+, with large CD4+CD8+ and CD4-CD8- populations (Figure 
3.6b). Due to the small number of cells, the one million CAR T cells were injected 
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directly into the most advanced tumor site, the left prescapular lymph node, to assess 
local effect. The remaining non-transduced T cells that were cultured in parallel were 
infused IV. The patient was treated with an estimated 0.28x10
5
 CAR T cells/kg and 
3.78x10
6
 total T cells/kg. 
14 days post-infusion, the volume of the injected left prescapular lymph node had 
remained largely unchanged (an increase of 1.72%), whereas the control non-injected 
right prescapular lymph node had doubled in volume (an increase of 113%) (Figure 3.6c); 
the left and right submandibular lymph nodes, also not injected with CAR T cells, had 
roughly doubled in volume as well (increases of 99% and 119%, respectively). In light of 
the rapidly advancing disease at all sites outside of the injected lymph node, the patient 
was treated with L-asparaginase chemotherapy as rescue treatment at 14 days post-
infusion. Some of the tumors were refractory to treatment, and the right prescapular 
lymph node had nearly tripled (196% increase) by day 28 post-infusion, and the injected 
lymph node had also begun to grow at this time (52% increase) (Figure 3.6c); the owners 
of the patient elected for euthanasia at day 32 post-infusion. In the first 14 days that 
lymph node aspirate data were available, minor increases in CD5+ T cells and minor 
decreases in CD79a+ B cells were observed in the injected left prescapular lymph node, 
while the control right prescapular lymph node demonstrated the opposite trend in this 
time (Figure 3.6d). Peripheral blood counts showed a consistent decline in CD5+ T cells 
from before infusion through post-infusion, while CD79a+ B cell counts varied (Figure 
3.6e); CBC determined no lymphocytes present at day 14 post-infusion though CD79a+ 
and CD5+ cells were still detected by flow cytometry. Frequencies of CD4+ and CD8+ T 
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cells remained stable through 14 days post-infusion in the peripheral blood and left 
prescapular lymph node, with an increase in CD8+ and decrease in CD4+ at day 14 post-
infusion in the right prescapular lymph node (Figure 3.6f). CD28 expression among both 
CD4+ and CD8+ T cells declined in the peripheral blood and right prescapular lymph 
node, but remained stable in the left prescapular lymph node (Figure 3.6g). qPCR for the 
presence of the CAR in the left prescapular lymph node was positive only at day 4 post-
infusion (44.71 copies/μg genomic DNA). The contrast between the injected lymph node 
and all other sites suggested a role for the small number of CAR T cells used in 
mediating temporary, local control. 
 
Treatment of Patient 429-003 
Patient 429-003 was diagnosed with at least stage IIIa B cell lymphoma, and treated with 
a novel indenoisoquinoline drug as part of another study. The patient then received 
CHOP chemotherapy one month later, and obtained a rapid clinical remission in two 
weeks. The patient relapsed six months later. Patient was referred for CAR T cell therapy 
at this time, and blood for ex vivo T cell culture and modification was drawn 13 days 
before infusion. In the intervening time, patient received 188mg/m
2
 of cyclophosphamide 
over the course of four days, finishing 2 days prior to infusion. 
Cells from Patient 429-003 grew 169-fold over the course of 12 days, and had 6.62% 
surface expression of the CAR by flow cytometry (Figure 3.7a). The majority of CD5+ T 
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cells were CD8+, with a large CD4+CD8+ population (Figure 3.7b). An estimated 
6.60x10
5
 CAR T cells/kg and 33.47x10
6
 total T cells/kg were infused IV. 
The two tracked lymph nodes, the right and left submandibular, remained relatively 
stable in volume until 48 days post-infusion and disease progressed at day 64 post-
infusion (Figure 3.7c). After disease progression, patient was treated with L-asparaginase 
at day 64 post-infusion, and was treated with further L-asparaginase and prednisone as 
necessary to maintain stable disease; after severe decline in health, the owner elected for 
euthanasia at day 167 post-infusion. The composition of the right popliteal lymph node 
was roughly 2:1 B cells to T cells at the time of infusion (Figure 3.7d, 66.6% to 30.9%, 
respectively). This varied following infusion until it reached a period of stable T cell 
dominance, beginning at day 28 post-infusion until it returned to majority B cells at the 
time of disease progression at day 64 post-infusion. A population expressing lower 
amounts of CD79a, matching a small lymphocyte population, became prominent at day 
14 post-infusion and could be seen until its disappearance at day 64 post-infusion (Figure 
3.7e). Beginning at Day 21, the expression of cCD20 on CD79a+ B cells began to 
diverge into two populations, and remained at two levels until day 64 post-infusion 
(Figure 3.7e); during the period when there were two levels of cCD20 expression, the 
population expressing lower levels comprised 40-45% of CD79a+ B cells. Within the 
peripheral blood, CD79a+ B cells and CD5+ T cells both increased in the 9 days post-
infusion, following by declines in both through day 28 post-infusion; at this point, the B 
and T cell populations diverge, with increases in T cells counts and stable B cell counts 
through day 48 post-infusion, and then a drop in T cells and increase in B cells at day 64 
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post-infusion (Figure 3.7f). T cells had increased and B cells decreased during the drug-
controlled stable disease at day 111 post-infusion. The majority of peripheral T cells were 
CD4+ until day 36 post-infusion, when the frequency of CD8+ T cells became transiently 
predominant, then equal at day 48 post-infusion and majority CD4+ at day 64 post-
infusion; the lymph node composition of CD4+ and CD8+ T cells remained relatively 
stable (Figure 3.7g). CD28 expression among both CD4+ and CD8+ T cells in both the 
peripheral blood and the lymph node dramatically increased at day 28 post-infusion and 
was maintained until day 64 post-infusion, tracking with the CD5+ T cell dominance in 
the lymph node and expansion in the peripheral blood (Figure 3.7h). The CAR was 
present in the peripheral blood through day 21 post-infusion, as measured by qPCR of 
genomic DNA taken from PBMCs (Figure 3.7i). CAMA was detected in the patient 
serum beginning at day 28 post-infusion, and increased through following timepoints 
(Figure 3.7j). 
 
Treatment of Patient 429-004 
Patient 429-004 was diagnosed with stage IV B cell lymphoma, and treated with CHOP 
chemotherapy. Patient was declared in clinical remission after one month, before 
relapsing seven months later. Patient was referred for CAR T cell therapy at this time, 
and blood for ex vivo T cell culture and modification was drawn 14 days before infusion. 
In the intervening time, patient received L-asparaginase and 197.5mg/m
2
 of 
cyclophosphamide over the course of four days, finishing 2 days prior to infusion. 
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Cells from Patient 429-004 grew 73-fold over the course of 13 days, and had 3.68% 
surface expression of CAR by flow cytometry (Figure 3.8a). The frequency of CD5+ 
CAR T cells was abnormally low at the end of culture, 47.4% compared to greater than 
90% for the other three patients (Figure 3.8b). The CD5- cells were negative for CD79a 
or hCD45 (Figure 3.8c). The plurality of CD5+ T cells were CD4+, with large 
CD4+CD8+ and CD4-CD8- populations (Figure 3.8d). An estimated 5.01x10
5
 CAR T 
cells/kg and 33.61x10
6
 total T cells/kg were infused IV, similar to Patient 429-003. 
Four days post-infusion, all six of the tracked lymph nodes - the left and right 
submandibulars, prescapulars, and popliteals - had all increased in size, with the increase 
in the longest dimension of the node ranging from 15% to 115% (Figure 3.8e). The 
frequency of CD79a+ B cells in the right popliteal node had also increased with a 
corresponding decrease in CD5+ T cells (Figure 3.8f). Peripheral blood counts of 
CD79a+ B cells and CD5+ T cells was tracked for 45 days post-infusion (Figure 3.8g). 
qPCR for the presence of the CAR detected a signal in the right popliteal lymph node 45 
days post-infusion (18.28 copies/μg genomic DNA), but only in 2 of 3 replicates. 
Patient was treated with L-asparaginase as rescue chemotherapy day 5 post-infusion, and 
disease was stabilized with vincristine, cytosine-arabinoside, and lomustine, until 
progression at day 45 post-infusion. Owners elected to euthanize day 59 post-infusion. 
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Patient survival correlates with ex vivo T cell expansion 
To investigate factors that may be related to therapy efficacy, overall survival of all four 
patients post-infusion was examined. Unexpectedly, survival did not correlate with the 
dosage of total T cells or even CAR T cells, but rather how well the cell expanded ex vivo 
during culture (Figure 3.9, p = 0.0417). This is best illustrated in the contrast in outcomes 
for Patients 429-003 and 429-004, despite similar total T cell and CAR T cell dosing. As 
cells from all patients were cultured the same way, this would suggest something intrinsic 
to the patient that affected the starting population of T cells that were isolated for product 
generation. 
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Figure 3.1. Comparison of CMV and EF-1α promoters in lentivirally transduced canine T 
cells. PBMCs from four healthy dogs were stimulated with Beads and infected with equal 
amount of pCLPS GFP (CMV promoter) or pELNS GFP (EF-1α promoter) lentivirus in 
parallel. Day 6 post-stimulation, live lymphocytes were analyzed by flow cytometry for 
(a,b) frequency and (a,c) MFI of GFP+ cells. Gated on live CD5+ cells, GFP+ 
determined by non-transduced cells from the same donor. Lines in b and c connect results 
from the same donor under different conditions. 
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Figure 3.2. Activation of canine T cells and elimination of aAPCs during culture. 
Enriched PBLs from three healthy dogs were stimulated with aAPCs, agonistic anti-
canine CD3, and rhIL-2 and rhIL-21. (a) Frequency of CD25low and CD25high 
expressers among live CD5+ cells measured by flow cytometry. Data representative of 
one of two independent experiments with three healthy dogs each. (b) aAPCs were 
enumerated by measuring live hCD45+ cells and normalizing to CountBright beads and 
comparing to the initial number added to culture. Data representative of one of two 
independent experiments with three healthy dogs each. Means ± SEM represented in both 
a and b. 
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Figure 3.3. Design and function of cCD20-8-28-ζ canine CAR T cells ex vivo. (a) 
Diagram of cCD20-8-28-ζ construct. (b) Amino acid sequence of CAR construct, color-
coded by domain as in a. (c) CAR surface expression among live CD5+ cells measured 
by flow cytometry 14 days after stimulation with aAPCs and infection with pELxPS (EF-
1α promoter) cCD20-8-28-ζ lentivirus. (d) Lysis of irradiated GL-1 (cCD20-) cells and 
CLBL-1 (cCD20+) cells after overnight co-culture with 1 T cell per 1 Target or 5 T cells 
per 1 Target, as calculated from enumerating live CD79a+ target cells by flow cytometry 
and normalizing to CountBright beads. Means ± SEM of triplicate wells represented. (e) 
CAR surface expression among live CD5+ cells measured by flow cytometry before and 
after 1 and 2 co-cultures with irradiated CLBL-1 cells at a 1:1 T cell:CLBL-1 ratio. (f) 
Absolute number CAR T cells calculated from total cell counts measured by trypan blue 
exclusion and the frequency of CD5+CAR+ cells among live cells measured by flow 
cytometry. 
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Figure 3.4. Histopathology of biopsy from Patient 429-001's left submandibular lymph 
node. Hematoxylin and eosin stain of a Tru-cut biopsy taken from Patient 429-001's left 
submandibular lymph node 2 days prior to CAR T cell infusion, 40x magnification.  
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Figure 3.5. Treatment of Patient 429-001. (a) Surface expression of the CAR on live 
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) CD4 and CD8 
expression on live CD5+ T cells as measured by flow cytometry at the end of initial 
culture. (c) Surface expression of the CAR on live CD5+ cells as measured by flow 
cytometry at the end of co-culture with irradiated CLBL-1 target cells and before 
infusion. (d) The calculated ellipsoid volume of the left submandibular lymph node (left 
axis, blue line) and the frequency of CD5+ cells (right axis, red line) among live cells 
within the right submandibular lymph node as measured by flow cytometry over time 
relative to CAR T cell infusion. (e) Absolute numbers of CD79a+ (blue line) and CD5+ 
(red line) cells over time relative to CAR T cell infusion, calculated from flow cytometry 
and CBC. (f,g) Frequency in the peripheral blood and lymph node of (f) CD4+ and CD8+ 
cells among live CD5+ cells and (g) CD28+ cells among live CD4+ or CD8+ cells 
measured by flow cytometry over time relative to infusion. 
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Figure 3.6. Treatment of Patient 429-002. (a) Surface expression of the CAR on live 
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) CD4 and CD8 
expression on live CD5+ T cells as measured by flow cytometry at the end of initial 
culture. (c) Percent change in calculated ellipsoid volume of the left (blue line) and right 
(red line) prescapular lymph nodes over time relative to CAR T cell treatment. (d) 
Frequency of CD79a+ (blue line, left axis) and CD5+ (red line, right axis) cells among 
live cells in the left and right prescapular lymph node as measured by flow cytometry 
over time relative to CAR T cell treatment. (e) Absolute numbers of CD79a+ (blue line) 
and CD5+ (red line) cells over time relative to CAR T cell treatment, calculated from 
flow cytometry and CBC. (f,g) Frequency in the peripheral blood and lymph node of (f) 
CD4+ and CD8+ cells among live CD5+ cells and (g) CD28+ cells among live CD4+ or 
CD8+ cells measured by flow cytometry over time relative to CAR T cell treatment. 
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Figure 3.7. Treatment of Patient 429-003. (a) Surface expression of the CAR on live 
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) CD4 and CD8 
expression on live CD5+ T cells as measured by flow cytometry at the end of initial 
culture. (c) Calculated ellipsoid volume of the left and right sumandibular lymph nodes 
over time relative to infusion. (d) Frequency of CD79a+ (blue line, left axis) and CD5+ 
(red line, right axis) cells among live cells in the right popliteal lymph node as measured 
by flow cytometry over time relative to infusion. (e) CD79a and cCD20 expression 
among live cells within the right popliteal lymph node as measured by flow cytometry 
over time relative to infusion. (f) Absolute numbers of CD79a+ (blue line) and CD5+ 
(red line) cells over time relative to infusion, calculated from flow cytometry and CBC. 
(g,h) Frequency in the peripheral blood and lymph node of (g) CD4+ and CD8+ cells 
among live CD5+ cells and (h) CD28+ cells among live CD4+ or CD8+ cells measured 
by flow cytometry over time relative to infusion. (i) Copies of integrated CAR gene per 
μg of PBMC genomic DNA over time relative to infusion, as measured by qPCR. (j) 
Levels of serum CAMA over time relative to infusion, as measured by ELISA with 
means ± SEM of well triplicates represented and the assay LLOD marked by the dashed 
line. 
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Figure 3.8. Treatment of Patient 429-004. (a) Surface expression of the CAR on live 
CD5+ cells as measured by flow cytometry at the end of initial culture. (b) Frequency of 
CD5+ cells among live cells as measured by flow cytometry at the end of initial culture. 
(c) Expression of CD79a and hCD45 among live CD5- cells as measured by flow 
cytometry at the end of initial culture. (d) CD4 and CD8 expression on live CD5+ T cells 
as measured by flow cytometry at the end of initial culture. (e) Length of the longest 
dimension of three pairs of contralateral lymph nodes as measured by calipers over time 
relative to infusion. (f) Frequency of CD79a+ and CD5+ cells among live cells in the 
right popliteal lymph node at baseline (left) and day 4 post-infusion (right) as measured 
by flow cytometry. (g) Absolute numbers of CD79a+ (blue line) and CD5+ (red line) 
cells over time relative to CAR T cell treatment, calculated from flow cytometry and 
CBC. 
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Figure 3.9. Correlations between infusion product and patient overall survival. Days of 
patient overall survival following CAR T cell therapy plotted against total T cells/kg 
infused, CAR T cells/kg infused, or the rate of cell product growth. Linear regression 
with R
2
 value, Spearman’s rho value, and p value shown.  
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Discussion 
Using lentivirus, we were able to permanently transduce primary canine T cells to 
express a second-generation cCD20-8-28-ζ CAR. Those canine CAR T cells were able to 
kill target antigen-expressing cells and proliferate in response to them in vitro, resulting 
in more CAR T cells. Antigen-induced CAR T cell expansion continued upon antigen re-
challenge, a positive indicator for anti-tumor response amplification in vivo. However, 
the decline in CAR T cells following the third challenge is concerning, given the shorter 
half-life of CD28-based CAR T cells in human clinical trials; this shorter half-life in 
human patients is believed to be due to exhaustion (Long et al., 2015). It should be noted 
that this preliminary result was from only one dog, and testing in further donor T cells 
with this CAR construct is needed for conclusive interpretation. 
Based on these data, we treated four canine patients with relapsed or refractory B cell 
lymphoma with autologous cCD20-8-28-ζ CAR T cells. At their current stage of disease, 
the expected median response would be expected to only last in the range of 1-2 months, 
even if they had received aggressive rescue chemotherapy (Vail et al., 2013). None of the 
patients reached an objective response, but observations from each of them informed the 
treatment of the next. 
The inverse relationship between T cell frequency in the lymph node and tumor 
outgrowth in Patient 429-001 suggested that the CAR T cells could traffic to the tumor 
site and exert an anti-tumor effect. However, the loss of T cells within the lymph node 
followed by outgrowth of that tumor, suggest that the lack of T cell persistence may have 
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contributed to therapy failure – just as CD28-based CAR T cells often fail to persist in 
human patients. While neurotoxicity has been observed in human patients, it is more 
likely that Patient 429-001’s seizures and abnormal behavior were due to the brain 
metastasis It should be noted that brain metastasis of B cell lymphoma is unusual, and 
leads one to speculate whether the CAR T cell infusion exerted pressure on malignant 
cells to move to an immunoprivileged niche (Seo et al., 2011). 
The product generated from Patient 429-002’s cells was suboptimal, likely due to 
ongoing treatment with a MOPP chemotherapy regimen when the cells were isolated for 
culture, and unlikely to halt or reverse clinical progression of disease. Nevertheless, we 
injected one tumor with the CAR T cells and let the others receive non-transduced T cells 
from circulation and found that the CAR T cells could exert local tumor control. 
Based on this evidence, our next goal was to increase overall CAR T cell numbers 
throughout the patient, which occurred with Patient 429-003. In this case, the patient’s 
disease became stable for two months, and survived for five months after infusion. 
Patient 429-003 provided a wealth of observations to consider. While the most striking 
data is that the dog survived 169 days post-infusion, 1-2 month survival after relapse is 
only an average and this patient may have been a naturally-occurring outlier even if it had 
not been treated with CAR T cells. However, the convergence of several observations 
forms a hypothetical timeline for transient effects and efficacy of the treatment. During 
the first three weeks after infusion with CAR T cells, qPCR can detect presence of the 
CAR in the peripheral blood and the dominance of the B and T cells in the lymph node 
goes back and forth until a T cell majority is achieved, and the B cell population begins to 
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modulate its expression of cCD20 – the target antigen of the CAR. Four weeks after 
infusion with the CAR T cells, an anti-CAR immune response is formed in the form of 
CAMA and CAR T cells can no longer be detected in the peripheral blood by qPCR. In 
the weeks that follow, the CAMA increases, the T cells can no longer control the 
malignant cells in the lymph nodes which grow, and cCD20 expression the B cells 
returns to normal. 
Whether the CAR T cells disappeared because they were eliminated by the CAMA or 
because they became exhausted and declined on their own, for which the ex vivo re-
challenge data may have been a harbinger, is unclear, but the suggestion is that presence 
of the CAR T cells played a role in exerting some control of the lymphoma and their loss 
led to its progression. It is unclear why Patient 429-003 continued to survive over 100 
days past progression if the CAR T cells were gone; perhaps the non-transduced ex vivo 
cultured T cells continued to have a positive effect, as suggested in another canine trial 
using adoptively transferred T cells (O'Connor et al., 2012). Perhaps the early CAR T 
cell-mediated control of the tumor allowed time for the recovery of the host’s other T 
cells, as suggested by the increase in CD28 expression, which were able to keep the 
disease at bay for an extended period of time with assistance of the L-asparaginase and 
prednisone. It is also unknown whether the change in cCD20 expression was even a 
decrease since each sample was stained and run at the time of collection, but qPCR and 
sequencing of cryopreserved samples could potentially elucidate this or possible escape 
mutants. 
90 
 
That Patient 429-003 alone generated CAMA is particularly fascinating. The one other 
patient that demonstrated this, 434-001 in Chapter 2, had been injected 3 times with 
transiently-expressing CAR T cells, which could explain a vaccination-like effect against 
the CAR. Patient 429-003 was infused only once, but, unlike the other three patients that 
received the permanently-expressed cCD20-8-28-ζ CAR, it had evidence of extended 
presence of CAR T cells in vivo – a persistently present antigen to form CAMA against. 
Additionally, Patient 429-003 never eliminated its B cell compartment, just a two month-
long stalemate during which the surviving B cells had ample opportunity to form a 
response against the CAR. HAMA is typically not measured in human patients receiving 
B-cell targeting CAR T cells, but our canine data highlights a potential risk to human 
patients if additional infusions of CAR T cell are attempted when an objective response is 
not achieved. In fact, in the one publication of human B cell lymphoma patients treated 
with CAR T cells that did examine anti-CAR immune responses, CD8+ T cell activity 
against peptides generated from the scFv component of the CAR was detected in patients 
that did not receive the more potent pre-conditioning chemotherapy regimen and left the 
patients’ immune compartments more intact (Turtle et al., 2016). 
Our attempt to replicate our findings with Patient 429-003 in Patient 429-004 failed, with 
rapid progression only 4 days after infusion despite similar numbers of total and CAR T 
cells. This experience taught us two important lessons. First, that the number of cells do 
not matter so much as their quality, as measured in proxy by their ability to expand ex 
vivo before infusion. The second was a reminder of the rapidity of this disease in dogs, 
which may not allow for culturing the cells for two weeks or longer and only give a 
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narrow window of opportunity for the treatment to work in vivo; in fact, the dog 
represented in Figure 3.3e-f, whose cells killed lymphoma cells and expanded ex vivo, 
was a B cell lymphoma patient being screened for this trial but died before it could be 
treated. 
These observations regarding T cells dosage are interesting in light of data from CAR T 
cell trials in human B cell lymphoma patients. Dosages in the range of 10
5
 CAR T 
cells/kg, 10
6
/kg, and 10
7
/kg showed that increasing from 10
6
 to 10
7
 did not increase 
clinical efficacy, just severity of neurotoxicity and CRS (Turtle et al., 2016). The primary 
determining factor for both efficacy and toxicity in these patients was more potent pre-
conditioning chemotherapy in the form of combined cyclophosphamide and fludarabine. 
Our dosages were in the range of 10
5
 to 10
6
 CAR T cells/kg and we did not use 
fludarabine, which may explain the limited efficacy. This may also explain why we did 
not see any clinical signs of CRS, though CBA data from patient serum samples are 
pending. 
In Patients 429-001 and 429-003, which remained on the trial long enough to better 
assess trends, it is particularly interesting that the expression of CD28 on the T cells 
corresponds with the "success" of the T cells at that timepoint. In 429-001, at day 4 post-
infusion when the target node shrinks and the peripheral and lymph node T cells increase, 
the frequency of CD28+ T cells is increased. As disease progresses, the frequency of 
CD28+ T cells decrease. In Patient 429-001, given the brief spike shortly after infusion, a 
possible explanation is that the infusion product contained a large number of CD28+ T 
cells, and that these cells eventually died or lost expression of the co-stimulatory receptor 
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as they terminally differentiated or were otherwise suppressed by the tumor. In Patient 
429-003, the parallel between the T cells becoming predominant in both the peripheral 
blood and the lymph node and the jump in CD28 expression at both sites during the time 
period between days 28 and 48 post-infusion and the rapid decline of both at day 64 post-
infusion is remarkable. That this occurred 4 weeks after infusion suggests that it is not 
just a transient boost from cells that have just been infused, but perhaps CD28 expression 
can be used as a broader marker of T cell health within the patient. This hypothesis is 
explored further in Chapter 4. 
The takeaway from this trial can be summarized in Figure 3.9, that quality of the T cells 
matters more than quantity for therapy efficacy. This quality could take a variety of 
forms. It could be the chemotherapy that the T cells were exposed to while in the patient 
prior to isolation; all patients did receive CHOP chemotherapy months prior to isolation, 
but Patient 429-002, whose T cells only grew 22-fold, was receiving a chemotherapy 
regimen (MOPP) at the time of isolation. While all the patients had progressive disease at 
the time of relapse, they were not staged until the time of infusion; each patient’s disease 
may have had different levels of immunosuppressive effects on their T cells that were 
then isolated. Indeed, since our starting product for culture was enriched PBLs, residual 
malignant cells or suppressive myeloid populations may have continued to have 
detrimental effects on the T cells ex vivo; the extent of this potential contamination’s 
effect could very well vary from patient to patient. We were unable to phenotype the 
patients’ T cells for surface inhibitory receptors due to a lack of reagents. Similarly, a 
starting population of T cells that is predominantly central memory cells or terminally 
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differentiated effector cells would have very different expansion results, but our reagents 
for differentiating those phenotypes were limited at the time. Our observations of T cell 
expansion could be indicative not just of the health of individual T cells, but also of a 
variety of factors that affect the entire T cell compartment of the patient, and the T cell 
compartment of the patient itself may be a proxy for the aggressiveness of the disease. By 
extension, the ability of a patient’s T cells to expand ex vivo may be prognostic of their 
future disease course and overall survival, independent of whether they are treated with 
those ex vivo expanded T cells. 
CAR T cell therapy depends not only on the CAR, but the T cell that bears it as well. 
Chapters 2 and 3 have demonstrated that it is possible to redirect primary canine T cells 
with a CAR to target spontaneously-occurring tumors in vivo for therapy, even 
establishing stable disease. In order to make the next step toward successful therapy, we 
will need to examine the quality of the T cells we isolate from patients to generate their 
products, how we can improve our culture system to retain or generate desirable subsets 
of T cells that will have greater therapeutic effect, and alter our CAR construct so that it 
not only targets the tumor but also reinforces these preferred T cell qualities. In short, 
Chapter 4 focuses on building a better T cell. 
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CHAPTER 4: Improvements in Canine CAR T Cell Generation & Their Effect on a 
Canine B Cell Lymphoma Patient 
 
Abstract 
Successful CAR T cell therapy hinges upon both an effective tumor-targeting CAR 
construct and T cells capable of long-lived and robust function to bear it. In Chapters 2 
and 3, we successfully developed a cCD20-targeting CAR and achieved permanent 
expression of it in primary canine T cells. In this chapter, we identified factors that are 
deleterious to T cells taken from patients and ways to potentially recover these cells. We 
also altered our culture system to combine stimuli and promote canine memory-like T 
cells through use of rhIL-7 and rhIL-15, and generated a cCD20-8-BB-ζ CAR that 
appears more resistant in CAR-induced exhaustion. The sum of these findings were 
applied in the treatment of a canine patient with stage V B cell lymphoma, who had 
molecular evidence of CAR T cell persistence for at least 50 days post-infusion. In 
addition, the patient’s tumor lost expression of the CAR antigen, suggesting adaptation in 
response to cCD20-targeting therapy-mediated immune pressure just as observed in 
human CAR T cell patients. 
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Introduction 
Data from Chapters 2 and 3 have demonstrated that canine T cells can be redirected 
against antigen-bearing tumor targets using a CAR, and that this CAR can be 
permanently expressed in canine T cells and infused back into patients for temporary or 
local tumor control. In the course of these experiments and clinical observations, the data 
repeatedly pointed us in the direction of the role that T cell quality may play in efficacy. 
Therefore, we explored the quality of the cells we obtained from dogs, how we could 
adapt our culture system to improve the quality, compared CAR constructs to see if 
activity through them altered the quality of the cells, and other factors that we thought 
may affect therapy efficacy. 
Our first comparison of stimuli in Chapter 2 (Figure 2.1) raised two questions: why do 
aAPCs outperform Beads in growing T cells, and why do some dogs respond to Beads 
while others do not? As the Beads can only give stimulation through CD3 and CD28, we 
hypothesized that different levels of CD28 expression on donor or patient T cells was the 
cause for different proliferative responses. Our attention was drawn to CD28 expression 
once more in Chapter 3, when we observed that frequency of CD28+ T cells in vivo 
tracked with tumor control in our CAR T cell-treated patients. For this reason, we 
undertook preliminary investigations into CD28 expression in donor T cells and its effect 
on proliferation in response to different stimuli. In the same vein of exploring potential 
determining factors in T cell health and growth, we examined the effects of recent 
chemotherapy on the expansion of T cells isolated from patients. Both of these factors, 
patient-to-patient variation in T cell phenotype and prior therapies, are of significant 
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consequence to human CAR T cell therapy but are entirely absent in immunodeficient 
mouse-xenograft studies. 
We also revisited two key aspects of our culturing system. First is the form and timing of 
stimulus; transduction of human T cells with lentivirus is typically performed within the 
initial 48 hours, whereas we have delayed until 4 days post-stimulation because the 
presence of aAPCs in culture. An increase in transduction efficiency would increase the 
number of CAR T cells infused into the patients; while CAR T cell dose did not correlate 
with overall survival in the clinical trial with cCD20-8-28-ζ CAR T cells (Figure 3.8), 
starting with a larger number of CAR T cells may blunt possible rapid tumor progression 
in the days immediately following infusion as occurred with Patient 429-004. The second 
component of our culture system we reassessed was cytokine supplementation. rhIL-2 
and rhIL-21 use in culturing canine T cells was reported previously, and we used this in 
Chapters 2 and 3 since we found that it generated large numbers of T cells with increased 
expression of granzyme B (O'Connor et al., 2012). However, this could potentially mean 
that these cells were closer to terminal differentiation as effector cells which would not 
persist in vivo. Stem- or naïve-like memory cells that are longer-lived and more 
pluripotent in their T cell fates have been identified in humans, and their increased 
presence in CAR T cell products infused into human patients is associated with increased 
in vivo expansion – the strongest correlate of therapy success (Gattinoni et al., 2011; Xu 
et al., 2014). Studies with human cells have found that ex vivo culture with IL-7 and IL-
15 preserves this T cell phenotype better than culture with IL-2, as does shorter culture 
times (Ghassemi et al., 2016; Xu et al., 2014). 
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The clinical trial reported in Chapter 3 used a second-generation CAR construct 
containing the intracellular signaling domain of CD28. The other most commonly used 
construct uses the intracellular signaling domain of the co-stimulatory receptor 4-1BB 
(BB). BB-based CAR T cells were found to have longer persistence in mouse studies, and 
recent publications have demonstrated that human T cells that receive a signal through a 
BB-containing CAR skew toward a central or stem-like memory fate rather than effector 
or effector memory fate as seen with as CD28-containing CARs, in part through the 
metabolic and gene expression shifts that accompany either CAR’s signaling (Carpenito 
et al., 2009; Kawalekar et al., 2016; Long et al., 2015; Milone et al., 2009). This 
difference is particularly important in CARs that have scFvs that have a tendency to self-
ligate, resulting in continuous tonic signaling that can cause the cells to spiral toward 
exhaustion depending on the co-stimulatory domain used (Frigault et al., 2015; Long et 
al., 2015). The eventual decline of CAR T cells we observed during ex vivo challenge 
(Figure 3.3f) and evidence of only brief presence within patients when using the cCD20-
8-28-ζ CAR construct led us to develop and test a cCD20-8-BB-ζ CAR in primary canine 
T cells. 
The findings of all these experiments led us to an improved protocol for generating 
canine CAR T cells that use the BB domain, which we used to treat a canine patient with 
spontaneous B cell lymphoma. This patient is still being monitored, and the results to 
date are described here. 
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Results 
Canine patients with late-stage lymphoma have low frequency of CD28-expressing 
CD4+ T cells and are unresponsive to Bead stimulation 
We compared the CD28 expression on T cells isolated from two dogs with late-stage 
lymphoma to six healthy controls dogs. While the frequency of CD28+ cells among 
CD8+ T cells was comparable (43.40 ± 1.50% vs. 39.77 ± 4.70%, respectively), it was 
dramatically decreased among the CD4+ T cells of the diseased dogs (17.10 ± 1.50% vs. 
90.68 ± 4.83%, respectively; Figure 4.1a). PBMCs from the two diseased dogs and a 
healthy control were stimulated with either Beads or aAPCs for 8 days, without cytokines 
to exclude other growth factors. While the healthy PBMCs grew equivalently with either 
stimuli (22.3-fold for Beads, 18.9-fold for aAPCs), PBMCs from the diseased dogs only 
grew in response to the aAPCs (9.0-fold and 6.2-fold for the two dogs with aAPCs). 
While the proliferative response of the diseased dog PBMCs to aAPCs was diminished in 
comparison to healthy dog PBMCs, indicative of other obstacles to proliferation, this is in 
stark contrast to the stimulation with Beads, with had few live cells remaining at the end 
of culture (Figure 4.1b). Frequency of CD28+ CD4+ and CD8+ T cells increased among 
the diseased dogs’ PBMCs during the culture with aAPCs, and the T cells were 
responsive to Bead stimulation after this (Figure 4.1c, data not shown). These data 
suggest that T cells from canine patients with advanced disease may not respond to Bead 
stimulation due to decreased expression of CD28 on their CD4+ T cells, and that aAPCs 
may recover these cells. 
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aAPCs grow more Canine T cells than Beads through cell-intrinsic, contact-dependent 
and -independent factors 
To identify the mechanism of how aAPCs support the growth of canine T cells better 
than Beads, we attempted to separate out the components of the stimulus. Beads and 
aAPCs both use the same agonistic anti-canine CD3 antibody, but Beads use an agonistic 
anti-canine CD28 antibody while aAPCs express canine CD86 – the ligand for CD28 – to 
provide co-stimulation. To determine if the source of co-stimulation via CD28 was the 
cause, we used an intermediate aAPC system: the same baseline K562 expressing human 
CD32 but without canine CD86, with the same agonistic anti-canine CD3 and CD28 
antibodies as on the Beads. PBMCs from three healthy dogs were stimulated with Beads, 
aAPCs, or the intermediate aAPCs that used only the agonistic antibodies. The 
intermediate aAPC system grew canine T cells just as well as the aAPC system (15.83 ± 
3.68-fold vs. 14.38 ± 1.15-fold, respectively), and both of them better than the Beads 
(8.90 ± 1.74-fold; Figure 4.2a), indicating that the source of CD28 stimulation does not 
account for the growth difference, but rather a factor intrinsic to the aAPCs. 
To determine if this factor was contact-dependent or not, a transwell experiment was set 
up. CFSE-labeled PBMCs from three healthy dogs were stimulated with Beads at the 
bottom of the transwell alone, or with aAPCs lacking canine CD86 and no soluble anti-
canine CD3 (Kt32 cells) either in the upper chamber separated from the PBMCs or in the 
lower chamber with the PBMCs. After 4 days, the presence of Kt32 aAPCs in the upper 
chamber enhanced cell division beyond that of Beads alone, and their presence in the 
lower chamber with the PBMCs enhanced it even further (Figure 4.2b). This would 
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suggest that the Kt32 aAPCs provide both soluble and cell-contact factors outside of CD3 
and CD28 binding to further stimulate growth of canine T cells. As human CD8+ T cells 
that lack CD28 have been found to be primarily dependent on CD58-binding for co-
stimulation, we investigated our aAPCs and found them to be positive for human CD58 
(Figure 4.2c) (Leitner et al., 2015). Additionally, whereas rhIL-21 alone can upregulate 
granzyme B expression in canine T cells cultured with aAPCs (Figure 2.2b), culture with 
Beads requires both rhIL-2 and rhIL-21 (Figure 4.2d), suggesting that the aAPCs are 
compensating for the IL-2 requirement, perhaps through the secretion of another 
cytokine. 
 
Recent chemotherapy hinders growth of canine T cells isolated from patients 
Both human CAR T cell therapy patients and canine patients that we have screened for 
our trials have typically received extensive prior therapy, often profoundly cytotoxic 
chemotherapy agents. In Chapter 3, we observed that cells from Patient 429-002 grew the 
poorest of the four trial patients, and the blood was drawn while the patient was receiving 
MOPP chemotherapy. We examined the growth of T cells from two canine lymphoma 
patients that had sequential blood draws after chemotherapy to generate CAR T cell 
products. Patient 434-001, described in Chapter 2, had received L-asparaginase before we 
drew our first blood sample; cells taken 10 days after L-asparaginase grew 34-fold, 
whereas those taken 17 and 23 days after grew 162-fold and 120-fold, respectively. 
Another patient that was screened but not treated had received doxorubicin 12 days 
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before the first draw; these cells expanded only 1.5-fold, but cells from blood drawn at 40 
days after doxorubicin grew 27-fold. In the case of Patient 434-001, the T cells grew 
better with increased time from chemotherapy in spite of advancing disease, while the 
second patient was in clinical remission at both timepoints. Together, these suggest that 
the ability of canine T cells to expand ex vivo is negatively impacted by recent treatment 
with chemotherapy. 
 
Beads stimulate a select population of canine T cells more robustly than aAPCs 
In light of changes to our growth protocol and observations regarding differences 
between aAPCs and Beads, we revisited the comparison of stimuli that was initially 
performed in Chapter 2 (Figure 2.1). CFSE-labeled enriched PBLs from 4 healthy dogs 
were stimulated with aAPCs, Beads, ConA, or left unstimulated, all supplemented with 
rhIL-2 and rhIL-21. As before, stimulation with aAPCs outperformed that of all other 
conditions, including the Beads (Figure 4.3a). Interestingly, CD5+ T cell responder 
frequency two days post-stimulation was highest amongst the Beads (72.0 ± 4.0% for 
Beads, 46.8 ± 2.1% for aAPCs, 20.2 ± 1.4% for ConA, and none for unstimulated; Figure 
4.3b). In fact, MFI of CD25 is increased during days 1 and 2 post-stimulation in Bead 
cultures compared to aAPC cultures, even when comparing cells that have undergone the 
same number of mitoses or have not divided at all (Figure 4.3c). This indicates that Beads 
provide a more potent activation signal to canine T cells that respond to them early in 
comparison to aAPCs. 
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Earlier infection of Bead-responsive cells leads to increased transduction compared to 
aAPCs 
As Beads are able to robustly activate a population of canine T cells, we explored 
whether these cells may be more efficiently transduced with lentivirus. In addition, 
Beads, unlike aAPCs, do not act as a viral sink, allowing infection with lentivirus at an 
earlier timepoint than with aAPCs, which remain in culture for multiple days (Figure 
3.2b). Enriched PBLs from three healthy dogs were cultured with aAPCs, or were 
incubated with Beads and Bead-bound cells were then isolated and cultured. Those 
cultured with aAPCs were infected on Day 4 post-stimulation, while those cultured with 
the Beads were infected either Day 1 or Day 2 post-stimulation; equal MOI of GFP-
encoding lentivirus was used for all conditions. After 7 days of culture, T cells cultured 
with the Beads were transduced at a remarkably higher efficiency than with aAPCs (24.1 
± 1.5% GFP+ for Day 1 Post-Beads, 25.4 ± 2.4% for Day 2 Post-Beads, 9.8 ± 1.1% Day 
4 Post-aAPCs; Figure 4.4a,b), and the transduced cells expressed higher levels of GFP 
(8257 ± 1466 for Day 1 Post-Beads GFP MFI, 7072 ± 932 for Day 2 Post-Beads, 4021 ± 
403 Day 4 Post-aAPCs; Figure 4.4a,c). The increased transduction during culture with 
the Beads compared to the aAPCs could be due to the stimulus or the timing, but former 
constrains options for the latter. These data suggest that Beads give an early, potent 
activation signal to canine T cells that permits more efficient transduction, but aAPCs 
stimulate more T cell growth overall, giving rise to the potential of stimulating with 
Beads, infecting with lentivirus, and then supplementing the culture with aAPCs. 
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Supplementation with rhIL-7 and rhIL-15 retains CD62L and CD27 expression on T cells 
compared to rhIL-2 and rh-IL21 
As IL-7 and IL-15 have been suggested to promote memory cell formation during ex vivo 
culture of human T cells in comparison to IL-2, we compared the effects of rhIL-7 and 
rhIL-15 to rhIL-2 and rhIL-21 on canine T cell culture (Xu et al., 2014). Enriched PBLs 
from four healthy dogs were stimulated with Beads with rhIL-2 and rhIL-21, rhIL-7 and 
rhIL-15, or no cytokines; aAPCs were not used since the additional growth factors they 
provide may act synergistically with one set of set cytokines but not the other. T cell 
growth rate for both sets of cytokines were similar through the first 7 days, but had 
diverged in favor of rhIL-2 and rhIL-21 by day 14 of culture though with a high degree of 
variability (45.1 ± 15.7-fold for rhIL-2 and rhIL-21 versus 18.1 ± 6.2-fold for rhIL-7 and 
rhIL-15 at day 14 of culture; Figure 4.5a). All conditions resulted in a skewing from 
mostly CD4+ to majority CD8+ among T cells (Figure 4.5b,c). CD62L and CD27 
expression in both CD4+ and CD8+ T cells was higher in cells cultured with rhIL-7 and 
rhIL-15 compared to rhIL-2 and rhIL-21, especially at day 14 of culture (Figure 4.5d-g). 
Based on these data, culture with rhIL-7 and rhIL-15 results in early growth similar to 
rhIL-2 and rhIL-21, but better retains memory-like cells that express CD62L and the co-
stimulatory receptor CD27. 
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Supplementation with rhIL-7 and IL-15 alters gene expression 
qRT-PCR was performed on T cells harvested at days 7 and 14 of culture in all three 
conditions to assess differences in expression profiles. Compared to T cells cultured with 
rhIL-2 and rhIL-21, T cells cultured with rhIL-7 and rhIL-15 had increased expression of 
CD44 and CD62L. Expression of BCL6, GZMB, and PRDM1 were relatively decreased. 
Expression of EOMES and TBX21 were increased at day 7 of culture, but returned closer 
to equivalent expression at day 14. (Figure 4.6) 
 
cCD20-8-BB-ζ CAR T cells have extended ex vivo proliferative capacity in response to 
antigen challenge 
A CAR construct targeting canine CD20 using the same scFv as in Chapters 2 and 3 was 
designed, using the following components from N to C terminus: canine CD8α leader, 
murine anti-canine CD20 scFv, canine CD8α hinge, canine CD8α transmembrane, canine 
4-1BB intracellular domain, and canine CD3ζ intracellular domain (Figure 4.7a, b). A 
nucleotide sequence that was codon-optimized for dogs was synthesized (Figure 4.7c), 
and inserted into the same lentivector (pELxPS) as used in the cCD20-8-28-ζ studies. 
Surface expression of the cCD20-8-BB-ζ CAR construct was successful after 
transduction of primary canine T cells (Figure 4.7d). Frequency of T cells with surface 
expression of the CAR increased after sequential challenges with the cCD20-expressing 
CLBL-1 canine B cell lymphoma cell line (Figure 4.7d). Absolute number of CAR T 
cells increased in multiple canine donors after 3 challenges with CLBL-1 cells (Figure 
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4.7e). Two of these donors were healthy dogs, and their T cells were initially cultured 
with rhIL-2 and rhIL-21; cells from the third dog were grown in rhIL-7 and rhIL-15, and 
continued to grow after 4 challenges, despite coming from a donor that was in remission 
from B cell lymphoma. cCD20-8-BB-ζ CAR T cells from all three dogs outperformed the 
cCD20-8-28-ζ CAR T cells described in Chapter 3 (Figure 3.3f, growth curve overlaid in 
Figure 4.7e). cCD20-8-BB-ζ CAR T cells from the dog in remission are also capable of 
lysing targets in an antigen-specific manner, killing GL-1 cells expressing cCD20 more 
efficiently than those without cCD20 in an overnight luciferase assay (Figure 4.7f). 
 
Treatment of Patient 429-006 
Having developed a culture system that would potentially increase the frequency of CAR 
T cells and preferentially grow memory-like cells, and developed a cCD20-8-BB-ζ CAR 
construct that appears to extend proliferative capacity, we recruited a patient with limited 
chemotherapy exposure to assess the efficacy of our updated CAR T cell therapy protocol 
that is closer to the best practices currently used in human CAR T cell therapy. 
Patient 429-006 was diagnosed with stage V B cell lymphoma with significant numbers 
of circulating blasts. Initial pathology report described the malignant cells as "large 
immature unclassed cells" with "finely granular chromatin, and variably distinct 
nucleoli." The patient was treated with L-asparaginase and prednisone, but owners 
declined continuing to CHOP chemotherapy and the patient was referred for CAR T cell 
therapy; blood for ex vivo T cell culture and modification was drawn 16 days before 
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infusion. In the intervening time, the patient received 10,000IU L-asparaginase, 
0.56mg/m
2
 vincristine 9 days prior to infusion, and 283mg/m
2
 of cyclophosphamide over 
the course of four days, finishing 3 days prior to infusion. 
As the patient was leukemic at the time of blood draw and had low frequency of CD5+ T 
cells, we sorted for CD5+ cells by flow cytometry, and started with an initial population 
of 85.8% CD5+ T cells for culture (Figure 4.8a,b). These cells were stimulated with 
Beads, infected on both day 1 and day 2 post-stimulation with lentivirus encoding the 
cCD20-8-BB-ζ CAR, and were supplemented with aAPCs and agonistic anti-canine CD3 
antibody on day 4 post-stimulation, receiving rhIL-7 and rhIL-15 throughout the culture 
period. By day 9 post-stimulation, cells had expanded 25-fold. Half the cells were 
cryopreserved while undergoing quality control testing, while the other half were re-
stimulated using irradiated autologous PBMCs, which contained 94.8% cCD20+ 
leukemic blasts (Figure 4.8c). Seven days later, cryopreserved cells were thawed and 
combined with the re-stimulated cells for the infusion product. The cryopreserved T cells 
were majority CD8+ prior at day 9 post-stimulation, and the combined product infused 
was also majority CD8+ with increased frequency of CD4+CD8+ cells (Figure 4.8d,e). 
2.18x10
6
 total T cells/kg were infused IV. The number of CAR T cells was unable to be 
determined, as the soluble anti-canine CD3 antibody in culture prevents accurate 
detection of CAR surface expression for at least 9 days after addition (Figure 4.8f). 
Peripheral counts of CD5+ T cells and CD79a+ B cells decreased dramatically during 
pre-conditioning, but mostly recovered by day 11 post-infusion (Figure 4.9a). Peripheral 
T cell counts were increased compared to the initial screen 16 days prior to infusion 
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through day 50 post-infusion, peaking at 64% above screening baseline at day 25 post-
infusion and suggesting a boost from our infused product. From day 11 through 46 post-
infusion, increases in peripheral CD5+ T cell numbers coincide with decreases in 
peripheral CD79a+ B cells, and vice versa, indicating a period of dynamic equilibrium 
following infusion. However, the peripheral blood remained overwhelmingly CD79a+ by 
frequency through day 50 post-infusion, and the target lymph node shifted further in 
favor of CD79a+ B cells over the same time (Figure 4.9b,c). The frequency of CD4+ and 
CD8+ cells among CD5+ T cells remained stable in the lymph node with a CD4+ 
majority, while there was a trend toward increasing CD8+ and decreasing CD4+ 
frequencies in the peripheral blood over the 50 days post-infusion (Figure 4.9d,e). CD28 
expression amongst peripheral blood CD8+ T cells increased immediately following 
infusion before returning to baseline, while in the lymph node both CD4+ and CD8+ T 
cells have a decrease in CD28+ frequency at day 11 post-infusion followed by a rebound 
that lasts until day 50 post-infusion (Figure 4.9f,g). qPCR showed evidence of the CAR 
gene in the peripheral blood for 11 days post-infusion, and intermittently in the lymph 
node including a peak at day 50 post-infusion (Figure 4.9h). In both the peripheral blood 
and the lymph node, a small population of cCD20-CD79a+ B cells became noticeable 
post-infusion and grew to 4.33% of peripheral blood CD79a+ B cells and 6.15% of 
lymph node CD79a+ B cells by day 50 post-infusion (Figure 4.10a). 
On day 46 post-infusion, the patient’s disease had progressed, and the patient was treated 
with prednisone, followed by L-asparaginase and lomustine on day 50 post-infusion. The 
patient continued on lomustine until progression, and was switched to doxorubicin 
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treatment on day 92 post-infusion. Samples taken during follow-up visits to the hospital 
for chemotherapy revealed that 65.82% of peripheral blood CD79a+ B cells and 89.10% 
of lymph node CD79a+ B cells were cCD20- at day 89 post-infusion (Figure 4.10b). At 
day 106 post-infusion, the few remaining peripheral B cells (326 cells/μL blood 
compared to 26875 cell/μL blood at day 50 post-infusion, 5% of PBMCs) no longer had 
distinct cCD20 staining. At day 138 post-infusion, 98.5% of lymph node B cells were 
cCD20- compared to 93.4% of peripheral blood B cells; the cCD20+ population that 
appeared is small in cell size and granularity, whereas the cCD20- B cells increased in 
size and granularity, suggesting that they had begun blasting again (Figure 4.10c). At day 
162 post-infusion, the patient was once again leukemic with circulating CD79a+ B cell 
blasts; over 99.5% of the peripheral blood and lymph node CD79a+ B cells are cCD20-, 
indicative of an antigen-negative, CAR therapy-refractory relapse. Pathology report at 
this time described the malignant cells as "intermediate to large, immature lymphoid cells 
with granular to finely granular chromatin and visible, medium-sized nucleoli." The 
patient is continuing to be monitored and, as of April 18
th
, 2017, is 166 days post-
infusion.  
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Figure 4.1. CD28 expression and stimulus response of canine T cells taken from healthy 
and diseased dogs. (a) Frequency of CD28+ cells among CD4+ or CD8+ live 
lymphocytes taken from healthy or diseased dogs as measured by flow cytometry. Bars 
represent means ± SEM. (b) PBMCs from a healthy (blue) or the two diseased dogs (red 
and green) were stimulated with either aAPCs (solid) or Beads (dashed) for 8 days and 
fold change calculated. (c) Frequency of CD28 expression among CD4+ and CD8+ live 
lymphocytes, as measured by flow cytometry, from the diseased dogs over time post-
aAPC stimulation. 
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Figure 4.2. Growth advantage of aAPC stimulus is cell-intrinsic through contact-
dependent and –independent mechanisms. (a) PBMCs from three healthy dogs were 
cultured with Beads, K562s expressing human CD32 and loaded with agonistic anti-
canine CD3 and CD28 antibodies, K562s expressing human CD32 and canine CD86 and 
loaded with agonistic anti-canine CD3 antibody, or left unstimulated, and lymphocytes 
were counted at the end of culture. Bars represent means ± SEM. (b) CFSE-labeled 
PBMCs from three healthy dogs were cultured in a transwell plate with Beads alone in 
the lower chamber, Beads in the lower chamber and K562s expressing human CD32 in 
the upper chamber, or Beads and K562s expressing human CD32 in the lower chamber; 
CFSE peaks of live lymphocytes four days after stimulation shown with the three stimuli 
for overlaid for each dog. (c) aAPCs were stained with an isotype (grey-filled) or anti-
CD58 antibody (black line). (d) qRT-PCR analysis of GZMB expression at day 7 post-
stimulation with Beads. Expression is compared to the no cytokine condition. *p < 0.05 
as measured by Dunn's multiple comparison test following one-way ANOVA. 
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Figure 4.3. Growth and activation comparison of canine T cells stimulated with Beads or 
aAPCs. CFSE-labeled enriched PBLs from four healthy dogs were stimulated with 
aAPCs with agonistic anti-canine CD3, Beads, ConA, or left unstimulated, and were 
supplemented with rhIL-2 and rhIL-21 every other day. (a) Growth curves of all four 
conditions, means ± SEM represented and statistical comparisons only at day 6 post-
stimulation shown. (b) Responder frequency of CD5+ T cells under all four conditions 
over time post-stimulation, means ± SEM represented and statistical comparisons only 
between Beads and aAPCs shown. (c,d) MFI of CD25 expression among CD5+ T cells at 
each mitotic division at (c) day 1 and (d) 2 post-stimulation. In all cases, * p <0.05, ** p 
<0.01, and *** p <0.001 as measured by Bonferroni post-tests following two-way 
ANOVA. 
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Figure 4.4. Increased lentiviral transduction efficiency of Bead-responsive cells than 
aAPC-stimulated cells. Enriched PBLs from three healthy dogs were stimulated with 
aAPCs and agonistic anti-canine CD3 and infected with pELxPS GFP lentivirus 4 days 
later, or incubated with Beads and bound cells were cultured and infected with pELxPS 
GFP lentivirus 1 or 2 days later. After 7 days of culture, live CD5+ cells were analyzed 
by flow cytometry for GFP expression. (a) Flow plots of live CD5+ T cells, with each 
row representing a donor, as well as graphs of (b) %GFP+ T cells and (c) MFI of GFP+ T 
cells with means ± SEM represented. 
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Figure 4.5. Phenotype of Canine T cells cultured with rhIL-2 and rhIL-21 or rhIL-7 and 
rhIL-15. Enriched PBLs from four healthy dogs were stimulated with Beads and 
supplemented with rhIL-2 and rhIL-21, rhIL-7 and rhIL-15, or no cytokines every other 
day for 14 days. (a) Growth curves of the three conditions over time, means ± SEM 
represented. (b,c) Frequency of (b) CD4+ and (c) CD8+ cells among live CD5+ cells 
over time, means ± SEM represented. (d-g) Donor-matched (d,e) CD62L and (f,g) CD27 
expression among (d,f) CD5+CD4+ and (e,g) CD5+CD8+ T cells. Lines in d-g connect 
results from the same donor under different conditions. * p <0.05, ** p <0.01, and *** p 
<0.001 as measured by Bonferroni post-tests following two-way ANOVA.  
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Figure 4.6. Gene expression of Canine T cells cultured with rhIL-2 and rhIL-21 or rhIL-7 
and rhIL-15. Enriched PBLs from four healthy dogs were stimulated with Beads and 
supplemented with rhIL-2 and rhIL-21, rhIL-7 and rhIL-15, or no cytokines every other 
day. qRT-PCR performed on cDNA synthesized from RNA harvested at day 7 and 14 
post-stimulation. Upper, Data normalized to GAPDH expression, and gene expression of 
rhIL-7 and rhIL-15 cultured T cells compared to rhIL-2 and rhIL-21 cultured T cells. 
Means ± SEM represented. Lower, relative quantitation compared to GAPDH of select 
genes shown for individual donors, lines connecting results from the same donor under 
different conditions. ** p <0.01 as measured by Bonferroni post-tests following two-way 
ANOVA. 
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Figure 4.7. Design and function of cCD20-8-BB-ζ canine CAR T cells ex vivo. (a) 
Diagram of cCD20-8-BB-ζ construct. (b) Amino acid sequence of CAR construct, color-
coded by domain as in a. (c) Nucleotide sequence of codon-optimized CAR construct. (d) 
CAR surface expression among live CD5+ cells measured by flow cytometry before and 
after 1, 2, and 3 co-cultures with irradiated CLBL-1 cells at a 1 T cell to 1 CLBL-1 ratio. 
(e) Fold change in CAR T cells numbers calculated from total cell counts measured by 
trypan blue exclusion and the frequency of CD5+CAR+ cells among live cells measured 
by flow cytometry. Blue lines represent healthy donors (cCD20-8-BB-ζ), red line 
represents donor in remission (cCD20-8-BB-ζ), and green represents cCD20-8-28-ζ CAR 
T cells from Figure 3.3f. (f) Lysis of irradiated GFP-Luciferase-expressing GL-1 cells 
with and without cCD20 overnight co-culture at varying T cell to Target ratios, as 
calculated from luminescence of triplicate wells (means ± SEM represented) normalized 
to target cells alone and compared to culture with non-transduced T cells from the same 
donor. 
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Figure 4.8. Characterization of Patient 429-006’s infusion product. (a,b) Frequency of 
CD5+ cells among live cells (a) before and (b) after sorting. (c) CD79a expression on 
live cells from the peripheral blood at the time of blood draw as measured by flow 
cytometry. (d,e) CD4 and CD8 expression on live CD5+ T cells as measured by flow 
cytometry (d) at the end of initial culture of 9 days and (e) in the combined product at the 
time of infusion. (f) Flow plots of surface staining for the CAR on live transduced canine 
T cells of a healthy donor 7, 8, and 9 days after addition of aAPCs with agonistic anti-
canine CD3 antibody. 
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Figure 4.9. Peripheral blood and lymph node composition of Patient 429-006 following 
CAR T cell infusion. (a) Absolute numbers of CD79a+ (blue line, right axis) and CD5+ 
(red line, left axis) cells over time relative to infusion, calculated from flow cytometry 
and CBC. (b,c) Frequency of CD79a+ (blue line) and CD5+ (red line) cells among live 
cells in the (b) peripheral blood and the (c) right prescapular lymph node as measured by 
flow cytometry over time relative to infusion. (d,e) Frequency of CD4+ and CD8+ cells 
among live CD5+ cells in the (d) right prescapular lymph node and (e) peripheral blood 
measured by flow cytometry over time relative to infusion. (f,g) Frequency of CD28+ 
cells among live CD4+ or CD8+ cells in the (f) peripheral blood and (g) right prescapular 
lymph node measured by flow cytometry over time relative to infusion. (h) Copies of 
integrated CAR gene per μg of genomic DNA in the peripheral blood (blue line) and right 
prescapular lymph node (red line) over time relative to infusion, as measured by qPCR. 
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Figure 4.10. Changes in cCD20 expression among Patient 429-006’s B cells following 
CAR T cell infusion. (a) Frequency of cCD20- cells among live CD79a+ cells in the 
peripheral blood (blue line) and right prescapular lymph node (red line) as measured by 
flow cytometry over time relative to infusion. (b) cCD20 and CD79a expression of live 
cells from the peripheral blood and right prescapular lymph node at day 89 post-infusion 
as measured by flow cytometry. (c) Overlaid FSC and SSC plots of cCD20- (red) and 
cCD20+ (blue) live CD79a+ cells in the peripheral blood at day 138 post-infusion as 
measured by flow cytometry. 
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Discussion 
While evidence of decreased expression of CD28 on CD4+ T cells of canine patients with 
end-stage lymphoma is limited, the functional consequence of their ability to respond to 
Beads or aAPCs is stark. This is particularly interesting in light of the fact that many 
human CLL patients are unable to participate in CAR T cell trials due to their inability to 
expand using human-specific beads (Fraietta et al., 2016; Porter et al., 2015). Combined 
with observations in vivo from Chapter 3, this strengthens the rationale for using 
frequency of CD28+ T cells as a marker of health in the canine T cell compartment. 
While the relationship may not be direct, and CD28 expression may be correlated to 
something else that has a greater impact on T cell functionality and survival, it is the best 
proxy available within the repertoire of markers for which there are canine-specific 
antibodies. In humans, levels of CD28 expression on CD8+ T cells decrease with 
increased differentiation as well as the age of the host (Leitner et al., 2015); it is possible 
that this decrease among canine CD4+ T cells may be associated with these same factors 
upon further investigation, but the patients that we treated were not much older than our 
healthy donors. That these CD28+ T cells are potentially the best starting T cell 
population from which to make a product is underlined by the potent activation and 
proliferation response elicited by the Beads. Early cell division and overall population 
growth are decoupled in our stimulus systems, as evidenced by the superior expansion by 
the aAPCs; the likely scenario is that T cells that respond to the Beads do so rapidly and 
strongly and those that do not die off in culture, increasing the responder frequency when 
examining only live cells as time progresses, while the T cells that would not respond to 
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the Beads are “rescued” by the aAPCs and eventually divide later on. Potential 
mechanisms for aAPC-mediated “recovery” of canine T cells, and possible ways to take 
advantage of them, are discussed in Chapter 5. 
Use of rhIL-7 and rhIL-15 instead of rhIL-2 and rhIL-21 seems to maintain more 
memory-like cells based on the increased frequency of CD62L+ cells. Interpretation here 
is limited, as some of the commonly used surface markers to differentiate memory and 
effector subpopulations are cannot be accurately measured in canine T cells; canine-
specific or cross-reactive antibodies to  CD44, CCR7, CD45RA, CD45RO, CD95, 
CD127, and KLRG1 are either lacking or unreliable in our use. Regardless, that these 
markers identify the same populations in dogs as they do in humans and mice would need 
to be validated. While qRT-PCR is limited when examining bulk T cells, the increase in 
CD62L expression matches our flow observations. The decrease in GZMB and PRDM1 
suggests an overall shift within the population away from effector cells. The decrease in 
BCL6 expression is puzzling, as it works in opposition with PRDM1 in mice and humans, 
but mRNA levels do not correlate with Bcl6 activity, as there is significant post-
transcriptional and post-translational control involved (Crotty et al., 2010). The initial 
increase and eventual decrease in both EOMES and TBX21 mRNA is difficult to interpret 
from a mixed pool of T cells, especially in light of the many roles each of these 
transcription factors plays, but it is worthy of deeper investigation considering their key 
part in T cell function and exhaustion. Overall, it would appear that culture of canine T 
with rhIL-7 and rhIL-15 is associated with decreased terminal differentiation, just as it is 
in human T cells. 
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Preliminary ex vivo functional assays with the cCD20-8-BB-ζ CAR in canine T cells 
demonstrate their impressive proliferative capacity in response to repeated target 
challenge. Compared to the limited expansion of the canine cCD20-8-28-ζ CAR T cells 
ex vivo, this suggests that the BB-based construct overcomes some of the limitations of 
the CD28-based construct, just as observed in human CAR T cells (Kawalekar et al., 
2016; Long et al., 2015). 
There were many factors that were different with Patient 429-006 compared to the four 
patients described in Chapter 3 – sorting of the T cells, different stimulus, different 
cytokines used in culture, shorter culture time, that the patient was profoundly leukemic, 
that the pre-conditioning chemotherapy had a significant lymphodepletive effect, a 
different co-stimulatory domain within the CAR construct – so it is impossible to credit 
the difference in outcome on any single change. However, the goal was to generate a 
better therapy overall, including whatever modifications at each step that may have 
contributed to that. The circulating malignant B cells rebounded following the end of 
chemotherapy pre-conditioning, and their numbers were never dramatically reduced until 
rescue chemotherapy was begun at day 46 post-infusion. Nevertheless, the presence of 
the CAR gene in the target lymph node 50 days post-infusion is encouraging, and qPCR 
results for peripheral blood and lymph node aspirate samples following that timepoint are 
pending. The most stunning outcome was the loss of cCD20 in both the circulating and 
lymph node B cells, which preceded rescue chemotherapy. It is possible that there was a 
spontaneous loss of cCD20 expression in some of the malignant cells or a second 
transformation occurred among cCD20- B cells, but the simplest explanation of this 
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observation is immune pressure selecting against cCD20 expression, and that the cCD20-
targeting CAR T cells which were still present at day 50 post-infusion were mediating 
this. The similarities in the pathology report descriptions at diagnosis and 162 days post-
infusion also support this. That the B cell populations became overwhelmingly cCD20- in 
the months that followed could be attributed to two potential scenarios: continued 
pressure from the CAR T cells, or the malignant population derived from the cCD20- 
clone had a proliferative advantage. Determining whether the CAR T cells persisted, 
measured by forthcoming qPCR data, will help clarify this. Antigen escape has been 
observed in human CAR T cell trials targeting CD19 in B cell leukemias; in those cases, 
CD19 is not lost, but instead a splice variant that does not include the epitope for the anti-
CD19 scFv within the CAR is expressed (Sotillo et al., 2015). Additionally, loss of CD20 
expression among human non-Hodgkin’s lymphomas that have relapsed following 
CD20-targeting antibodies such as rituximab is common, and these can also be in the 
form of epitope-negative splice variants (Gamonet et al., 2016; Haidar et al., 2003). 
Efforts to sequence the ostensibly cCD20- B cells are underway to determine whether we 
have encountered a similar phenomenon, and samples of the cCD20- cells and the 
original tumor are being submitted for PARR to confirm that the cCD20- cells are clonal 
and are derived from the original tumor. 
Altogether, these steps have led to a current canine CAR T cell therapy protocol that, 
while still unable to elicit a clinical remission, appears to be forcing specific tumor 
immunoediting in order to escape elimination, just as in humans (Sotillo et al., 2015). 
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General conclusions and potential avenues for therapy improvement are discussed in 
Chapter 5. 
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CHAPTER 5: Conclusions and Discussion 
 
CAR T cell therapy is not between 500 and 600 amino acids long. It is the patient, their 
disease, and their history of prior therapy. It is how the T cells are isolated from the 
patient, and what they experienced while in there. It is how these T cells are stimulated 
and fed, how they are grown and for how long. It is when and how the CAR is expressed, 
by what delivery, for how long, and at what level. It is how these T cells are preserved, 
and what has happened to the immune and tumor environment within the patient before 
they are infused back in. It is how these T cells circulate and traffic into tissues, it is how 
they expand and contract, metabolize and differentiate, survive and die. It is how the T 
cells, the tumor, the tissues, and the other immune cells of the patient all interact with 
each other. 
CAR T cell therapy is re-creating the essentials of T cell immunobiology, but with a 
synthetic antigen receptor. Any attempt at modeling CAR T cell therapy, or any 
immunotherapy, must recapitulate all of these factors and more to have a hope at being 
accurate and predictive. We believe that dogs and the treatment of their spontaneous 
malignancies are the best potential model we have for human patients, and that the 
advances described in this thesis have made this goal attainable. Indeed, in treating just 
six dogs over the course of two years, our results have recapitulated the effects of patient 
chemotherapy, the development of anti-CAR immune responses, the CAR T cell 
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persistence issues, and the antigen-negative relapses that were seen after years of human 
clinical trials, and had not been predicted in mouse models. 
This chapter consists of three major themes: conclusions of our findings, 
recommendations for near-term investigations that follow our observations, and 
suggestions for long-term future directions with a discussion of broader implications. 
 
Obtaining Better Initial Cell Products from Patients 
We have found in dogs, as in humans, that prior cytotoxic chemotherapy can damage the 
T cell compartment before it is isolated from the patient to be expanded for the 
therapeutic product. While the proliferative capacity of the canine T cells recovers as the 
time of isolation moves farther and farther away from the last dose of chemotherapy, it 
shortens the time available to generate a CAR T cell product before the patient relapses 
or the disease reaches a stage of rapid progression that does not allow a window of 
opportunity for the CAR T cells to expand in vivo and establish control. One potential 
solution for this is to collect blood to generate a product from newly-diagnosed canine 
patients when they are unexposed to chemotherapy, and generate and preserve the 
product while the patient receives CHOP chemotherapy until they are in clinical 
remission; this would allow the initial T cells to be unexposed to harmful chemotherapy, 
and infusion of CAR T cells during remission would allow the CAR T cells to establish 
themselves in the patient and expand against normal B cells until the malignant clone 
resurfaces; as greater than 80% of canine B cell lymphoma patient relapse in less than a 
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year following CHOP-induced remission, our measurement of clinical efficacy would be 
disease-free survival. Another option is the use of the BTK inhibitor ibrutinib; studies in 
humans with CLL have found that patient T cells are similarly hindered in their 
expansion, but that inclusion of ibrutinib in the patient anti-CLL treatment prior to 
apheresis for T cell collection markedly improved the health of the T cells (Fraietta et al., 
2016; Ruella et al., 2016). The mechanism appears to be both counteracting 
immunosuppression by the malignant B cells, as well as direct positive effects on the T 
cells. In particular, ibrutinib treatment was associated with decreased expression of the 
inhibitory ligand CD200 on the malignant B cells and decreased expression of inhibitory 
receptors on the T cells; ibrutinib also appears to inhibit ITK in T cells, pushing them 
from a Th2 phenotype to a more effective anti-tumor Th1 phenotype. Ibrutinib has been 
tested in canines before, with signs of cross-species bioactivity (Honigberg et al., 2010). 
We currently collect canine T cells through Ficoll gradient separation of whole blood. In 
addition to contamination with other components of the PBMC compartment and 
platelets, as well as dead cells due to Ficoll’s toxicity, a significant number of canine 
neutrophils migrate at PBMC level in Ficoll with the commercially available specific 
gravity of 1.077 (Wunderli and Felsburg, 1989). In Chapters 2 and 3, we enriched for live 
PBLs by culturing the collected cells on tissue culture plates overnight, allowing 
platelets, dead cells, and adherent monocytes to stick to the plate, before harvesting cells 
remaining in suspension for stimulation. Interestingly, two very recent studies in the field 
of human CAR T cells therapy have also focused on enriching for lymphocytes and 
avoiding myeloid-derived suppressor cells, using elutriation and the same tissue culture 
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plate-adherence method that we used (Stroncek et al., 2017; Stroncek et al., 2016). 
Nevertheless, residual malignant cells or myeloid-derived suppressor cells could remain 
in culture and hinder ex vivo T cell expansion. To select for T cells specifically, we also 
developed a negative selection protocol by MACS, depleting CD11b, CD11c, CD14, and 
CD21-expressing cells, that resulted in 95% CD5+ cell purity for a trial patient that was 
treated too recently to include in Chapter 4. Flow-sorting is highly efficient for purity, but 
expensive for the required cell number yield. However, sorting specifically for CD28+ T 
cells could be an attractive option, especially from patients that may have a low 
frequency of them, given their potency that we have observed so far. 
 
Understanding ex vivo T cell Recovery 
Understanding the consequences of CD28 expression on canine T cells has traced our 
work from our earliest in vitro experiments, when some canine donor PBMCs did not 
respond to Bead stimulation, to our in vivo immune monitoring, where increased CD28 
expression in T cells in the patient is associated with disease control. Our preliminary 
data shows lowered frequency of CD28-expressing CD4+ T cells in dogs with late-stage 
lymphoma, and a differential response to Bead or aAPC stimulus. The ability to not only 
expand T cells from a Bead-refractory population, but also increase CD28 expression 
among those cells, is a particularly exciting feature of the aAPCs. Examining a larger 
cohort of canine patients with various stages of malignancy and different amounts of 
chemotherapy treatment and comparing to age-matched healthy canine donors their levels 
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of CD28 expression as well as their ability to respond to Beads or aAPCs is an obvious 
next step to confirm this observation. This rationalizes identification of stimulatory 
factors on the aAPCs and its parental cell line, the K562. Our first candidate is the co-
stimulatory ligand CD58, which we found to be expressed on K562 cells; gain and loss of 
function experiments using recombinant CD58 bound to CD3/CD28 Beads and using a 
CD58-blocking antibody with aAPCs are already planned. While aAPCs are superior in 
their stimulatory abilities and, as a cell line, a cheap and self-renewing resource, they are 
an additional cell in culture to uptake virus, and use of a xenogenic cell line in CAR T 
cell product manufacturing poses issues for GMP compliance that magnetic beads do not. 
The eventual generation of an aAPC-on-a-Bead would be breakthrough for both canine 
and human CAR T cell therapy, as human patients are often excluded because of 
inadequate expansion with human Beads. This is particularly fitting as K562s were 
identified first as an aAPC of choice for human T cells, and their adaptation to canine T 
cells has led to findings that can improve human T cell expansion. 
We described two iterations of cytokine supplementation for canine T cell culture, use of 
rhIL-2 and rhIL-21 and the use of rhIL-7 and rhIL-15. Exploration of other cytokines, or 
combinations of more than two cytokines could very easily produce a much more potent 
milieu for T cell growth and preferred differentiation (Xu et al., 2016). Another 
consideration is the use of canine cytokines instead of human ones, as several have 
become commercially available recently. Use of canine IL-2 resulted in the growth of 
roughly twice as many canine NK cells in ex vivo culture than human IL-2, suggesting 
stronger species-specific bioactivity (Foltz et al., 2016). 
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Opportunities for Improved CAR Design 
While CAR constructs using CD28 or 4-1BB co-stimulatory domains were both used in 
our in vitro experiments, they were never compared in the same conditions in T cells 
from the same donors. Efforts to confirm the differences and advantages of each in 
canine T cells are worthwhile, as they may be different from the findings in human 
studies. To perform this, isolated and purified peripheral T cells could be electroporated 
with mRNA encoding either CAR, as in Chapter 2, and cytokine production, 
proliferation, and differentiation following signaling through either CAR could be 
compared within each donor; this would allow assessment of the effects of the CAR 
independent of culture conditions or variable expression levels following transduction. 
Another compelling study would be treating canine patients with both cCD20-8-28-ζ and 
cCD20-8-BB-ζ CAR T cells, and track the expansion, contraction, and engraftment of 
either population among the peripheral blood and various tumor sites over time by qPCR. 
We have already designed primers that would differentiate between the two CAR 
constructs, and are actively preparing for this next trial. 
There has been a significant amount of debate surrounding what the success of CD19-
targeting CAR T cells in humans is predicated on, especially since its success rate is an 
outlier among CAR T cell therapy targets. There are two major competing, albeit not 
mutually exclusive, hypotheses: that it is the CD19 target, or the CD19-targeting scFv. In 
case of the former, CD19 is restricted to the B cell lineage, so it can be targeted without 
concern for off-tumor on-target lethal toxicities, and constant low-level replenishing of 
CD19+ non-malignant target cells keeps the CAR T cells primed against relapse; 
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additionally, trafficking to sites that contain the CD19 target through circulation, tissues, 
lymph nodes, B cell-producing niches of the bone marrow, and others put the CAR T cell 
in prime locations for receiving survival signals. Evidence for the latter is that scFvs 
naturally aggregate, and expression on the cell surface while attached to signaling 
domains leads to constant self-signaling and eventual self-exhaustion (Whitlow et al., 
1994). However, the commonly used anti-human CD19 scFv FMC63 does not have this 
“sticky” characteristic; in fact, swapping out the framework regions of FMC63 – 
retaining its specificity – with those of a “sticky” anti-GD2 scFv leads to exhaustion and 
lack of efficacy (Long et al., 2015). Based on these two hypotheses for the success of 
anti-CD19 CAR therapy, there are two avenues to explore. First is to determine whether 
the cCD20 scFv we use in our CAR constructs leads to self-signaling. Secondly, we are 
in the process of developing an anti-canine CD19 antibody and screening for canine 
CD19-reactive scFvs among phage libraries. 
Another major consideration in our choice of targeting moiety is the species of origin. 
While B cell-targeting CAR T cells will not run into the problem of anti-murine 
antibodies being developed against the scFv if they are successful in B cell clearance, 
targeting other tumors in humans has led to the development of HAMA and we have 
observed the development of CAMA when B cell clearance is not achieved (Kershaw et 
al., 2006; Maus et al., 2013). Alteration of the scFv to match the patient species will 
avoid this outcome, and we are currently assembling resources for a canine phage library. 
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Canine Patient Pre-Conditioning 
Lymphodepletion, particularly the regimen used, has been found to be critical for success 
in human CAR T cell therapy (Turtle et al., 2016). Not only does it reduce tumor burden 
in hematological malignancies and decrease established regulatory T cells and myeloid-
derived suppressor cells that can hinder therapy efficacy, the reduction of competing T 
cells aids homeostatic expansion and engraftment of the infused CAR T cells. In only one 
patient, 429-006, can we say that we made any real effect on the lymphocyte population 
by the time of infusion. It is unclear whether it is because the patient’s cells were 
particularly susceptible, or that the combination of vincristine and cyclophosphamide in 
that short period of time was effective. 
The pre-conditioning chemotherapy regimen of choice in human therapy has been a 
combination of cyclophosphamide and fludarabine (Porter et al., 2011; Turtle et al., 
2016). While cyclophosphamide is commonly used in canine patients, fludarabine has 
only been used in an experimental canine bone marrow transplant models (Gyurkocza et 
al., 2009). The combination of the two has been a double-edged sword in human therapy: 
the magnitude of its efficacy on treatment success is matched only by the severity of its 
side effects. While it has led to remarkable expansion and efficacy of human T cells in 
vivo and prevented anti-CAR immune responses, it has also increased the likelihood and 
severity of cytokine release syndrome (Turtle et al., 2016). The role of canine patients as 
companion pets gives the side-effects of CAR T cell therapy and its associated pre-
conditioning unique consideration, as owners are especially sensitive to quality of life 
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when determining end of care. This challenge in privately-owned animals may pressure 
the field to focus on determining the minimum effective dose – in all species. 
 
Efficacy and Safety in Canine CAR T Cell Therapy 
Clinical response and CRS appear to go hand-in-hand in human CAR T cell therapy, and 
whether that toxicity is necessary for efficacy is an area of open debate. We have 
observed neither yet in our canine patients, suggesting perhaps that this correlation is 
across species. Our patient data that we have collected over the course of this thesis 
suggest that we are getting closer to obtaining a clinical response, and possibly CRS 
along with it, but several steps are necessary before we can claim that canine CAR T cell 
therapy is finally on par with human CAR T cell therapy. Some of these improvements 
have already been mentioned in discussions in other chapters as well as this one. Based 
on observations from our canine patients as well as human patients, a theoretical ideal 
protocol would consist of the following. T cells would be isolated and purified from 
patients that have not yet received chemotherapy, to avoid negative effects of 
chemotherapy and other suppressive cells on the T cells. These would undergo a short 
expansion period, supplemented with aAPCs and possibly ibrutinib to recover these cells, 
and would be cultured with rhIL-7 and rhIL-15 to maintain central and stem-like memory 
populations. To achieve a target cell dose in the range 10
6
 CAR T cells/kg, a larger 
starting number of T cells could be used; alternatively, technological advancements for 
rapid human T cell growth, such as a wave-bioreactor system or G-Rex flasks, could be 
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used in lieu of standard tissue culture flasks. These T cells would express a cCD20-8-BB-
ζ CAR, ideally in which the scFv is of canine origin to avoid anti-CAR immune 
responses in vivo and has been shown to not self-stick. The patient would be pre-
conditioned with cyclophosphamide and fludarabine, to reduce tumor burden and 
suppressive immune cells as well as create a niche for the CAR T cells to engraft and 
expand in. The reduction in tumor burden will also be important because of the 
aggressiveness of canine lymphoma once it progresses, and the time for a clinical 
response in treating human B cell lymphomas with CAR T cells is on the order of 
months. To counteract any CRS, the cross-reactivity of the human IL-6R blocking 
antibody tocilizumab, standard of care now for ameliorating CAR-mediated CRS in 
humans, would need to be validated in dogs or a new canine-specific blocking antibody 
would need to be developed. A model of how several of these steps are expected to affect 
the clinical outcome is shown in Figure 5.1. 
 
Genetic Modification of Primary Canine T Cells 
Lentiviruses have been found to naturally infect primate, equine, bovine, ovine, caprine, 
and even feline species, but no naturally-occurring canine infection with lentivirus has 
been discovered. In fact, exogenous retroviruses as a whole have been curiously absent 
from canine pathology. Nevertheless, we have been able to infect primary canine T cells 
with lentivirus, albeit at much lower efficiencies than primary human T cells in head-to-
head comparisons that we have performed. We pseudotype with the VSV-G envelope, 
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which should allow broad mammalian tropism due to its binding of the LDL receptor 
(Finkelshtein et al., 2013); while cells of hematopoietic origin are known to express low 
levels of surface LDL receptor while resting, it rapidly increases upon stimulation, and 
the canine T cells are almost entirely CD25+ by the time we infect with lentivirus 
(Amirache et al., 2014). This would suggest that the major hurdle in successful 
transduction is post-entry. mTOR inhibitors have been suggested to alleviate this block, 
but preliminary testing we have performed with rapamycin and Torin1 has been limited 
by toxicity (Wang et al., 2014). We have also attempted transduction with 
gammaretroviruses using the MMLV and MSCV promoters, but head-to-head 
comparisons with lentivirus showed decreased transduction efficiency, and we expect 
that they face the same canine-intrinsic post-entry challenge. 
The level of CAR expression in a cell is crucial to its function. Too little, and there is 
little dimerization upon antigen-binding and no productive signal transduction. Too 
much, and the CAR will aggregate on the cell surface on its own, and self-signal without 
antigen. While the choice of promoter plays a significant role in the expression level of 
the transgene, the location in the genome where the lentivirus or gammaretrovirus 
integrates is just as, if not more important. Entry into a silenced site is unproductive, and 
insertion into functional exons could be deleterious in many respects. The ideal level of 
expression and gene control would match the T cell’s own endogenous antigen receptor. 
Combined with the advent of CRISP/Cas9 technologies, this presents a unique 
opportunity: disruption of the TCR locus with CRISPR, followed by using the CAR 
transgene as a donor sequence to insert in its place (Eyquem et al., 2017). Not only would 
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this allow CAR expression to be controlled under same “Goldilocks” conditions as the 
TCR, but, combined with elimination of MHC expression, this could be used to generate 
allogeneic CAR T cell products that cannot perform GVHD and avoid clearance by 
recipient T cells. As CRISPR gRNAs and Cas9 mRNA can be electroporated and AAVs, 
which are the gene donors of choice, are used in canine disease models (Koeberl et al., 
2008), this is an attractive long-term strategy for dogs for which an autologous CAR T 
cell product cannot be generated – and also one that dogs are well-suited for, given their 
history of pioneering allogeneic transfers since the 1950s (Ferrebee et al., 1958). 
 
Accurate Identification of Canine Immune Cell Populations 
As particularly evident in our attempts to generate and identify canine memory T cells in 
Chapter 4, the lack of available antibodies for identifying canine surface markers is a 
major frustration for this field. CD5 is the canine T cell identifier of choice in no small 
part because the anti-canine CD3ε antibody is of such low affinity and varying quality 
batch-to-batch that it cannot be relied upon for accurate staining. There is no anti-canine 
CD19, leaving an anti-CD79a antibody that stains intracellularly as the only pan-B cell 
marker available for canine studies, limiting experiments on sorted live canine B cells. A 
concerted effort to identify and validate potential cross-reactive antibodies among those 
available for other species or to generate canine-specific ones in their absence is not only 
necessary, but worthwhile. This will allow us to more accurately identify and characterize 
the cells we are getting from our patients, the cells that we are growing ex vivo and 
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putting back into our patients, and what they are doing in vivo – all critical for the 
advancement of the canine model of therapy and, with it, human therapy. 
A case in point is the identification of canine NK cells. Due to the limited markers, this is 
an area of not only active exploration but also controversy in the canine field since they 
cannot be readily differentiated from canine T cells (Foltz et al., 2016; Huang et al., 
2008; Michael et al., 2013). CD3 staining is unreliable, and validated anti-CD56 or anti-
CD16 antibodies are not available for dogs. In our own experience, we have observed a 
lymphocyte population in the peripheral blood of healthy canine donors that stains 
distinctly CD5low, and these cells are uniformly CD8+, CD79a-, CD28-, CD27-, and 
only stain for CD3ε when permeabilized. Whether these are NK cells or a different 
lymphocyte subset is unknown. Understanding what these cells are is of importance to 
use for two reasons. First, these cells are in our starting cultures, even if we purify for 
only CD5-expressing cells, and are likely still present in our infusion product. Second, in 
the course of screening canine patients with lymphoid malignancies, we have come 
across multiple patients with tumors with the same expression pattern. A canine-specific 
NKp46 antibody has been recently reported, and we are in the process of obtaining it to 
characterize both normal and banked tumor samples (Foltz et al., 2016). 
 
Bringing Canine Molecular Immunology Up to Speed 
Next-generation sequencing, and the precipitous drop in cost for performing it, has been 
transformative for basic, translational, and clinical immunology. Tumor-specific 
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mutations can be rapidly identified and exploited by whole exome sequencing, and the 
expression and epigenetic profiles of even the smallest subset of cells can be 
characterized by RNA-seq and ATAC-seq. However, all of this depends on a foundation 
of robust and well-annotated reference sequences. In this particular capacity, canine 
genetic analysis is woefully and, considering the wealth of information and opportunities 
that can be derived from it at such a relatively low cost, inexcusably lacking. Raw reads, 
especially from ancient dog samples used for evolutionary studies, are available, but the 
NCBI canine reference genome is from a single boxer (NCBI Accession NC_006621.3) 
(Frantz et al., 2016; Lindblad-Toh et al., 2005). In our own experience, the predicted 
sequences for multiple canine genes from this reference genome have been inaccurate. 
We and another group have independently found the same amino-acid level differences 
from the reference sequence when cloning canine PD-1 (NCBI Accession 
NP_001301026.1) (Maekawa et al., 2014). The predicted sequence for canine CD3ζ has 
only 2 intact ITAMs, and a CAR construct including the predicted intracellular domain 
sequence does not express on the cell surface (NCBI Accession XP_005623027.1); we 
found at least 18 amino acid differences in the intracellular domain alone when we cloned 
it ourselves from canine cDNA. These discrepancies among such a small sample size are 
troubling, and we strongly encourage the generation of a more accurate and higher-
quality canine reference genome from many more canine donors across breeds. These 
efforts can be de novo, or whole exome sequencing data of tumor and normal tissue in 
comparative oncology studies can be made public. 
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Concluding Remarks 
Dogs have been used as a model for human immunotherapy for decades, since the days of 
bone marrow transplantation studies in the mid-20th century. Using canine patients with 
spontaneous malignancies, from cancers of the blood to the bone, to model CAR T cell 
therapy and other cutting-edge technologies is the natural evolution of looking to our 
companions for insight. It took over twenty years since the first CAR, and over ten years 
since the development of anti-human CD3 and CD28 beads to grow T cells, before the 
clinical success of CAR T cell therapy in humans. Our work here in dogs has mirrored 
some of the successes – and many of the challenges – found in the treatment of our own 
species in just over four years, and the development of canine reagents and resources is 
the only barrier to further breakthrough therapies for our dogs and ourselves. 
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Figure 5.1. Model of improvements for canine CAR T cell therapy. Diagram of patient 
product generation and treatment, with negatively-associated factors in red and 
positively-associated factors in blue. 
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CHAPTER 6: Materials & Methods 
 
Generation of cell-based artificial APCs 
The human erythroleukemic cell line K562 was stably transduced with a self-inactivating 
lentiviral vector, pCLPS, containing the human FcγRII (CD32) and cloned by single cell 
sorting to produce Kt32 as previously described (Maus et al., 2002; Suhoski et al., 
2007). KT32 cells expressing cCD86 were generated. Briefly, canine CD86 was 
amplified from cDNA derived from PHA and rhIL-2 stimulated canine PBMCs by RT-
PCR using gene specific primers flanked with BamHI and XhoI restriction sites. The 
resulting cDNA was cloned into the pCLPS vector. Lentivirus was generated as 
previously described and used to transduce KT32 cells (Parry et al., 2003; Reiser, 
2000). KT32 cells expressing high levels of cell surface canine CD86 were bulk sorted to 
produce KT32/cCD86, referred herein as aAPCs. aAPCs were cultured in K562 media 
containing Roswell Park Memorial Institute media (RPMI) 1640 with 2 mM L-glutamine 
(Mediatech, Manassas, VA), 10% heat-inactivated fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA), 10 mM HEPES (Gibco, Grand Island, NY), 1 mM 
sodium pyruvate (Mediatech), 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco), 
and 30 μg/ml gentamicin (Gibco), filtered through a 0.22 μm filter Stericup (Millipore, 
Billerica, MA). 
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Generation of anti-canine CD3/CD28 magnetic beads 
Agonistic mouse anti-canine CD3 (clone CA17.2A12, ABD Serotec, Raleigh, NC) and 
mouse anti-canine CD28 (clone 5B8, a generous gift of Dr. Rainer Storb) were 
conjugated to magnetic tosylactivated Dynabeads (Life Technologies, Grand Island, NY) 
according to the manufacturer's protocol. In brief, 25 μg of both antibodies were 
incubated with 10
8
 activated beads for 24 hours at room temperature in the presence of 
sterile filtered 0.01% bovine serum albumin (Sigma-Aldrich, St. Louis, MO) to prevent 
nonspecific binding. Beads were then incubated at 37°C for 4 hours to deactivate unused 
tosyl-groups. Conjugated beads were stored at 4 × 10
8
/ml in 0.1% bovine serum albumin 
w/v in Dulbecco's phosphate-buffered saline (DPBS) (Mediatech) with 2 mM EDTA 
(Gibco) and 0.01% sodium azide (Amresco, Solon, OH) at 4°C. 
 
Canine PBMC isolation and T cell culture 
Canine PBMCs were isolated by discontinuous density centrifugation over Ficoll-Paque 
PLUS (s.g. 1.077, GE Healthcare, Uppsala, Sweden). PBMCs were washed twice in T 
cell media (TCM) containing RPMI 1640 with 2 mM L-Glutamine (Mediatech), 10% 
heat-inactivated fetal bovine serum (Atlanta Biologicals), 10 mM HEPES (Gibco), and 
100 U/ml penicillin and 100 μg/ml streptomycin (Gibco), filtered through a 0.22 μm filter 
Stericup (Millipore). Live PBMCs were enumerated by hemocytometer using trypan blue 
exclusion, and plated on 10 cm diameter tissue culture dishes (Falcon, Corning, NY) at 1 
× 10
6
 cells/ml and incubated overnight at 37°C and 5% CO2. Supernatants enriched for 
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viable peripheral blood lymphocytes (enriched PBLs) were collected on the following 
day and cells were pelleted following centrifugation at 218g for 5 minutes. When aAPCs 
were used for T cell activation and expansion, aAPCs cells were irradiated with 10,000 
rads, washed in TCM, and resuspended at 5 × 10
5
 cells/ml. Cells were co-cultured with at 
a 1:2 ratio of aAPCs:enriched PBLs to a final concentration of 5 × 10
5
 enriched PBLs and 
2.5 × 10
5
 aAPCs per ml with 0.5 μg/ml mouse anti-canine CD3. When antibody-
conjugated beads were used for T cell activation and expansion, beads were washed three 
times with DPBS and once with TCM before addition to enriched PBLs at a 3:1 ratio of 
beads:enriched PBLs in Chapter 3, and then 4:1 in Chapters 3 and 4. During lectin-
induced proliferation, PBMCs were cultured with 2.5 ng/ml of concanavalin A (Sigma-
Aldrich) with 100 U/ml recombinant human IL-2 (Gibco) added after 48 hours, unless 
described otherwise. In all cases, cells were cultured at 37°C and 5% CO2 with TCM. 
Where indicated, 30 U/ml rhIL-2 (Gibco) and 10 ng/ml rhIL-21 (eBioscience) were 
added at the time of stimulation and every second day thereafter. Where indicated, 10 
ng/mL rhIL-7 (Peprotech, Rocky Hill, NJ) and 5 ng/mL rhIL-15 (Peprotech) were added 
at the time of stimulation and every second day after; for Patient 429-006, 20 ng/mL of 
rhIL-7 and 10 ng/mL rhIL-15 were used. 
Trial patient T cells were grown as described in Chapters 2, 3, and 4. Cell culture 
supernatants at the time of harvest were submitted to the University of Pennsylvania Cell 
Center Services core for mycoplasma testing; all samples returned negative. An aliquot of 
each infusion product was submitted to the VHUP microbiology lab for gram stains; all 
samples returned negative. Aliquots of cultured cells of the lentivirus trial patients were 
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taken 3, 5, and 7 days post-infection and submitted to the University of Pennsylvania 
Translational and Correlative Studies Laboratory for Replication Competent Lentivirus 
testing; samples passed prior to infusion. 
 
Flow cytometric analysis of canine cells 
Where indicated, PBMCs were washed twice with DPBS, resuspended to 1 × 10
7
 cells/ml 
in DPBS, and labeled with carboxy-fluoroscein succinimidyl esterase (CFSE, 5μmol/l, 
Sigma Aldrich) for 5 minutes at 37°C. Labeling was quenched with 5 volumes of TCM. 
Cells were washed twice and resuspended in TCM prior to stimulation. At the time points 
indicated, cells were harvested and washed in fluorescence-activated cell sorting (FACS) 
buffer (1% heat-inactivated fetal bovine serum in DPBS with calcium and magnesium) 
prior to surface staining with a combination of the following antibodies: APC- or 
PacificBlue-labeled rat anti-dog CD4 (clone YKIX302.9, ABD Serotec), PE-labeled rat 
anti-dog CD5 (clone YKIX322.3, eBioscience), PE- FITC- or AF647-labeled rat anti-dog 
CD8 (clone YCATE55.9, ABD Serotec), mouse anti-dog CD20 (clone 6C12, Invivogen, 
San Diego, CA) with BrilliantViolet421- or AlexaFluor488-labeled goat anti-mouse IgG 
secondary (clone Poly4053, Biolegend or Life Technologies), eFluor660-labeled mouse 
anti-dog CD25 (clone P4A10, eBioscience), PECy7-labeled Armenian hamster anti-
mouse CD27 (clone LG.7F9, eBioscience), PECy7-labeled mouse anti-human CD45 
(clone HI30, Biolegend, San Diego, CA), FITC-labeled mouse anti-human CD62L (clone 
FM46, ABD Serotec), and the cell viability dye 7-AAD (Biolegend). Following surface 
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staining, cells were washed twice in FACS buffer and fixed in 1% paraformaldehyde 
(Ted Pella, Redding, CA). Where indicated, cells were permeabilized with 0.1% saponin 
(Sigma Aldrich) post-fixation and stained with a cross-reactive APC-labeled mouse anti-
human CD79a antibody (clone HM57, BD Biosciences, San Jose, CA). Surface detection 
of the CAR was performed by labeling with a biotinylated rabbit anti-mouse IgG H+L 
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) followed by fluor-
conjugated streptavidin secondary (BD Biosciences) prior to all other surface staining. 
T cells were defined by expression of CD5, B cells were defined by expression of 
CD79a, and aAPCs were defined by expression of human CD45. For flow cytometric 
enumeration, labeled samples were spiked with a known number of CountBright Beads 
(Life Technologies) prior to acquisition, and cell numbers were calculated based on bead 
recovery. Acquisition was performed on a FACSCalibur, FACSCanto II, or LSR Fortessa 
flow cytometer (BD Biosciences) and data was analyzed using FlowJo software version 
X (Treestar, Ashland, OR). Patient 429-006 cells were sorted for 7-AAD-CD5+ on a 
FACS Aria. 
 
Cell lines 
K562 cells, K562 cells expressing human CD19 (K562.hCD19), and the human primary 
pancreatic adenocarcinoma cell line BxPC3.hCD19 were kindly provided by Dr. Carl 
June. The murine fibroblast line 3T3 was kindly provided by Dr. Jonathan Maltzman. 
GL-1 cells expressing GFP-CBG-Luciferase with and without cCD20 were kindly 
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provided by Dr. Avery Posey. Jurkat cells were kindly provided by Dr. Daniel Powell, 
and Jurkat cells expressing the hCD19-8-ζ CAR were kindly provided by Dr. Michael 
Milone. To generate canine CD20 (cCD20) expressing target cell lines, cCD20 was 
amplified from PBMC cDNA and cloned into pCLPS. The cCD20 transgene and the 
IRES-GFP reporter cassette following the transgene were under the control of a CMV 
promoter. Lentivirus was generated as previously described, and concentrated 
supernatant was used to infect K562 and 3T3 cells to generate cCD20-expressing K562 
cells (K562.cCD20) and 3T3 cells (3T3.cCD20). 
3T3 and 3T3.cCD20 cells were grown in Dulbecco's modified essential medium 
(Mediatech) with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals), L-
glutamine (2 mM), and 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco), filtered 
through a 0.22 μm filter Stericup (Millipore). All K562 cell lines were grown in K562 
media, while BxPC3.hCD19, Jurkat cell lines, canine malignant B cell lines 17–71, GL-1, 
and canine B cell lymphoma cell line CLBL-1 were grown in TCM. All cell lines were 
cultured at 37°C and 5% CO2. 
 
qRT -PCR 
Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA). 
Reverse transcription was performed using random hexamers and Superscript II reverse 
transcriptase according to the manufacturer's instructions (Life Technologies). Primers 
were designed using Primer3 software version 0.4.0 (http://frodo.wi.mit.edu/primer3/) 
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with the maximum self-complementarity score set at 5 and the maximum three self-
complementarity score set to 0 to minimize primer-dimer formation. Primers are as 
follows: 
BCL6 
Forward: 5'-GTTCTGCATCCTCCTGGACTT-3' 
Reverse: 5'-GTACATCGCCGTAGCCATCA-3' 
CCR7 
Forward: 5'-GATGAAGGAGGCTTGAGATGG-3' 
Reverse: 5'-TGCTGCAATAGGGATCAGGAG-3' 
CD44 
Forward: 5'-CACCTTCCAACTGCATACCC-3' 
Reverse: 5'-CCGATGAGTCGTGGTCTTTG-3' 
CD62L 
Forward: 5'-TCATGTAGCAACCACGGAGA-3' 
Reverse: 5'-GGCTCACACTGAATCACGAA-3' 
EOMES 
Forward: 5'-AATCGGGCTGTGAAGATTTGAG-3' 
Reverse: 5'-GCCACTCTGGGATTCTCCTT-3' 
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GAPDH  
Forward: 5′-GGCAAATTCCACGGCACAGTCAAGGC-3′ 
Reverse: 5′-CAGAGGGGCCGTCCACGGTCTTCTGGGTGG-3′ 
GZMB 
Forward: 5′-ATCAAGTGTGGTGGGTTCCT-3′ 
Reverse: 5′-TGCTGGGTCTTCTCCTGTTC-3′ 
PRDM1 
Forward: 5'-TTGCAAAGAAACATGGGGAATGGA-3' 
Reverse: 5'-ACAGGCCCCAGAGGTAGTG-3' 
 
TBX21 
Forward: 5'-GTTCGTGGACGTGGTCTTG-3' 
Reverse: 5'-GACGTACAGGCGGTTTCCT-3' 
 
Primers were synthesized by Sigma-Aldrich. qRT-PCR assays were performed in 
triplicate using cDNA generated from 2.5-8.3ng of RNA depending on the assay, SYBR 
Green (ThermoFisher), and 100 nM primers. Assays were performed on an Applied 
BioSystems 7500 Fast Real-Time PCR System device and analyzed using 7500 Fast 
System Software version 1.4.0, or an Applied Biosystems ViiA7 device and analyzed 
using QuantStudio RealTimePCR Software version 1.3 (Applied Biosystems, Carlsbad, 
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CA). Dissociation curves were analyzed after each experiment to confirm the specificity 
of product amplification. 
 
RT-PCR 
For samples taken from Patient 434-001, RT-PCR for the CAR was performed using 
primers designed to anneal to non-homologous regions of human CD3ζ included in the 
RNA CAR construct: Forward 5’-GTACCAGCAGGGCCAGAAC-3', Reverse 5’-
TCCTGAGGGTTCTTCCTTCTC-3”. 
For CD19 RT-PCR, primers designed for cloning CD19 with a XhoI cut site were used: 
Forward 5’-GGTTCCCTGGTGAGCTTTCT-3', Reverse 5’- 
CTGCACTCGAGTTGACGCTGTCTGCTTAGGTT-3”. 
1kb+ Ladder shown in gel images from Life Technologies. 
 
Generation of anti-cCD20 and anti-hCD19 mRNA CAR vectors 
The anti-cCD20 scFv was generated through a fusion of the heavy and light chains of the 
variable fragments of a mouse-anti-human CD20 antibody, synthesized by Geneart (La 
Jolla, CA) and cloned into a DNA plasmid by our collaborator, Dr. Colleen M. 
O’Connor, while in the lab of Dr. Laurence Cooper (O'Connor et al., 2013). From this 
plasmid, cCD20 scFv sequence was PCR-amplified using the following primers: cCD20 
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scFv-Forward 5′-ACGCGGATCCGACATCGTGCTGTCCCAGAGCCCCGCCATC-3′ 
(BamHI) and cCD20 scFv-Reverse 5′-
ACGCGCTAGCGCTGGACACGGTCAGTGTGGTGCCCTGGCC-3′ (NheI). A DNA 
plasmid containing the human, FMC63-based, hCD19-CD28-ζ CAR was used as a 
template to amplify the hCD19 scFv using the following primers: CD19 scFv- Forward 
5′- ACGCGGATCCGACATCCAGATGACACAGACTACATCCTCC-3′ (BamHI) and 
CD19 scFv-Reverse 5′-
ACGCGCTAGCTGAGGAGACGGTGACTGAGGTTCCTTGGCC-3′ 
(NheI). Amplified sequences were gel purified, double digested with the indicated 
restriction enzymes, and ligated into a BamHI and NheI-digested pD-A.lenti cloning 
site.2bg.150A (PDA) vector backbone that contained the following human components: 
CD8α leader, CD8α hinge, CD8α transmembrane domain, and a CD3ζ intracellular 
signaling domain. Insertion of the scFv was confirmed by sequencing. RNA was 
synthesized as previously described. Briefly, the cCD20-ζ CAR PDA plasmid was 
linearized by digestion with SpeI. RNA in vitro transcription was then performed using 
the T7 mScript Standard mRNA production system (CellScript, Madison, WI) as per the 
manufacturer's instructions to obtain capped and tailed RNA. RNA vector was aliquoted 
into single use vials and stored at –150°C until use. 
Additional anti-human CD19-targeting scFv clones (21D4, 12B, and one derived from 
blinatumomab) were provided by the lab of Dr. Michael Milone. 
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RNA electroporation 
Canine T cells were electroporated with mRNA vectors after 14–16 days post-stimulation 
with the aAPC platform once T cells were rested down (<300 fL size, Coulter Count, 
Beckman Coulter, Indianapolis, IN). Previously described methods for electroporation of 
human T cells were used to guide testing of optimal conditions for canine T cells 
(Schutsky et al., 2015). T cells were washed twice with cold Opti-MEM media (Gibco) 
and resuspended at 10
8
 cells/ml. Increasing voltages (range: 200–600 V) with constant 
time (700 μs) and RNA (1 μg/106 cells), increasing time (700 μs, 1 ms) with constant 
voltage (500 V) and RNA (1 μg/106 cells), and increasing RNA (0.1, 1, and 2 
μg/106 cells) with constant voltage (500 V) and time (700 μs) were assessed. Optimal 
conditions were similar to those previously described for human T cells (Schutsky et al., 
2015). Briefly, canine T cells were washed twice with cold Opti-MEM media (Gibco) 
and resuspended at 10
8
 cells/ml. 20 μg mRNA CAR vector and 2 × 107 cells (1 
μg/106 cells) were electroporated in cuvettes (0.2 cm, Bio Rad, Hercules, CA) at 500 V 
for 700 μs (Electro Square Porator, BTX Harvard Apparatus, Holliston, MA). Cells were 
then cultured in TCM with rhIL-2 at 1–2 × 107cells/ml in multiple wells of 12-well plates 
(BioExpress, Kaysville, UT). 
 
Generation of lentivirus CAR vectors 
The lentivector pELNS was kindly provided by Dr. Michael Milone. pELNS is a third-
generation, self-inactivating lentivector derived from pCLPS, with the EF-1α promoter in 
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place of the CMV promoter and the insertion of an NheI cut site within the multiple 
cloning site of the vector 5’ of the transgene. A point mutation within that NheI site was 
generated using a compatible cohesive overhang from an SpeI-digested insert, resulting 
in the NheI sequence GCTAGC within the multiple cloning site become GCTAGT, 
allowing easier insertion and removal of scFvs within the vector; all CAR constructs 
were inserted into this new vector, called pELxPS. Plasmids for CAR constructs, the 
helper plasmids pCI VSV-G, pRSV Rev, and pMDL gag/pol.RRE, as well as all other 
plasmids were maxiprepped using the Qiagen EndoFree plasmid purification kits 
(Valencia, CA); later production of pELxPS cCD20-8-28-ζ, pELxPS cCD20-8-BB-ζ, and 
pCI VSV-G plasmids was sourced to Nature Technology Corporation (Lincoln, NE). 
Canine CD8α, CD28, 4-1BB, and CD3ζ components were originally cloned from canine 
PBMC cDNA by Dr. Nicola J. Mason, and synthesized together using overlap extension 
PCR with an anti-hCD19 (FMC63) scFv flanked with NheI sites as a stuffer and cloned 
into pCLPS, and then later into pELxPS. cCD20-8-28ζ CAR construct was generated in-
house by digestion of the hCD19 scFv-containing CAR contruct within pELxPS and the 
PCR amplified cCD20 scFv sequence with NheI and exchange of the scFvs; codon-
optimized cCD20-8-BB-ζ construct sequence was synthesized from the determined 
amino acid sequence by Genscript (Piscataway, NJ) and cloned into pELxPS by XbaI and 
SalI digestion. 
Lentivirus was produced through transient transfection of 293T cells using Lipofectamine 
200 (Life Technologies) as previously described. Lentivirus-contained supernatants were 
concentrated by centrifugation for at least 8 hours and at least 15,000g. Concentrated 
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lentivirus titer was determined by limiting dilution infection of either bead-stimulated 
primary human CD4+ T cells or Jurkat cells. Parallel infections of Jurkats and multiple 
primary human CD4+ T cell donors showed a 2.9-fold increase in GFP transduction 
efficiency and 5-fold increase in CAR transduction efficiency of Jurkat cells compared to 
primary human CD4+ T cells. Titrations performed on Jurkat cells had the resulting 
calculated titer converted back to primary CD4+ T cell equivalents when determining 
MOI for canine T cell infection. 
 
CAR T cell functional assays 
All functional assays for RNA CAR T cells were performed 24 hours post-
electroporation of mRNA CAR vectors; transfection efficiency was generally >90%. 
For cytokine release assays, 10
6
 T cells were co-cultured with 10
6
 cell targets in 200 μl 
TCM in triplicate wells. After 24 hours of co-culture, canine IFNγ production in cell-free 
supernatants was assessed via ELISA (R&D Systems, Minneapolis, MN). 
For chromium-release cytotoxicity assays, 10
4
 chromium-labeled targets were plated in 
sextuplicate in 96-well plates. T cells were added at the indicated E:T ratios. Co-cultures 
were incubated for 4 hours at 37°C in phenol-free TCM. Specific lysis was measured 
using a liquid scintillation counter (1450 Microbeta Plus, Long Island Scientific). Percent 
lysis = 100 – ((experimental cpm – spontaneous cpm) / (maximum cpm – spontaneous 
cpm wells)) × 100, where spontaneous is cpm of target cells with T cells electroporated 
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without mRNA and maximum lysis is cpm of target cells with addition of 5% dimethyl 
sulfoxide. 
For luciferase-based cytotoxicity assays, a fixed number of irradiated target cells were 
plated in 96-well plates. T cells were added at the indicated E:T ratios in triplicate, with 
total T cell number as the Effector regardless of transduction efficiency. Co-cultures were 
incubated for 24 hours at 37°C. Cultures were transferred to a 96-well V-bottom plate, 
pelleted, and supernatant transferred to another 96-well plate and stored at -80°C for later 
cytokine measurement. Cells washed twice with PBS, and then manufacturer’s 
instructions were followed for the Luciferase Assay System (Promega, Madison, WI) and 
measured on a luminometer. Percent lysis = 100 x (1 – (Experimental/Target Alone)), 
percent specific lysis = 100 x (1 – (CAR Experimental/Non-transduced Experimental)). 
For flow cytometry-based cytotoxicity assay, a fixed number of irradiated target cells 
were plated in 96-well plates. T cells were added at the indicated E:T ratios in triplicate, 
with total T cell number as the Effector regardless of transduction efficiency. Co-cultures 
were incubated for 24 hours at 37°C. Cultures were transferred to a 96-well V-bottom 
plate, pelleted, and supernatant transferred to another 96-well plate and stored at -80°C 
for later cytokine measurement. Cells washed with FACS buffer, and stained for 7-AAD 
and CD79a (if target cells did not express GFP). 10μL Countbright beads added to the 
samples before collection on a FACS Canto II. The number of live target cells was 
enumerated by back-calculating from the count of 7-AAD-, target marker positive events 
and Countbright bead events in each tube. Percent lysis = 100 x (1 – 
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(Experimental/Target Alone)), percent specific lysis = 100 x (1 – (CAR 
Experimental/Non-transduced Experimental)). 
For proliferation assays, T cells were assessed for CAR T cell expression and then equal 
numbers of T cells and irradiated target cells were incubated at 37°C for the indicated 
period of time. Live cells were then counted by trypan exclusion, and the number of CAR 
T cells was enumerated using the frequency of CD5+CAR+ cells measured by flow 
cytometry. 
 
Ethics statement and regulatory approvals  
These studies were approved by the University of Pennsylvania's Institutional Animal 
Care and Use Committee (Protocol number 805496 for the mRNA CAR T cells in 
Chapter 2, Protocol Number 805389 for the lentivirus CAR T cells in Chapter 3 and 4) 
and signed owner consent was required prior to enrollment. The use of recombinant DNA 
was approved by the University of Pennsylvania's Institutional Biosafety Committee 
(IBC #14–103 for the mRNA CAR T cells in Chapter 2, and IBC#13-164 for the 
lentivirus CAR T cells in Chapter 3 and 4). 
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Eligibility criteria and study design  
The purpose of the 434 study was to determine the safety and effectiveness of mRNA-
transfected, autologous T cells expressing a cCD20-specific first-generation CAR against 
B cell lymphoma. The purpose of the 429 study was to determine the safety and 
effectiveness of lentivirally-transduced, autologous T cells expressing a cCD20-specific 
second-generation CAR against B cell lymphoma. For the 434 mRNA study, dogs with a 
histopathological and immunohistochemical diagnosis of B cell lymphoma that had 
relapsed following a 25-week course of induction chemotherapy with a standard CHOP-
based protocol (L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and 
prednisone) were eligible for screening. For the 429 lentivirus study, dogs with a 
cytological diagnosis of B cell lymphoma that had relapsed following or during induction 
chemotherapy (or dogs for which standard-of-care multi-agent induction chemotherapy 
was not elected) were eligible for screening. In both studies, expression of cCD20 on 
malignant lymphocytes was confirmed by flow cytometry, and patients were required to 
have at least one measureable target lesion that could be repeatedly measured and 
evaluated by either aspiration or biopsy. A thorough physical exam, complete blood 
count, chemistry screen, and urinalysis were performed to determine general health status 
for both studies. Thoracic radiographs and abdominal ultrasound were also performed to 
determine extent of disease burden for both studies. 
In both studies, dogs were pre-treated with diphenhydramine (2 mg/kg i.m.) and 
ondansetron (0.2 mg/kg i.v.) prior to administration of CAR T cells. CAR T cells were 
infused in 0.9% plasmalyte. Blood samples and lymph node aspirates were taken pre-
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infusion and timepoints post-infusion indicated in the results, to characterize the T and B 
cells and to assess presence of CAR T cells. Affected lymph nodes were measured by 
caliper measurements and ultrasonographically pre-infusion and timepoints post-infusion 
indicated in the results, with at least 2 perpendicular dimensions taken for each enlarged 
lymph node. Lymph node volume was calculated as previous described (Gaurnier-
Hausser et al., 2011).  
 
Cytokine bead array  
Peripheral blood was collected in glass vacutainers (BD) and allowed to clot for 30 
minutes before centrifugation at 1983g for 5 minutes. Serum was separated and stored at 
–80°C prior to analysis. Samples were run in duplicate using the Canine Cytokine 
Magnetic Bead Panel (Catalog No. PN CCYTOMAG-90K-PX13, EMD Millipore). 
Calibration, data collection and verification were performed on the Luminex 200 using 
xPONENT software according to the manufacturer's instructions. The data report was 
generated using Millipore Analyst Software. 
 
Detection of serum anti-mouse immunoglobulin antibodies  
Serum samples, collected and stored as above, were analyzed by ELISA in triplicate 
using a human-anti-mouse Ig Kit (Biolegend). Anti-mouse immunoglobulin antibody 
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concentrations were calculated from standard dilutions fit to a 5-parameter curve and 
validated by QC samples included in the kit. 
 
qPCR for CAR Gene Quantification 
qPCR for CAR gene performed by the University of Pennsylvania Translational and 
Correlative Studies Laboratory. In brief, Taqman assays were performed on canine 
genomic DNA samples for WPRE, a component of the lentivector backbone that is 
integrated into the genome, and canine MC1R, a canine reference gene to normalize 
genomic DNA input, alongside a plasmid standard curve to quantify integrated copies per 
μg of canine genomic DNA. 
 
Statistical analyses 
Tests performed as described in results, using Prism software version 5.03 (Graphpad, La 
Jolla, CA).  
164 
 
BIBLIOGRAPHY 
Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, 
A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., et al. (2013). Signatures of 
mutational processes in human cancer. Nature 500, 415-421. 
Amirache, F., Levy, C., Costa, C., Mangeot, P.E., Torbett, B.E., Wang, C.X., Negre, D., 
Cosset, F.L., and Verhoeyen, E. (2014). Mystery solved: VSV-G-LVs do not allow 
efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the 
LDL receptor. Blood 123, 1422-1424. 
Ankri, C., Shamalov, K., Horovitz-Fried, M., Mauer, S., and Cohen, C.J. (2013). Human 
T cells engineered to express a programmed death 1/28 costimulatory retargeting 
molecule display enhanced antitumor activity. Journal of immunology (Baltimore, Md : 
1950) 191, 4121-4129. 
Atkins, M.B., Lotze, M.T., Dutcher, J.P., Fisher, R.I., Weiss, G., Margolin, K., Abrams, 
J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999). High-dose recombinant 
interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients 
treated between 1985 and 1993. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 17, 2105-2116. 
Atkins, M.B., Robertson, M.J., Gordon, M., Lotze, M.T., DeCoste, M., DuBois, J.S., 
Ritz, J., Sandler, A.B., Edington, H.D., Garzone, P.D., et al. (1997). Phase I evaluation of 
intravenous recombinant human interleukin 12 in patients with advanced malignancies. 
165 
 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 3, 409-417. 
Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, 
A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. (2014). Mesothelin-specific chimeric 
antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid 
malignancies. Cancer immunology research 2, 112-120. 
Billingham, R.E., Brent, L., and Medawar, P.B. (1954a). Quantitative studies on tissue 
transplantation immunity. II. The origin, strength and duration of actively and adoptively 
acquired immunity. Proceedings of the Royal Society of London Series B, Biological 
sciences 143, 58-80. 
Billingham, R.E., Brent, L., Medawar, P.B., and Sparrow, E.M. (1954b). Quantitative 
studies on tissue transplantation immunity. I. The survival times of skin homografts 
exchanged between members of different inbred strains of mice. Proceedings of the 
Royal Society of London Series B, Biological sciences 143, 43-58. 
Bismarck, D., Schutze, N., Moore, P., Buttner, M., Alber, G., and Buttlar, H. (2012). 
Canine CD4+CD8+ double positive T cells in peripheral blood have features of activated 
T cells. Veterinary immunology and immunopathology 149, 157-166. 
Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, 
C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. (2012). Safety and activity of anti-PD-
L1 antibody in patients with advanced cancer. The New England journal of medicine 
366, 2455-2465. 
166 
 
Breen, M., and Modiano, J.F. (2008). Evolutionarily conserved cytogenetic changes in 
hematological malignancies of dogs and humans--man and his best friend share more 
than companionship. Chromosome research : an international journal on the molecular, 
supramolecular and evolutionary aspects of chromosome biology 16, 145-154. 
Bucher, C., Koch, L., Vogtenhuber, C., Goren, E., Munger, M., Panoskaltsis-Mortari, A., 
Sivakumar, P., and Blazar, B.R. (2009). IL-21 blockade reduces graft-versus-host disease 
mortality by supporting inducible T regulatory cell generation. Blood 114, 5375-5384. 
Burnet, M. (1957a). Cancer: a biological approach. III. Viruses associated with neoplastic 
conditions. IV. Practical applications. British medical journal 1, 841-847. 
Burnet, M. (1957b). Cancer; a biological approach. I. The processes of control. British 
medical journal 1, 779-786. 
Carpenito, C., Milone, M.C., Hassan, R., Simonet, J.C., Lakhal, M., Suhoski, M.M., 
Varela-Rohena, A., Haines, K.M., Heitjan, D.F., Albelda, S.M., et al. (2009). Control of 
large, established tumor xenografts with genetically retargeted human T cells containing 
CD28 and CD137 domains. Proc Natl Acad Sci U S A 106, 3360-3365. 
Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, 
A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., et al. (2015). Cancer 
immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma 
neoantigen-specific T cells. Science (New York, NY) 348, 803-808. 
167 
 
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E.S., Ittmann, M.M., 
Marchetti, D., and Dotti, G. (2015). Heparanase promotes tumor infiltration and 
antitumor activity of CAR-redirected T lymphocytes. Nature medicine 21, 524-529. 
Chen, B.J., Chapuy, B., Ouyang, J., Sun, H.H., Roemer, M.G., Xu, M.L., Yu, H., 
Fletcher, C.D., Freeman, G.J., Shipp, M.A., et al. (2013). PD-L1 expression is 
characteristic of a subset of aggressive B-cell lymphomas and virus-associated 
malignancies. Clinical cancer research : an official journal of the American Association 
for Cancer Research 19, 3462-3473. 
Clay, T.M., Custer, M.C., Sachs, J., Hwu, P., Rosenberg, S.A., and Nishimura, M.I. 
(1999). Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood 
lymphocytes confers anti-tumor reactivity. Journal of immunology (Baltimore, Md : 
1950) 163, 507-513. 
Couto, J.I., Bear, M.D., Lin, J., Pennel, M., Kulp, S.K., Kisseberth, W.C., and London, 
C.A. (2012). Biologic activity of the novel small molecule STAT3 inhibitor LLL12 
against canine osteosarcoma cell lines. BMC veterinary research 8, 244. 
Crotty, S., Johnston, R.J., and Schoenberger, S.P. (2010). Effectors and memories: Bcl-6 
and Blimp-1 in T and B lymphocyte differentiation. Nature immunology 11, 114-120. 
Davis, M.M., and Bjorkman, P.J. (1988). T-cell antigen receptor genes and T-cell 
recognition. Nature 334, 395-402. 
168 
 
Di Stasi, A., De Angelis, B., Rooney, C.M., Zhang, L., Mahendravada, A., Foster, A.E., 
Heslop, H.E., Brenner, M.K., Dotti, G., and Savoldo, B. (2009). T lymphocytes 
coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved 
homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392-6402. 
Ehrlich, P. (1909). Über den jetzigen stand der karzinomforschung. Nederlands 
Tijdschrift voor Geneeskunde 5, 273-290. 
Eshhar, Z., Waks, T., Gross, G., and Schindler, D.G. (1993). Specific activation and 
targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-
binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell 
receptors. Proc Natl Acad Sci U S A 90, 720-724. 
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S.J.C., Hamieh, M., 
Cunanan, K.M., Odak, A., Gönen, M., and Sadelain, M. (2017). Targeting a CAR to the 
TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113-117. 
Fedorov, V.D., Themeli, M., and Sadelain, M. (2013). PD-1- and CTLA-4-based 
inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy 
responses. Science translational medicine 5, 215ra172. 
Felsburg, P.J., De Ravin, S.S., Malech, H.L., Sorrentino, B.P., Burtner, C., and Kiem, 
H.P. (2015). Gene therapy studies in a canine model of X-linked severe combined 
immunodeficiency. Hum Gene Ther Clin Dev 26, 50-56. 
169 
 
Ferrebee, J.W., Lochte, H.L., Jr., Jaretzki, A., 3rd, Sahler, O.D., and Thomas, E.D. 
(1958). Successful marrow homograft in the dog after radiation. Surgery 43, 516-520. 
Finkelshtein, D., Werman, A., Novick, D., Barak, S., and Rubinstein, M. (2013). LDL 
receptor and its family members serve as the cellular receptors for vesicular stomatitis 
virus. Proc Natl Acad Sci U S A 110, 7306-7311. 
Finney, H.M., Akbar, A.N., and Lawson, A.D. (2004). Activation of resting human 
primary T cells with chimeric receptors: costimulation from CD28, inducible 
costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. Journal 
of immunology (Baltimore, Md : 1950) 172, 104-113. 
Finney, H.M., Lawson, A.D., Bebbington, C.R., and Weir, A.N. (1998). Chimeric 
receptors providing both primary and costimulatory signaling in T cells from a single 
gene product. Journal of immunology (Baltimore, Md : 1950) 161, 2791-2797. 
Foltz, J.A., Somanchi, S.S., Yang, Y., Aquino-Lopez, A., Bishop, E.E., and Lee, D.A. 
(2016). NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic 
Similarity to Human Natural Killer Cells. Frontiers in immunology 7, 521. 
Fraietta, J.A., Beckwith, K.A., Patel, P.R., Ruella, M., Zheng, Z., Barrett, D.M., Lacey, 
S.F., Melenhorst, J.J., McGettigan, S.E., Cook, D.R., et al. (2016). Ibrutinib enhances 
chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127, 1117-
1127. 
170 
 
Frantz, L.A.F., Mullin, V.E., Pionnier-Capitan, M., Lebrasseur, O., Ollivier, M., Perri, A., 
Linderholm, A., Mattiangeli, V., Teasdale, M.D., Dimopoulos, E.A., et al. (2016). 
Genomic and archaeological evidence suggest a dual origin of domestic dogs. Science 
(New York, NY) 352, 1228-1231. 
Frigault, M.J., Lee, J., Basil, M.C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, 
O.U., Guedan, S., McGettigan, S.E., Posey, A.D., Jr., et al. (2015). Identification of 
Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T 
Cells. Cancer immunology research. 
Gamonet, C., Bole-Richard, E., Delherme, A., Aubin, F., Toussirot, E., Garnache-Ottou, 
F., Godet, Y., Ysebaert, L., Tournilhac, O., Dartigeas, C., et al. (2016). New CD20 
alternative splice variants: molecular identification and differential expression within 
hematological B cell malignancies. Experimental Hematology & Oncology 5, 7. 
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M., Quigley, M.F., Almeida, J.R., 
Gostick, E., Yu, Z., Carpenito, C., et al. (2011). A human memory T cell subset with 
stem cell-like properties. Nature medicine 17, 1290-1297. 
Gaurnier-Hausser, A., Patel, R., Baldwin, A.S., May, M.J., and Mason, N.J. (2011). 
NEMO-binding domain peptide inhibits constitutive NF-kappaB activity and reduces 
tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 17, 4661-4671. 
171 
 
Ghassemi, S., Bedoya, F., Nunez-Cruz, S., June, C., Melenhorst, J., and Milone, M. 
(2016). Shortened T cell culture with IL-7 and IL-15 provides the most potent chimeric 
antigen receptor (CAR)-modified T cells for adoptive immunotherapy. The Journal of 
Immunology 196, 214.223. 
Graves, S.S., Stone, D.M., Loretz, C., Peterson, L.J., Lesnikova, M., Hwang, B., Georges, 
G.E., Nash, R., and Storb, R. (2011). Antagonistic and agonistic anti-canine CD28 
monoclonal antibodies: tools for allogeneic transplantation. Transplantation 91, 833-840. 
Gross, G., Waks, T., and Eshhar, Z. (1989). Expression of immunoglobulin-T-cell 
receptor chimeric molecules as functional receptors with antibody-type specificity. Proc 
Natl Acad Sci U S A 86, 10024-10028. 
Grupp, S.A. (2016). CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B 
cell ALL patients. Cancer discovery 126, 2123-2138. 
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, 
D.T., Chew, A., Hauck, B., Wright, J.F., et al. (2013). Chimeric antigen receptor-
modified T cells for acute lymphoid leukemia. The New England journal of medicine 
368, 1509-1518. 
Gyurkocza, B., Cao, T.M., Storb, R.F., Lange, T., Leisenring, W., Franke, G.N., Sorror, 
M., Hoppe, R., Maloney, D.G., Negrin, R.S., et al. (2009). Salvage allogeneic 
hematopoietic cell transplantation with fludarabine and low-dose total body irradiation 
after rejection of first allografts. Biology of blood and marrow transplantation : journal of 
the American Society for Blood and Marrow Transplantation 15, 1314-1322. 
172 
 
Haidar, J.H., Shamseddine, A., Salem, Z., Mrad, Y.A., Nasr, M.R., Zaatari, G., and 
Bazarbachi, A. (2003). Loss of CD20 expression in relapsed lymphomas after rituximab 
therapy. European journal of haematology 70, 330-332. 
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., 
Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and KrasG12D 
cooperate to promote chromosomal instability and widely metastatic pancreatic ductal 
adenocarcinoma in mice. Cancer cell 7, 469-483. 
Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., 
Pan, Z., Thamm, D.H., Miller, R.A., et al. (2010). The Bruton tyrosine kinase inhibitor 
PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease 
and B-cell malignancy. Proc Natl Acad Sci U S A 107, 13075-13080. 
Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, 
H.E., Rooney, C.M., Brenner, M.K., and Dotti, G. (2010). Engineering CD19-specific T 
lymphocytes with interleukin-15 and a suicide gene to enhance their anti-
lymphoma/leukemia effects and safety. Leukemia 24, 1160-1170. 
Huang, Y.C., Hung, S.W., Jan, T.R., Liao, K.W., Cheng, C.H., Wang, Y.S., and Chu, 
R.M. (2008). CD5-low expression lymphocytes in canine peripheral blood show 
characteristics of natural killer cells. J Leukoc Biol 84, 1501-1510. 
Ito, D., Brewer, S., Modiano, J.F., and Beall, M.J. (2015). Development of a novel anti-
canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk 
Lymphoma 56, 219-225. 
173 
 
Ito, D., Frantz, A.M., and Modiano, J.F. (2014). Canine lymphoma as a comparative 
model for human non-Hodgkin lymphoma: recent progress and applications. Veterinary 
immunology and immunopathology 159, 192-201. 
June, C.H. (2014). Allogeneic chimeric antigen receptor-modified cells for adoptive cell 
therapy of cancer. Science translational medicine 14, 947-954. 
Kalos, M., and June, C.H. (2013). Adoptive T cell transfer for cancer immunotherapy in 
the era of synthetic biology. Immunity 39, 49-60. 
Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., and June, C.H. 
(2011). T cells with chimeric antigen receptors have potent antitumor effects and can 
establish memory in patients with advanced leukemia. Science translational medicine 3, 
95ra73. 
Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., 
Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. (2010). Sipuleucel-T 
immunotherapy for castration-resistant prostate cancer. The New England journal of 
medicine 363, 411-422. 
Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., and 
Schreiber, R.D. (1998). Demonstration of an interferon gamma-dependent tumor 
surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95, 7556-
7561. 
174 
 
Kato, M., Watarai, S., Nishikawa, S., Iwasaki, T., and Kodama, H. (2007). A novel 
culture method of canine peripheral blood lymphocytes with concanavalin a and 
recombinant human interleukin-2 for adoptive immunotherapy. J Vet Med Sci 69, 481-
486. 
Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., Posey, A.D., 
Jr., Patel, P.R., Guedan, S., Scholler, J., Keith, B., et al. (2016). Distinct Signaling of 
Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory 
Development in CAR T Cells. Immunity 44, 380-390. 
Kennedy, D.R., Hartnett, B.J., Kennedy, J.S., Vernau, W., Moore, P.F., O'Malley, T., 
Burkly, L.C., Henthorn, P.S., and Felsburg, P.J. (2011). Ex vivo gamma-retroviral gene 
therapy of dogs with X-linked severe combined immunodeficiency and the development 
of a thymic T cell lymphoma. Veterinary immunology and immunopathology 142, 36-48. 
Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., 
White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., et al. (2006). A phase I 
study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 12, 6106-6115. 
Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., 
Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., et al. (2010). 
Eradication of B-lineage cells and regression of lymphoma in a patient treated with 
autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102. 
175 
 
Koeberl, D.D., Pinto, C., Sun, B., Li, S., Kozink, D.M., Benjamin, D.K., Jr., Demaster, 
A.K., Kruse, M.A., Vaughn, V., Hillman, S., et al. (2008). AAV vector-mediated reversal 
of hypoglycemia in canine and murine glycogen storage disease type Ia. Molecular 
therapy : the journal of the American Society of Gene Therapy 16, 665-672. 
Lamers, C.H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, 
C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013). Treatment of 
metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation 
and management of on-target toxicity. Molecular therapy : the journal of the American 
Society of Gene Therapy 21, 904-912. 
Lanitis, E., Poussin, M., Klattenhoff, A.W., Song, D., Sandaltzopoulos, R., June, C.H., 
and Powell, D.J., Jr. (2013). Chimeric antigen receptor T Cells with dissociated signaling 
domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. 
Cancer immunology research 1, 43-53. 
Leitner, J., Herndler-Brandstetter, D., Zlabinger, G.J., Grubeck-Loebenstein, B., and 
Steinberger, P. (2015). CD58/CD2 Is the Primary Costimulatory Pathway in Human 
CD28-CD8+ T Cells. Journal of immunology (Baltimore, Md : 1950) 195, 477-487. 
Levine, B.L., Bernstein, W.B., Connors, M., Craighead, N., Lindsten, T., Thompson, 
C.B., and June, C.H. (1997). Effects of CD28 costimulation on long-term proliferation of 
CD4+ T cells in the absence of exogenous feeder cells. Journal of immunology 
(Baltimore, Md : 1950) 159, 5921-5930. 
176 
 
Levine, B.L., Cotte, J., Small, C.C., Carroll, R.G., Riley, J.L., Bernstein, W.B., Van 
Epps, D.E., Hardwick, R.A., and June, C.H. (1998). Large-scale production of CD4+ T 
cells from HIV-1-infected donors after CD3/CD28 costimulation. Journal of 
hematotherapy 7, 437-448. 
Li, Z. (2016). PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR) Modified T 
Cells and Induces Tumor Regression: Refueling the CAR. Cancer immunology, 
immunotherapy : CII. 
Lindblad-Toh, K., Wade, C.M., Mikkelsen, T.S., Karlsson, E.K., Jaffe, D.B., Kamal, M., 
Clamp, M., Chang, J.L., Kulbokas, E.J., 3rd, Zody, M.C., et al. (2005). Genome 
sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438, 
803-819. 
Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., 
Litzky, L., Bagg, A., Carreno, B.M., Cimino, P.J., et al. (2013). Cardiovascular toxicity 
and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 
122, 863-871. 
Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., and Ledbetter, J.A. 
(1991). CTLA-4 is a second receptor for the B cell activation antigen B7. The Journal of 
experimental medicine 174, 561-569. 
Lo, A., Wang, L.C., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, 
R.A., Bajor, D.J., Clendenin, C., et al. (2015). Tumor-Promoting Desmoplasia Is 
Disrupted by Depleting FAP-Expressing Stromal Cells. Cancer research 75, 2800-2810. 
177 
 
Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., 
Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. (2015). 4-1BB 
costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric 
antigen receptors. Nature medicine 21, 581-590. 
Maekawa, N., Konnai, S., Ikebuchi, R., Okagawa, T., Adachi, M., Takagi, S., Kagawa, 
Y., Nakajima, C., Suzuki, Y., Murata, S., et al. (2014). Expression of PD-L1 on canine 
tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by 
PD-L1 blockade. PloS one 9, e98415. 
Marconato, L., Gelain, M.E., and Comazzi, S. (2013). The dog as a possible animal 
model for human non-Hodgkin lymphoma: a review. Hematological oncology 31, 1-9. 
Mason, N.J., Gnanandarajah, J.S., Engiles, J.B., Gray, F., Laughlin, D., Gaurnier-
Hausser, A., Wallecha, A., Huebner, M., and Paterson, Y. (2016). Immunotherapy with a 
HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential 
Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clinical cancer research : 
an official journal of the American Association for Cancer Research 22, 4380-4390. 
Mata, M., Vera, J.F., Gerken, C., Rooney, C.M., Miller, T., Pfent, C., Wang, L.L., 
Wilson-Robles, H.M., and Gottschalk, S. (2014). Toward immunotherapy with redirected 
T cells in a large animal model: ex vivo activation, expansion, and genetic modification 
of canine T cells. Journal of immunotherapy (Hagerstown, Md : 1997) 37, 407-415. 
178 
 
Maus, M.V., Haas, A.R., Beatty, G.L., Albelda, S.M., Levine, B.L., Liu, X., Zhao, Y., 
Kalos, M., and June, C.H. (2013). T cells expressing chimeric antigen receptors can cause 
anaphylaxis in humans. Cancer immunology research 1, 26-31. 
Maus, M.V., Thomas, A.K., Leonard, D.G., Allman, D., Addya, K., Schlienger, K., 
Riley, J.L., and June, C.H. (2002). Ex vivo expansion of polyclonal and antigen-specific 
cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, 
CD28 and 4-1BB. Nature biotechnology 20, 143-148. 
Michael, H.T., Ito, D., McCullar, V., Zhang, B., Miller, J.S., and Modiano, J.F. (2013). 
Isolation and characterization of canine natural killer cells. Veterinary immunology and 
immunopathology 155, 211-217. 
Milone, M.C., Fish, J.D., Carpenito, C., Carroll, R.G., Binder, G.K., Teachey, D., 
Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009). Chimeric 
receptors containing CD137 signal transduction domains mediate enhanced survival of T 
cells and increased antileukemic efficacy in vivo. Molecular therapy : the journal of the 
American Society of Gene Therapy 17, 1453-1464. 
Modiano, J.F., Breen, M., Valli, V.E., Wojcieszyn, J.W., and Cutter, G.R. (2007). 
Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-
Hodgkin's lymphoma. Leukemia 21, 184-187. 
Moon, E.K., Wang, L.C., Dolfi, D.V., Wilson, C.B., Ranganathan, R., Sun, J., Kapoor, 
V., Scholler, J., Pure, E., Milone, M.C., et al. (2014). Multifactorial T-cell hypofunction 
that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T 
179 
 
cells in solid tumors. Clinical cancer research : an official journal of the American 
Association for Cancer Research 20, 4262-4273. 
Morey, D.F. (2006). Burying key evidence: the social bond between dogs and people. 
Journal of Archaeological Science 33, 158-175. 
Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., 
Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., et al. (2013). Cancer regression 
and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of 
immunotherapy (Hagerstown, Md : 1997) 36, 133-151. 
Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and Rosenberg, 
S.A. (2010). Case Report of a Serious Adverse Event Following the Administration of T 
Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2. Molecular 
therapy : the journal of the American Society of Gene Therapy 18, 843-851. 
Mueller, D.L., Jenkins, M.K., and Schwartz, R.H. (1989). Clonal expansion versus 
functional clonal inactivation: a costimulatory signalling pathway determines the 
outcome of T cell antigen receptor occupancy. Annual review of immunology 7, 445-
480. 
Nadler, L.M., Ritz, J., Hardy, R., Pesando, J.M., Schlossman, S.F., and Stashenko, P. 
(1981). A unique cell surface antigen identifying lymphoid malignancies of B cell origin. 
The Journal of clinical investigation 67, 134-140. 
180 
 
National Cancer Policy, F., Board on Health Care, S., Institute of, M., National 
Academies of Sciences, E., and Medicine (2015). In The Role of Clinical Studies for Pets 
with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary 
(Washington (DC): National Academies Press (US) 
Copyright 2015 by the National Academy of Sciences. All rights reserved.). 
O'Connor, C.M., Olivares, S., Ang, S., Champlin, R.E., Wilson-Robles, H.M., and 
Cooper, L.J. (2013). Chimeric Antigen Receptor T-Cell Therapy for Companion Canines 
with Spontaneous B-Cell Non-Hodgkin Lymphoma. Molecular therapy : the journal of 
the American Society of Gene Therapy 21, S249. 
O'Connor, C.M., Sheppard, S., Hartline, C.A., Huls, H., Johnson, M., Palla, S.L., Maiti, 
S., Ma, W., Davis, R.E., Craig, S., et al. (2012). Adoptive T-cell therapy improves 
treatment of canine non-Hodgkin lymphoma post chemotherapy. Scientific reports 2, 
249. 
Parry, R.V., Rumbley, C.A., Vandenberghe, L.H., June, C.H., and Riley, J.L. (2003). 
CD28 and inducible costimulatory protein Src homology 2 binding domains show 
distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in 
primary human CD4 T lymphocytes. Journal of immunology (Baltimore, Md : 1950) 171, 
166-174. 
Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, 
A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. (2016). Epigenetic stability of exhausted T 
181 
 
cells limits durability of reinvigoration by PD-1 blockade. Science (New York, NY) 354, 
1160-1165. 
Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., 
Marcucci, K.T., Shen, A., Gonzalez, V., et al. (2015). Chimeric antigen receptor T cells 
persist and induce sustained remissions in relapsed refractory chronic lymphocytic 
leukemia. Science translational medicine 7, 303ra139. 
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric antigen 
receptor-modified T cells in chronic lymphoid leukemia. The New England journal of 
medicine 365, 725-733. 
Rech, A.J., Mick, R., Martin, S., Recio, A., Aqui, N.A., Powell, D.J., Jr., Colligon, T.A., 
Trosko, J.A., Leinbach, L.I., Pletcher, C.H., et al. (2012). CD25 blockade depletes and 
selectively reprograms regulatory T cells in concert with immunotherapy in cancer 
patients. Science translational medicine 4, 134ra162. 
Reiser, J. (2000). Production and concentration of pseudotyped HIV-1-based gene 
transfer vectors. Gene Ther 7, 910-913. 
Richards, K.L., Motsinger-Reif, A.A., Chen, H.W., Fedoriw, Y., Fan, C., Nielsen, D.M., 
Small, G.W., Thomas, R., Smith, C., Dave, S.S., et al. (2013). Gene profiling of canine 
B-cell lymphoma reveals germinal center and postgerminal center subtypes with different 
survival times, modeling human DLBCL. Cancer research 73, 5029-5039. 
182 
 
Robinson, J., Halliwell, J.A., Hayhurst, J.D., Flicek, P., Parham, P., and Marsh, S.G. 
(2015). The IPD and IMGT/HLA database: allele variant databases. Nucleic acids 
research 43, D423-431. 
Romeo, C., and Seed, B. (1991). Cellular immunity to HIV activated by CD4 fused to T 
cell or Fc receptor polypeptides. Cell 64, 1037-1046. 
Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., 
Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T., et al. (1985). Observations on the 
systemic administration of autologous lymphokine-activated killer cells and recombinant 
interleukin-2 to patients with metastatic cancer. The New England journal of medicine 
313, 1485-1492. 
Ruella, M., Kenderian, S.S., Shestova, O., Fraietta, J.A., Qayyum, S., Zhang, Q., Maus, 
M.V., Liu, X., Nunez-Cruz, S., Klichinsky, M., et al. (2016). The Addition of the BTK 
Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) 
Improves Responses against Mantle Cell Lymphoma. Clinical cancer research : an 
official journal of the American Association for Cancer Research 22, 2684-2696. 
Salavoura, K., Kolialexi, A., Tsangaris, G., and Mavrou, A. (2008). Development of 
cancer in patients with primary immunodeficiencies. Anticancer research 28, 1263-1269. 
Schiffman, J.D., and Breen, M. (2015). Comparative oncology: what dogs and other 
species can teach us about humans with cancer. Philosophical transactions of the Royal 
Society of London Series B, Biological sciences 370. 
183 
 
Scholler, J., Brady, T.L., Binder-Scholl, G., Hwang, W.T., Plesa, G., Hege, K.M., Vogel, 
A.N., Kalos, M., Riley, J.L., Deeks, S.G., et al. (2012). Decade-long safety and function 
of retroviral-modified chimeric antigen receptor T cells. Science translational medicine 4, 
132ra153. 
Schutsky, K., Song, D.G., Lynn, R., Smith, J.B., Poussin, M., Figini, M., Zhao, Y., and 
Powell, D.J., Jr. (2015). Rigorous optimization and validation of potent RNA CAR T cell 
therapy for the treatment of common epithelial cancers expressing folate receptor. 
Oncotarget 6, 28911-28928. 
Seo, K.W., Choi, U.S., Lee, J.B., Kim, M.I., Oh, Y.I., Chung, J.Y., Lee, S.K., Hwang, 
C.Y., and Youn, H.Y. (2011). Central nervous system relapses in 3 dogs with B-cell 
lymphoma. The Canadian Veterinary Journal 52, 778-783. 
Sommermeyer, D., Hudecek, M., Kosasih, P.L., Gogishvili, T., Maloney, D.G., Turtle, 
C.J., and Riddell, S.R. (2015). Chimeric antigen receptor-modified T cells derived from 
defined CD8 and CD4 subsets confer superior antitumor reactivity in vivo. Leukemia. 
Song, D.G., Ye, Q., Poussin, M., Harms, G.M., Figini, M., and Powell, D.J., Jr. (2012). 
CD27 costimulation augments the survival and antitumor activity of redirected human T 
cells in vivo. Blood 119, 696-706. 
Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., 
Lanauze, C., Ruella, M., Gazzara, M.R., et al. (2015). Convergence of Acquired 
Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 
Immunotherapy. Cancer discovery 5, 1282-1295. 
184 
 
Storb, R., Epstein, R.B., Ragde, H., Bryant, J., and Thomas, E.D. (1967). Marrow 
engraftment by allogeneic leukocytes in lethally irradiated dogs. Blood 30, 805-811. 
Straathof, K.C., Pule, M.A., Yotnda, P., Dotti, G., Vanin, E.F., Brenner, M.K., Heslop, 
H.E., Spencer, D.M., and Rooney, C.M. (2005). An inducible caspase 9 safety switch for 
T-cell therapy. Blood 105, 4247-4254. 
Stroncek, D.F., Lee, D.W., Ren, J., Sabatino, M., Highfill, S., Khuu, H., Shah, N.N., 
Kaplan, R.N., Fry, T.J., and Mackall, C.L. (2017). Elutriated lymphocytes for 
manufacturing chimeric antigen receptor T cells. Journal of translational medicine 15, 59. 
Stroncek, D.F., Ren, J., Lee, D.W., Tran, M., Frodigh, S.E., Sabatino, M., Khuu, H., 
Merchant, M.S., and Mackall, C.L. (2016). Myeloid cells in peripheral blood 
mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. 
Cytotherapy 18, 893-901. 
Suhoski, M.M., Golovina, T.N., Aqui, N.A., Tai, V.C., Varela-Rohena, A., Milone, M.C., 
Carroll, R.G., Riley, J.L., and June, C.H. (2007). Engineering artificial antigen-presenting 
cells to express a diverse array of co-stimulatory molecules. Molecular therapy : the 
journal of the American Society of Gene Therapy 15, 981-988. 
Textor, A., Listopad, J.J., Wuhrmann, L.L., Perez, C., Kruschinski, A., Chmielewski, M., 
Abken, H., Blankenstein, T., and Charo, J. (2014). Efficacy of CAR T-cell therapy in 
large tumors relies upon stromal targeting by IFNgamma. Cancer research 74, 6796-
6805. 
185 
 
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., 
Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. (2012). Safety, activity, 
and immune correlates of anti-PD-1 antibody in cancer. The New England journal of 
medicine 366, 2443-2454. 
Turtle, C.J., Hanafi, L.A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, 
R., Chaney, C., Cherian, S., Chen, X., et al. (2016). Immunotherapy of non-Hodgkin's 
lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen 
receptor-modified T cells. Science translational medicine 8, 355ra116. 
Vail, D.M., Pinkerton, M.E., and Young, K.M. (2013). 32 - Hematopoietic Tumors A2 - 
Withrow, Stephen J. In Withrow and MacEwen's Small Animal Clinical Oncology (Fifth 
Edition), D.M. Vail, and R.L. Page, eds. (Saint Louis: W.B. Saunders), pp. 608-678. 
Wang, C.X., Sather, B.D., Wang, X., Adair, J., Khan, I., Singh, S., Lang, S., Adams, A., 
Curinga, G., Kiem, H.P., et al. (2014). Rapamycin relieves lentiviral vector transduction 
resistance in human and mouse hematopoietic stem cells. Blood 124, 913-923. 
Whitlow, M., Filpula, D., Rollence, M.L., Feng, S.L., and Wood, J.F. (1994). Multivalent 
Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv. 
Protein engineering 7, 1017-1026. 
Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, 
W., Schadendorf, D., Smylie, M., Guthrie, T., Jr., et al. (2010). Ipilimumab monotherapy 
in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, 
phase 2, dose-ranging study. The Lancet Oncology 11, 155-164. 
186 
 
Wunderli, P.S., and Felsburg, P.J. (1989). An improved method for the isolation of 
enriched canine peripheral blood mononuclear cell and peripheral blood lymphocyte 
preparations. Veterinary immunology and immunopathology 20, 335-344. 
Xu, X.J., Song, D.G., Poussin, M., Ye, Q., Sharma, P., Rodriguez-Garcia, A., Tang, 
Y.M., and Powell, D.J. (2016). Multiparameter comparative analysis reveals differential 
impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo. 
Oncotarget 7, 82354-82368. 
Xu, Y., Zhang, M., Ramos, C.A., Durett, A., Liu, E., Dakhova, O., Liu, H., Creighton, 
C.J., Gee, A.P., Heslop, H.E., et al. (2014). Closely related T-memory stem cells 
correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-
15. Blood 123, 3750-3759. 
Zhao, Y., Moon, E., Carpenito, C., Paulos, C.M., Liu, X., Brennan, A.L., Chew, A., 
Carroll, R.G., Scholler, J., Levine, B.L., et al. (2010). Multiple injections of 
electroporated autologous T cells expressing a chimeric antigen receptor mediate 
regression of human disseminated tumor. Cancer research 70, 9053-9061. 
 
